dalteparin has been researched along with Embolism, Pulmonary in 487 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compared with no prophylaxis, the use of low-dose warfarin would be expected to reduce the number of cases of confirmed deep-vein thrombosis from about 1000 (per 10,000 patients) to 420 and the number of thromboembolic deaths from about 250 to 110." | 10.17 | Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. ( Colditz, GA; Menzin, J; Oster, G; Regan, MM; Richner, RE, 1995) |
| "Among patients undergoing hip or knee arthroplasty for osteoarthritis, aspirin compared with enoxaparin resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism." | 9.51 | Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. ( Ackerman, I; Adie, S; Bastiras, D; Brighton, R; Buchbinder, R; Burns, AWR; Cashman, K; Chong, BH; Clavisi, O; Cripps, M; de Steiger, R; Dekkers, M; Dixon, M; Ellis, A; Graves, SE; Griffith, EC; Hale, D; Hansen, A; Harris, A; Harris, IA; Hau, R; Horsley, M; James, D; Kelly, TL; Khorshid, O; Kuo, L; Lewis, P; Lieu, D; Lorimer, M; MacDessi, S; McCombe, P; McDougall, C; Mulford, J; Naylor, JM; Page, RS; Pratt, N; Radovanovic, J; Sidhu, VS; Solomon, M; Sorial, R; Summersell, P; Tran, P; Walter, WL; Webb, S; Wilson, C; Wysocki, D, 2022) |
| "Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding." | 9.34 | Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Muñoz, A; Sueiro, MR; Torbicki, A; Verso, M; Vescovo, G, 2020) |
| "To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer-associated venous thromboembolism (Ca-VTE), consecutive patients treated with apixaban, rivaroxaban, or enoxaparin at Mayo Thrombophilia Clinic (March 1, 2013 to January 31, 2018)) were followed prospectively." | 9.30 | Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. ( Bott-Kitslaar, DM; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; Mcbane, RD; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2019) |
| "The 80-mg betrixaban dose achieves higher plasma concentrations than the 40-mg dose and, in contrast to the 40-mg dose, is associated with improved efficacy across all cohorts relative to standard-dose enoxaparin without an excess risk of major bleeding in the management of medically ill subjects." | 9.24 | The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. ( Arbetter, DF; Bandman, O; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Halaby, R; Harrington, RA; Hernandez, AF; Hull, R; Korjian, S; Leeds, JM; Lu, SP; Yee, MK, 2017) |
| "Sixty-two PE patients with or without deep venous thrombosis (DVT) was randomized to rivaroxaban mono-therapy or standard-therapy with enoxaparin followed by vitamin K antagonist (VKA)." | 9.22 | Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism. ( Chen, R; Duan, L; Guo, Y; Hong, C; Liu, C; Su, X; Yan, H; Yang, X; Zhang, N; Zhong, N; Zhou, Y, 2016) |
| "In the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) trial, apixaban was noninferior to enoxaparin/warfarin in preventing recurrent symptomatic venous thromboembolism (VTE) or venous thromboembolism-related death, with significantly less bleeding." | 9.20 | Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. ( Cohen, AT; Johnson, M; Liu, X; Mardekian, J; Phatak, H; Thompson, J, 2015) |
| " We aimed to perform a competing risk analysis to assess the efficacy of the low molecular weight heparin dalteparin versus unfractionated heparin (UFH) in venous thromboembolism (VTE) in medical-surgical critically ill patients, taking death as a competing risk." | 9.20 | Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients. ( Arabi, YM; Bellomo, R; Cook, DJ; Cooper, DJ; Crowther, M; Ferguson, ND; Finfer, S; Guyatt, G; Heels-Ansdell, D; Holbrook, A; Lamontagne, F; Levine, MAH; Li, G; Thabane, L; Walter, SD, 2015) |
| "Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding." | 9.20 | Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2015) |
| "The phase III EINSTEIN DVT and EINSTEIN PE trials demonstrated the potential of oral rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)." | 9.19 | Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. ( Bamber, L; Correa de Carvalho, F; Lensing, AW; Prins, M; van Bellen, B; Wang, M, 2014) |
| "Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear." | 9.17 | Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. ( Büller, HR; Décousus, H; Grosso, MA; Mercuri, M; Middeldorp, S; Prins, MH; Raskob, GE; Schellong, SM; Schwocho, L; Segers, A; Shi, M; Verhamme, P; Wells, P, 2013) |
| "Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 9.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
| "Idrabiotaparinux could provide an attractive alternative to warfarin for the long-term treatment of pulmonary embolism, and seems to be associated with reduced bleeding." | 9.16 | Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. ( Büller, HR; Gallus, AS; Pillion, G; Prins, MH; Raskob, GE, 2012) |
| "In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months." | 9.16 | Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. ( Agnelli, G; Berkowitz, SD; Bounameaux, H; Büller, HR; Chlumsky, J; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Jacobson, BF; Lensin, AW; Minar, E; Misselwitz, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2012) |
| "Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation." | 9.14 | Oral rivaroxaban for symptomatic venous thromboembolism. ( Agnelli, G; Bauersachs, R; Berkowitz, SD; Bounameaux, H; Brenner, B; Buller, HR; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Lensing, AW; Misselwitz, F; Piovella, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2010) |
| "Dalteparin 5000 IU once daily halved the rate of venous thromboembolism with a low risk of bleeding." | 9.11 | Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. ( Cohen, AT; Goldhaber, SZ; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2004) |
| "In patients undergoing surgery for hip fracture, fondaparinux was more effective than enoxaparin in preventing venous thromboembolism and equally safe." | 9.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| " The fondaparinux group had a significantly lower incidence of venous thromboembolism by day 11 (12." | 9.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| "This was a prospective cohort study of eligible patients with pulmonary embolism managed as outpatients using dalteparin (200 U/kg s/c daily) for a minimum of five days and warfarin for 3 months." | 9.09 | Outpatient treatment of pulmonary embolism with dalteparin. ( Anderson, D; Gray, L; Kovacs, MJ; Morrow, B; Touchie, D; Wells, PS, 2000) |
| "To compare the effectiveness and safety of fixed-dose enoxaparin and adjusted dose warfarin in preventing venous thromboembolism after knee arthroplasty." | 9.08 | Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. ( Cruickshank, M; Delorme, F; Demers, C; Desjardins, L; Geerts, WH; Kassis, J; L'Espérance, B; Laflamme, GH; Leclerc, JR; Whitman, L, 1996) |
| " with coumarin) is still the most widely used treatment for deep venous thromboembolism." | 9.07 | Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. ( del Rio, L; Lafoz, E; Monreal, M; Olive, A; Vedia, C, 1994) |
| "In the EINSTEIN-Pulmonary Embolism (PE) trial, subjects randomized to rivaroxaban versus enoxaparin bridging to vitamin K antagonist (VKA) therapy experienced a reduced index hospital length of stay (LOS)." | 8.95 | Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. ( Ashton, V; Baugh, CW; Coleman, CI; Crivera, C; Fermann, GJ; Kohn, CG; Peacock, WF; Schein, JR; Wells, PS; Wildgoose, P, 2017) |
| "In conclusion, our results confirmed that direct Xa inhibitors (rivaroxaban and apixaban) were more effective for prevention of VTE after total knee replacement as compared with enoxaparin, without increasing major bleeding risk." | 8.91 | Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. ( Ma, G; Wang, D; Wu, X; Ying, K; Zhang, R, 2015) |
| "A 70-year-old man on enoxaparin and warfarin sodium therapy due to pulmonary embolism was admitted for evaluation of a sudden, sharp pain in the left inguinal region." | 8.82 | Surgical management of enoxaparin- and/or warfarin-induced massive retroperitoneal bleeding: report of a case and review of the literature. ( Anadol, AZ; Gök, A; Topgül, K; Uzun, O, 2005) |
| "Apixaban has a higher rate of major bleeding in patients with luminal GI cancer compared with patients with non-GI cancer and compared with enoxaparin in patients with luminal GI cancer." | 8.02 | Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. ( Brunton, N; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; McBane, RD; Meverden, RA; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2021) |
| "The reduction in inpatient utilization, recurrences, and major bleeding resulting from a 25% shift from standard therapy to rivaroxaban following acute VTE would conserve ∼$860,475 for every 1 million commercial health plan enrollees." | 7.81 | The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism. ( Bookhart, B; Mody, SH; Ogden, K; Patel, AA, 2015) |
| " A multicenter blinded, randomized trial compared the effectiveness of the most common pharmocoprevention strategies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding no difference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill medical-surgical patients who received dalteparin." | 7.80 | Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. ( Arabi, Y; Cade, JF; Chan, B; Cook, D; Cooper, J; Dodek, P; Doig, CJ; Ferguson, ND; Finfer, S; Fowler, RA; Geerts, W; Gould, MK; Guyatt, G; Hall, R; Heels-Ansdell, D; Jacka, MJ; Klinger, JR; Krahn, M; Marshall, JC; McIntyre, L; Mehta, S; Mittmann, N; Muscedere, J; Orford, N; Ormanidhi, O; Pinto, R; Qushmaq, I; Rocha, MG; Seppelt, I; Skrobik, YK; Sud, S; Vlahakis, N, 2014) |
| "Cost considered: the drugs for the prevention of VTE (apixaban, dabigatran, enoxaparin, fondaparinux, other heparins, rivaroxaban and warfarin) and the complications of VTE in the short term and in 5 years (deep vein thrombosis, pulmonary embolism, bleedings and the post-thrombotic syndrome)." | 7.78 | [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012) |
| "The in-hospital incidence of pulmonary embolism (PE) in patients undergoing elective joint arthroplasty who receive a minimum of 10 days of dalteparin prophylaxis is reported to be less than 1%." | 7.76 | High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis. ( Kerr, J; Linkins, LA, 2010) |
| "In ICU patients with renal insufficiency, the incidence of DVT and major bleeding are considerable but appear related to patient comorbidities rather than to an inadequate or excessive anticoagulant from thromboprophylaxis with dalteparin." | 7.74 | Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. ( Albert, M; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Friedrich, J; Geerts, W; Granton, J; Guyatt, G; Hebert, P; Heels-Ansdell, D; Karachi, T; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| "This multicenter, prospective, open label, observational study evaluated practice patterns of physicians using tinzaparin, a low-molecular-weight heparin (LMWH), and warfarin for the treatment of deep venous thrombosis (DVT) with or without pulmonary embolism (PE)." | 7.74 | Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. ( Hyers, TM; Spyropoulos, AC, 2007) |
| "Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence." | 6.90 | Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. ( Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J, 2019) |
| "Although venous thromboembolism is one of the leading causes of morbidity after knee arthroplasty, little data exist on the risk of deep venous thrombosis (DVT) after unicompartmental knee arthroplasty (UKA)." | 6.84 | Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. ( Boettner, F; Mayman, DJ; Pearle, AD; Schmidt-Braekling, T; Waldstein, W; Westrich, GH, 2017) |
| "Symptomatic acute pulmonary embolism treatment with full therapeutic doses of tinzaparin for 6 months is a feasible alternative to conventional treatment with vitamin K antagonists." | 6.75 | Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. ( Colomé-Nafria, E; Golpe, R; Leiro-Fernández, V; Méndez-Marote, L; Núñez-Delgado, JM; Palacios-Bartolomé, A; Pérez-de-Llano, LA, 2010) |
| "Warfarin dosing with a target international normalized ratio (INR) range of 1." | 6.71 | Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. ( Enyart, JJ; Jones, RJ, 2005) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 6.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| "Fondaparinux is a synthetic polysaccharide that selectively binds to antithrombin, the primary endogenous regulator of blood coagulation." | 6.41 | Fondaparinux versus enoxaparin for the prevention of venous thromboembolism. ( Doggrell, SA, 2002) |
| "Compared with no prophylaxis, the use of low-dose warfarin would be expected to reduce the number of cases of confirmed deep-vein thrombosis from about 1000 (per 10,000 patients) to 420 and the number of thromboembolic deaths from about 250 to 110." | 6.17 | Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. ( Colditz, GA; Menzin, J; Oster, G; Regan, MM; Richner, RE, 1995) |
| "Nonischemic CRVO with cystoid macular edema was diagnosed and an intravitreal injection of ranibizumab was performed." | 5.72 | Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case Report. ( Biskup, M; Kal, M; Krupińska, J; Odrobina, D; Płatkowska-Adamska, B, 2022) |
| " We assessed for an effect modification of thromboprophylaxis (dalteparin or unfractionated heparin [UFH]) by sex on thrombotic (deep venous thrombosis [DVT], pulmonary embolism [PE], VTE) and mortality outcomes in a secondary analysis of the Prophylaxis for Thromboembolism in Critical Care Trial (PROTECT)." | 5.69 | Sex differences in thromboprophylaxis of the critically ill: a secondary analysis of a randomized trial. ( Bhuptani, P; Burns, KEA; Cook, DJ; Crowther, MA; Finfer, S; Heels-Ansdell, D; Kahn, SR; Lauzier, F; Mehta, S; Ostermann, M; Thabane, L, 2023) |
| "She was diagnosed with a large pulmonary embolism and was hemodynamically unstable therefore requiring endotracheal intubation and norepinephrine support." | 5.56 | Potential role for furosemide in the treatment of acute respiratory distress syndrome (ARDS) and an unusual presentation of pulmonary embolism in a complex patient. ( Bornstein, G; Zornitzki, L, 2020) |
| "Among patients undergoing hip or knee arthroplasty for osteoarthritis, aspirin compared with enoxaparin resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism." | 5.51 | Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. ( Ackerman, I; Adie, S; Bastiras, D; Brighton, R; Buchbinder, R; Burns, AWR; Cashman, K; Chong, BH; Clavisi, O; Cripps, M; de Steiger, R; Dekkers, M; Dixon, M; Ellis, A; Graves, SE; Griffith, EC; Hale, D; Hansen, A; Harris, A; Harris, IA; Hau, R; Horsley, M; James, D; Kelly, TL; Khorshid, O; Kuo, L; Lewis, P; Lieu, D; Lorimer, M; MacDessi, S; McCombe, P; McDougall, C; Mulford, J; Naylor, JM; Page, RS; Pratt, N; Radovanovic, J; Sidhu, VS; Solomon, M; Sorial, R; Summersell, P; Tran, P; Walter, WL; Webb, S; Wilson, C; Wysocki, D, 2022) |
| "In a randomized open-label noninferiority trial, patients with active cancer who had proximal DVT, pulmonary embolism (PE), or both were assigned randomly to therapeutic doses of rivaroxaban or dalteparin for 3 months." | 5.51 | Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial. ( Aquilanti, S; Bertoletti, L; Brebion, N; Brisot, D; Bura-Rivière, A; Burnod, A; Charles-Nelson, A; Chatellier, G; Constans, J; Couturaud, F; Elias, A; Falvo, N; Girard, P; Grange, C; Laporte, S; Mahé, I; Meyer, G; Mismetti, P; Pernod, G; Planquette, B; Ray, V; Roy, PM; Sanchez, O; Sevestre, MA; Timar-David, M, 2022) |
| "Apixaban is a new oral anticoagulant with the potential to overcome these limitations." | 5.43 | Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. ( Dickison, DM; King, DA; Pow, RE; Vale, PR, 2016) |
| "ESSENTIALS: Does thrombus stability alter the presentation of venous thromboembolism and do anticoagulants alter this? In a murine model, we imaged a femoral vein thrombus and quantified emboli in the pulmonary arteries." | 5.43 | Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. ( Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J, 2016) |
| "We also investigated the occurrence of pulmonary embolism (PE) and its associated risk factors." | 5.42 | Prophylactic effect of fondaparinux and enoxaparin for preventing pulmonary embolism after total hip or knee arthroplasty: A retrospective observational study using the Japanese Diagnosis Procedure Combination database. ( Fushimi, K; Horiguchi, H; Kadono, Y; Matsuda, S; Shoda, N; Tanaka, S; Yasunaga, H, 2015) |
| " Of the eight papers comparing chemical prophylaxis medications in patients with hip or lower limb injuries, fondaparinux and enoxaparin were found to be significantly superior to placebo in respect of prevention of DVT, with no increased risk of bleeding." | 5.41 | The effectiveness of venous thromboembolism prophylaxis interventions in trauma patients: A systematic review and network meta-analysis. ( Jin, J; MacCormick, AD; Peng, S; Zhang, M, 2023) |
| "Priapism is a rare disorder defined as a persistent penile erection that continues hours beyond, or is unrelated to, sexual stimulation." | 5.35 | Stuttering priapism complicating warfarin therapy in a patient with protein C deficiency. ( Abu Sham'a, RA; Kufri, FH; Yassin, IH, 2008) |
| "In this international, parallel-group, randomized, double-blind, noninferiority trial, we randomly assigned adult patients undergoing lower-limb nonmajor orthopedic surgery who were considered to be at risk for venous thromboembolism on the basis of the investigator's judgment to receive either rivaroxaban or enoxaparin." | 5.34 | Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. ( Cucherat, M; Deygas, B; Duverger, D; Fisher, W; Girard, P; Laporte, S; Llau, J; Martínez-Martín, J; Mismetti, P; Mouret, P; Presles, E; Rosencher, N; Samama, CM, 2020) |
| "Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding." | 5.34 | Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Muñoz, A; Sueiro, MR; Torbicki, A; Verso, M; Vescovo, G, 2020) |
| "To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer-associated venous thromboembolism (Ca-VTE), consecutive patients treated with apixaban, rivaroxaban, or enoxaparin at Mayo Thrombophilia Clinic (March 1, 2013 to January 31, 2018)) were followed prospectively." | 5.30 | Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. ( Bott-Kitslaar, DM; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; Mcbane, RD; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2019) |
| "Upper extremity deep vein thrombosis (DVT) is now recognized as a major cause of morbidity and mortality." | 5.30 | Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. ( Cruickshank, M; Goudie, D; Kovacs, MJ; Morrow, B; Savage, KJ; Schulz, V; Wells, PS, 1999) |
| " APEX investigated the efficacy of extended-duration betrixaban versus standard-duration enoxaparin to prevent a composite of symptomatic deep-vein thrombosis (proximal or distal), nonfatal pulmonary embolism, or venous thromboembolism (VTE)-related death in acute medically ill patients (n = 7513)." | 5.24 | Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. ( Arbetter, DF; Cohen, AT; Gibson, CM; Gold, A; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, RD; Jain, P; Michalak, N; Yee, MK, 2017) |
| "The 80-mg betrixaban dose achieves higher plasma concentrations than the 40-mg dose and, in contrast to the 40-mg dose, is associated with improved efficacy across all cohorts relative to standard-dose enoxaparin without an excess risk of major bleeding in the management of medically ill subjects." | 5.24 | The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. ( Arbetter, DF; Bandman, O; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Halaby, R; Harrington, RA; Hernandez, AF; Hull, R; Korjian, S; Leeds, JM; Lu, SP; Yee, MK, 2017) |
| "Sixty-two PE patients with or without deep venous thrombosis (DVT) was randomized to rivaroxaban mono-therapy or standard-therapy with enoxaparin followed by vitamin K antagonist (VKA)." | 5.22 | Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism. ( Chen, R; Duan, L; Guo, Y; Hong, C; Liu, C; Su, X; Yan, H; Yang, X; Zhang, N; Zhong, N; Zhou, Y, 2016) |
| "In the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) trial, apixaban was noninferior to enoxaparin/warfarin in preventing recurrent symptomatic venous thromboembolism (VTE) or venous thromboembolism-related death, with significantly less bleeding." | 5.20 | Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. ( Cohen, AT; Johnson, M; Liu, X; Mardekian, J; Phatak, H; Thompson, J, 2015) |
| " We aimed to perform a competing risk analysis to assess the efficacy of the low molecular weight heparin dalteparin versus unfractionated heparin (UFH) in venous thromboembolism (VTE) in medical-surgical critically ill patients, taking death as a competing risk." | 5.20 | Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients. ( Arabi, YM; Bellomo, R; Cook, DJ; Cooper, DJ; Crowther, M; Ferguson, ND; Finfer, S; Guyatt, G; Heels-Ansdell, D; Holbrook, A; Lamontagne, F; Levine, MAH; Li, G; Thabane, L; Walter, SD, 2015) |
| "Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding." | 5.20 | Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2015) |
| "The phase III EINSTEIN DVT and EINSTEIN PE trials demonstrated the potential of oral rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)." | 5.19 | Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. ( Bamber, L; Correa de Carvalho, F; Lensing, AW; Prins, M; van Bellen, B; Wang, M, 2014) |
| "Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear." | 5.17 | Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. ( Büller, HR; Décousus, H; Grosso, MA; Mercuri, M; Middeldorp, S; Prins, MH; Raskob, GE; Schellong, SM; Schwocho, L; Segers, A; Shi, M; Verhamme, P; Wells, P, 2013) |
| "Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 5.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
| "Idrabiotaparinux could provide an attractive alternative to warfarin for the long-term treatment of pulmonary embolism, and seems to be associated with reduced bleeding." | 5.16 | Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. ( Büller, HR; Gallus, AS; Pillion, G; Prins, MH; Raskob, GE, 2012) |
| "In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months." | 5.16 | Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. ( Agnelli, G; Berkowitz, SD; Bounameaux, H; Büller, HR; Chlumsky, J; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Jacobson, BF; Lensin, AW; Minar, E; Misselwitz, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2012) |
| "In this double-blind, double-dummy, placebo-controlled trial, we randomly assigned acutely ill patients who had congestive heart failure or respiratory failure or other medical disorders and at least one additional risk factor for venous thromboembolism and who were hospitalized with an expected stay of at least 3 days to receive apixaban, administered orally at a dose of 2." | 5.15 | Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. ( Goldhaber, SZ; Haas, SK; Kakkar, AK; Knabb, RM; Leizorovicz, A; Merli, G; Weitz, JI, 2011) |
| "Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation." | 5.14 | Oral rivaroxaban for symptomatic venous thromboembolism. ( Agnelli, G; Bauersachs, R; Berkowitz, SD; Bounameaux, H; Brenner, B; Buller, HR; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Lensing, AW; Misselwitz, F; Piovella, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2010) |
| "We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty." | 5.13 | Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. ( Ageno, W; Bandel, TJ; Borris, LC; Lassen, MR; Lieberman, JR; Misselwitz, F; Rosencher, N; Turpie, AG, 2008) |
| "This study aimed to determine whether a weight-adjusted dose of subcutaneous enoxaparin is as effective and safe as oral acenocoumarol for the secondary prophylaxis of pulmonary embolism." | 5.12 | Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism. ( Castro, DJ; Díaz, G; Escobar, C; García-Rull, S; Martí, D; Ortega, J; Picher, J; Sueiro, A, 2007) |
| "Dalteparin 5000 IU once daily halved the rate of venous thromboembolism with a low risk of bleeding." | 5.11 | Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. ( Cohen, AT; Goldhaber, SZ; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2004) |
| "Evaluation of the effectiveness and safety of the low molecular weight heparin (LMWH) tinzaparin versus unfractionated heparin (UFH) followed by acenocoumarol in proximal deep venous thrombosis (DVT)." | 5.11 | Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. ( Daskalopoulos, ME; Daskalopoulou, SS; Dimitroulis, D; Kakissis, I; Liapis, CD; Nikolaou, A; Sfiridis, P; Tzortzis, E, 2005) |
| "In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral anticoagulant in reducing the risk of recurrent thromboembolism without increasing the risk of bleeding." | 5.10 | Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. ( Baker, RI; Bowden, C; Gent, M; Haley, S; Julian, JA; Kakkar, AK; Kovacs, MJ; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2003) |
| "We compared enoxaparin and adjusted-dose warfarin with respect to their safety and their efficacy in the prevention of clinically important venous thromboembolic disease, defined as distal or proximal deep venous thrombosis or pulmonary embolism, or both, during hospitalization after total hip arthroplasty." | 5.09 | Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. ( Bigler, GT; Collis, DK; Colwell, CW; Hardwick, ME; Lutz, S; McCutchen, JW; Paulson, R, 1999) |
| " Rates of overall venous thromboembolism (and proximal deep vein thrombosis or pulmonary embolism) for the 8-, 12-, 18-, and 24-mg doses of ximelagatran were 27% (6." | 5.09 | Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. ( Berkowitz, SD; Colwell, CW; Francis, CW; Ginsberg, JS; Heit, JA; Peters, G; Whipple, J, 2001) |
| "In patients undergoing surgery for hip fracture, fondaparinux was more effective than enoxaparin in preventing venous thromboembolism and equally safe." | 5.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| " The fondaparinux group had a significantly lower incidence of venous thromboembolism by day 11 (12." | 5.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| "This was a prospective cohort study of eligible patients with pulmonary embolism managed as outpatients using dalteparin (200 U/kg s/c daily) for a minimum of five days and warfarin for 3 months." | 5.09 | Outpatient treatment of pulmonary embolism with dalteparin. ( Anderson, D; Gray, L; Kovacs, MJ; Morrow, B; Touchie, D; Wells, PS, 2000) |
| "To compare the effectiveness and safety of fixed-dose enoxaparin and adjusted dose warfarin in preventing venous thromboembolism after knee arthroplasty." | 5.08 | Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. ( Cruickshank, M; Delorme, F; Demers, C; Desjardins, L; Geerts, WH; Kassis, J; L'Espérance, B; Laflamme, GH; Leclerc, JR; Whitman, L, 1996) |
| "The purpose of this study was to compare the efficacy and safety of treating mobile iliofemoral patients with deep venous thrombosis (DVT) with subcutaneous low-molecular-weight heparin (dalteparin sodium) either 200 IU/kg once-daily (group 1) or 100 IU/kg twice-daily (group 2)." | 5.08 | Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin. ( Kechavarz, B; Köhn, H; Lipp, C; Mostbeck, A; Partsch, H, 1996) |
| " with coumarin) is still the most widely used treatment for deep venous thromboembolism." | 5.07 | Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. ( del Rio, L; Lafoz, E; Monreal, M; Olive, A; Vedia, C, 1994) |
| " This study aims to use a network meta-analysis to compare effects of 9 anticoagulant drugs (edoxaban, dabigatan, apixaban, rivaroxaban, warfarin, heparin, bemiparin, ximelagatran, and enoxaparin) in preventing postoperative complications in arthroplasty patients." | 4.95 | Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. ( Chu, XC; Gao, JH; Ning, B; Wang, LL; Zhao, CX, 2017) |
| "In the EINSTEIN-Pulmonary Embolism (PE) trial, subjects randomized to rivaroxaban versus enoxaparin bridging to vitamin K antagonist (VKA) therapy experienced a reduced index hospital length of stay (LOS)." | 4.95 | Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. ( Ashton, V; Baugh, CW; Coleman, CI; Crivera, C; Fermann, GJ; Kohn, CG; Peacock, WF; Schein, JR; Wells, PS; Wildgoose, P, 2017) |
| "In conclusion, our results confirmed that direct Xa inhibitors (rivaroxaban and apixaban) were more effective for prevention of VTE after total knee replacement as compared with enoxaparin, without increasing major bleeding risk." | 4.91 | Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. ( Ma, G; Wang, D; Wu, X; Ying, K; Zhang, R, 2015) |
| "A 70-year-old man on enoxaparin and warfarin sodium therapy due to pulmonary embolism was admitted for evaluation of a sudden, sharp pain in the left inguinal region." | 4.82 | Surgical management of enoxaparin- and/or warfarin-induced massive retroperitoneal bleeding: report of a case and review of the literature. ( Anadol, AZ; Gök, A; Topgül, K; Uzun, O, 2005) |
| " My physician recommended I use dalteparin during this pregnancy although, during my previous pregnancy, I had received subcutaneous heparin injections three times daily." | 4.82 | Low-molecular-weight heparins during pregnancy. ( Koren, G; Many, A, 2005) |
| "Dalteparin is an LMWH indicated for patients undergoing abdominal surgery who are considered to be at risk for deep-vein thrombosis (DVT), which may lead to pulmonary embolism (PE)." | 4.79 | Dalteparin: a low-molecular-weight heparin. ( Howard, PA, 1997) |
| " The incidence of VTE and hematoma formation was evaluated and compared between patients who received aspirin versus enoxaparin or heparin." | 4.12 | Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular Fractures? ( Du, JY; Metcalf, KB; Ochenjele, G, 2022) |
| "Apixaban has a higher rate of major bleeding in patients with luminal GI cancer compared with patients with non-GI cancer and compared with enoxaparin in patients with luminal GI cancer." | 4.02 | Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. ( Brunton, N; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; McBane, RD; Meverden, RA; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2021) |
| " The aim of our study was to evaluate the clinical impact of venous thromboembolism prophylaxis with fondaparinux versus enoxaparin among 100 hospitalized COVID-19 patients." | 3.96 | Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience. ( Agrusta, F; Amitrano, M; Bellizzi, A; Cardillo, G; Cavalli, A; Di Micco, P; Fontanella, A; Iannuzzo, M; Lodigiani, C; Mangiacapra, S; Russo, V; Sacco, C; Viggiano, GV, 2020) |
| "5mg/kg subcutaneously daily for recent pulmonary embolism and deep vein thrombosis that developed while on warfarin therapy previously." | 3.85 | Pharmacological management of cerebral venous sinus thrombosis with full-dose IV heparin infusion and its clinical outcomes. ( Fernandez, A; Ho, J; Mckeone, A; Nair, V, 2017) |
| " We report a rare case of spontaneous rupture of liver hematoma in patient treated with warfarin end enoxaparin sodium because of pulmonary embolism." | 3.85 | Spontaneous liver rupture associated with anticoagulant therapy A case report. ( Amicucci, G; Clementi, M; Colozzi, S; Della Penna, A; Guadagni, S; Pessia, B; Schietroma, M; Sista, F, 2017) |
| "There was no evidence that fondaparinux, enoxaparin, or warfarin were superior to aspirin in the prevention of pulmonary embolism, deep vein thrombosis, or venous thromboembolism or that aspirin was safer than these alternatives." | 3.85 | Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty. ( Bini, SA; Cafri, G; Cheetham, CT; Chen, Y; Gould, MK; Khatod, M; Paxton, EW; Sluggett, J, 2017) |
| "The Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism (RECORD) 1 to 4 trials compared rivaroxaban 10 mg daily with commonly used doses of enoxaparin and demonstrated similar rates of VTE and bleeding." | 3.83 | Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban or Enoxaparin. ( Cluck, D; Cornett, L; El-Bazouni, H; Freshour, J; Odle, B; Ricket, AL; Stewart, DW; Wood, RC, 2016) |
| "01) the rate of transfusion, units of packed red blood cells, hemoglobin drop, and hematocrit drop compared to aspirin in both unilateral and bilateral TKA patients, without significantly decreasing venous thromboembolism events (aspirin: 3 pulmonary embolisms and 4 deep venous thrombosis; Lovenox: 3 pulmonary embolisms and 2 deep venous thrombosis)." | 3.83 | Rate of Transfusions After Total Knee Arthroplasty in Patients Receiving Lovenox or High-Dose Aspirin. ( Hall, KE; Nakasone, CK; Radzak, KN; Wages, JJ, 2016) |
| "The reduction in inpatient utilization, recurrences, and major bleeding resulting from a 25% shift from standard therapy to rivaroxaban following acute VTE would conserve ∼$860,475 for every 1 million commercial health plan enrollees." | 3.81 | The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism. ( Bookhart, B; Mody, SH; Ogden, K; Patel, AA, 2015) |
| " She is currently on warfarin, with which she has been adequately controlled most of the time, presenting with only one haemorrhagic event consisting of haematuria and prolonged international normalised ratio (INR) without bleeding." | 3.81 | Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher? ( Baquero-Salamanca, M; Calderon-Ospina, C; Téllez-Arévalo, AM, 2015) |
| " A multicenter blinded, randomized trial compared the effectiveness of the most common pharmocoprevention strategies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding no difference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill medical-surgical patients who received dalteparin." | 3.80 | Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. ( Arabi, Y; Cade, JF; Chan, B; Cook, D; Cooper, J; Dodek, P; Doig, CJ; Ferguson, ND; Finfer, S; Fowler, RA; Geerts, W; Gould, MK; Guyatt, G; Hall, R; Heels-Ansdell, D; Jacka, MJ; Klinger, JR; Krahn, M; Marshall, JC; McIntyre, L; Mehta, S; Mittmann, N; Muscedere, J; Orford, N; Ormanidhi, O; Pinto, R; Qushmaq, I; Rocha, MG; Seppelt, I; Skrobik, YK; Sud, S; Vlahakis, N, 2014) |
| "Our institution has used a thromboprophylaxis regimen consisting of inpatient enoxaparin and outpatient aspirin for patients at standard risk for venous thrombosis after hip and knee arthroplasty." | 3.78 | Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study. ( Anderson, BJ; Bradbury, TL; Erens, GA; Hamilton, SC; Roberson, JR; Whang, WW, 2012) |
| "Cost considered: the drugs for the prevention of VTE (apixaban, dabigatran, enoxaparin, fondaparinux, other heparins, rivaroxaban and warfarin) and the complications of VTE in the short term and in 5 years (deep vein thrombosis, pulmonary embolism, bleedings and the post-thrombotic syndrome)." | 3.78 | [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012) |
| "The risk of late thrombosis and pulmonary embolism is discussed from pathogenetic factors and data on frequencies of thromboembolic complications in the literature." | 3.78 | Prolonged prophylaxis against postoperative venous thromboembolism. ( Bergqvist, D, 1996) |
| " We report a case of HIT in a postoperative orthopedic 75-year-old woman in treatment with LMWH (nadroparin) complicated by pulmonary embolism and treated successfully with recombinant hirudin." | 3.76 | Heparin-induced thrombocytopenia associated with pulmonary embolism. ( Cei, M; Mumoli, N, 2010) |
| "The in-hospital incidence of pulmonary embolism (PE) in patients undergoing elective joint arthroplasty who receive a minimum of 10 days of dalteparin prophylaxis is reported to be less than 1%." | 3.76 | High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis. ( Kerr, J; Linkins, LA, 2010) |
| "In the initial treatment of venous thromboembolism (VTE) fondaparinux, a pentasaccharide, is a good alternative to heparin." | 3.75 | Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; van Doormaal, FF, 2009) |
| "In ICU patients with renal insufficiency, the incidence of DVT and major bleeding are considerable but appear related to patient comorbidities rather than to an inadequate or excessive anticoagulant from thromboprophylaxis with dalteparin." | 3.74 | Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. ( Albert, M; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Friedrich, J; Geerts, W; Granton, J; Guyatt, G; Hebert, P; Heels-Ansdell, D; Karachi, T; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| "This multicenter, prospective, open label, observational study evaluated practice patterns of physicians using tinzaparin, a low-molecular-weight heparin (LMWH), and warfarin for the treatment of deep venous thrombosis (DVT) with or without pulmonary embolism (PE)." | 3.74 | Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. ( Hyers, TM; Spyropoulos, AC, 2007) |
| "To compare the efficacy of dalteparin, a low-molecular-weight heparin, to unfractionated heparin (UFH) in the prevention of deep venous thrombosis (DVT) and pulmonary embolism in patients after surgery for gynecologic malignancy." | 3.73 | Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy. ( DeBernardo, RL; Duska, LR; Krasner, CN; Littell, RD; Perkins, RB, 2005) |
| " The initial treatment consisted of a 7-day course of subcutaneous dalteparin according to body weight." | 3.72 | Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. ( Jiménez, JA; Monreal, M; Roncales, J; Vilaseca, B; Zacharski, L, 2004) |
| "No DVT developed in COVID-19 patients hospitalized in general wards, independently of enoxaparin dosing used for thromboprophylaxis." | 3.11 | Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial. ( Agostinis, M; Antolini, L; Barberis, D; Birocchi, S; Bonacchini, L; Carioti, G; Cattaneo, M; Gazzaniga, G; Grazia Valsecchi, M; Massaini, G; Merli, M; Morici, N; Podda, G; Saverio Serino, F; Trezzi, M, 2022) |
| "Patients with active cancer have a 4-sevenfold increased risk for venous thromboembolism (VTE) especially during systematic anticancer treatment." | 3.11 | Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study. ( Charalambakis, N; Kosmas, C; Lianos, E; Liatsos, AN; Mazlimoglou, E; Papageorgiou, G; Pouliakis, A; Simeonidis, D; Xynogalos, S; Ziras, N, 2022) |
| "To determine whether the presence of multiple renal clearance estimates affects pharmacist drug dosing decisions." | 3.01 | The Impact of Multiple Renal Estimates on Pharmacist Dosing Recommendations: A Randomized Trial. ( Hanni, CM; McConachie, SM; Mohammad, RA; Raub, JN; Wilhelm, SM, 2021) |
| "Proximal deep vein thrombosis and/or pulmonary embolism occurred in seven patients (3·4 per cent) in the IPC group and one patient (0·5 per cent) in the IPC with enoxaparin group (P = 0·050)." | 2.94 | Intermittent pneumatic compression versus additional prophylaxis with enoxaparin for prevention of venous thromboembolism after laparoscopic surgery for gastric and colorectal malignancies: multicentre randomized clinical trial. ( Amano, T; Funakoshi, T; Homma, S; Ichikawa, N; Kamachi, H; Kawamura, H; Maeda, Y; Ohno, Y; Takahashi, N; Taketomi, A; Yokota, R; Yoshida, T, 2020) |
| "Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence." | 2.90 | Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. ( Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J, 2019) |
| "The primary outcome was deep vein thrombosis (DVT) identified by color Doppler ultrasonography and/or pulmonary embolism (PE)." | 2.84 | Enoxaparin versus No Anticoagulation Prophylaxis after Total Knee Arthroplasty in Thai Patients: A Randomized Controlled Trial. ( Intiyanaravut, T; Kunopart, M; Sinthuvanich, N; Teavirat, S; Thongpulsawasdi, N, 2017) |
| "Although venous thromboembolism is one of the leading causes of morbidity after knee arthroplasty, little data exist on the risk of deep venous thrombosis (DVT) after unicompartmental knee arthroplasty (UKA)." | 2.84 | Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. ( Boettner, F; Mayman, DJ; Pearle, AD; Schmidt-Braekling, T; Waldstein, W; Westrich, GH, 2017) |
| "No episodes of transfusion, pulmonary embolism, or major bleeding occurred in either group." | 2.84 | Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study. ( Huang, Q; Ma, J; Pei, F; Xie, J; Yue, C, 2017) |
| " Analysis 3 compared standard dosing to dose adjustment with the primary outcome being anti-Xa adequacy; secondary outcomes were VTE, pulmonary embolism, and bleeding complications." | 2.82 | Relationship between anti-Xa level achieved with prophylactic low-molecular weight heparin and venous thromboembolism in trauma patients: A systematic review and meta-analysis. ( Anantha, RV; Connell, M; Kung, JY; Parker, A; Raffael, K; Strickland, M; Verhoeff, K, 2022) |
| "The incidence of symptomatic VTE (deep vein thrombosis and pulmonary embolism) events was lower (0/377) in participants who received bemiparin than in those who received no pharmacologic intervention (12/380, 3." | 2.80 | Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial. ( Al Tawil, NG; Alalaf, SK; Ali, MS; Jawad, AK; Jawad, RK, 2015) |
| "The Hokusai VTE-cancer study is a randomised, open-label, clinical trial to evaluate whether edoxaban, an oral factor Xa inhibitor, is non-inferior to LMWH for treatment of VTE in patients with cancer." | 2.80 | Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. ( Beyer-Westendorf, J; Bleker, SM; Boda, Z; Büller, HR; Carrier, M; Chlumsky, J; Décousus, H; Di Nisio, M; Garcia, D; Gibbs, H; Grosso, MA; Kakkar, A; Kamphuisen, PW; Mercuri, MF; Monreal, M; Ockelford, P; Pabinger, I; Raskob, GE; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Weitz, JI, 2015) |
| "In the group of patients without pulmonary embolism at baseline, 2." | 2.79 | Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin. ( Becker, LK; Harenberg, J; Melzer, N; Riess, H, 2014) |
| " The authors hypothesize that early chemoprophylaxis in patients with TBI is safe and efficacious." | 2.78 | Safety and efficacy of early thromboembolism chemoprophylaxis after intracranial hemorrhage from traumatic brain injury. ( Barnes, SL; Farooqui, A; Hiser, B; Litofsky, NS, 2013) |
| "Traditionally, patients with pulmonary embolism (PE) are initially treated in the hospital with low molecular weight heparin (LMWH)." | 2.76 | Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. ( Creemers-Schild, D; de Vreede, MJ; Dekkers, OM; Dolsma, J; Eijsvogel, M; Faber, LM; Hofstee, HM; Hoogerbrugge, AD; Hovens, MM; Huisman, MV; Jonkers, GJ; Kruip, MJ; Mos, IC; van Kralingen, KW; Vlasveld, T; Zondag, W, 2011) |
| "In selected low-risk patients with pulmonary embolism, outpatient care can safely and effectively be used in place of inpatient care." | 2.76 | Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. ( Aujesky, D; Beer, HJ; Cornuz, J; Egloff, M; Fine, MJ; Hugli, O; Legall, C; N'gako, A; Osterwalder, J; Perrier, A; Pugh, NA; Renaud, B; Righini, M; Roy, PM; Sanchez, O; Stone, RA; Verhamme, P; Verschuren, F; Yealy, DM, 2011) |
| " The first received low-molecular-weight heparin for 10 days at therapeutic dosage (nadroparin 180 anti-activated factor X units once daily) and compression therapy for three months, and the second received compression therapy alone." | 2.75 | Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study. ( Beyer, J; Buschmann, L; Halbritter, K; Rastan, A; Schellong, S; Schwarz, T, 2010) |
| "Fondaparinux has a low allergenic potential." | 2.75 | Low allergenic potential with fondaparinux: results of a prospective investigation. ( Boehncke, WH; Garbaraviciene, J; Hecking, C; Kaufmann, R; Kroll, H; Lindhoff-Last, E; Ludwig, RJ; Marzi, I; Scheuermann, J; Schindewolf, M; Wolter, M, 2010) |
| "In acutely ill medical patients of at least 40 years of age, thromboprophylaxis with certoparin 3000 IU daily is effective and safe in comparison with 7500 IU twice daily UFH." | 2.75 | An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. ( Abletshauser, C; Bramlage, P; Greinacher, A; Haas, S; Riess, H; Schellong, SM; Schwanebeck, U; Sieder, C, 2010) |
| "Edoxaban is a new oral direct factor Xa inhibitor." | 2.75 | Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. ( Bocanegra, T; Cohen, AT; Eriksson, BI; Puskas, D; Raskob, G; Shi, M; Weitz, JI, 2010) |
| "Symptomatic acute pulmonary embolism treatment with full therapeutic doses of tinzaparin for 6 months is a feasible alternative to conventional treatment with vitamin K antagonists." | 2.75 | Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. ( Colomé-Nafria, E; Golpe, R; Leiro-Fernández, V; Méndez-Marote, L; Núñez-Delgado, JM; Palacios-Bartolomé, A; Pérez-de-Llano, LA, 2010) |
| " The betrixaban dosage was blinded, but enoxaparin was not." | 2.74 | A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). ( Bauer, KA; Davidson, BL; Fisher, WD; Gent, M; Gretler, DD; Huo, MH; Sinha, U; Turpie, AG, 2009) |
| "There were not differences on pulmonary embolism extension, (P 0." | 2.74 | Improving adjunctive treatment in pulmonary embolism and fibrinolytic therapy. The role of enoxaparin and weight-adjusted unfractionated heparin. ( Archondo, T; Arriaga, R; Bermudez, M; Castillo, F; Comparan-Nuñez, A; Garcia, H; Garcia, J; Garcia-Sosa, A; Garza, A; Gutierrez, J; Hernandez, JM; Jasso, O; Jerjes-Sánchez, C; Martinez, P; Miguel-Canseco, L; Ramírez-Rivera, A; Rangel, F; Reyes, E; Villarreal-Umaña, S, 2009) |
| "Acute pulmonary embolism (APE) causes right ventricular dysfunction (RVD)." | 2.73 | Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism. ( Dai, H; Pang, B; Tong, Z; Wang, C; Wu, Y; Yang, Y; Zhai, Z; Zhu, L, 2008) |
| "There are limited data on appropriate dosing of low-molecular-weight heparins (LMWHs) for venous thromboembolism (VTE) prophylaxis in bariatric surgery." | 2.73 | Prophylaxis of thromboembolism in bariatric surgery with parnaparin. ( Cuocolo, A; De Caterina, M; Ferrari, P; Forestieri, P; Formato, A; Pilone, V; Quarto, G; Ruocco, A, 2007) |
| "A significant dose-response effect for VTE was observed for SR123781A (p < 0." | 2.73 | SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study. ( Dahl, O; Lassen, MR; Mismetti, P; Turpie, AG; Zielske, D, 2008) |
| " The primary efficacy analysis did not demonstrate any significant trend in dose-response relationship for BAY 59-7939." | 2.72 | Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. ( Borris, L; Dahl, OE; Eriksson, BI; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Misselwitz, F, 2006) |
| "Patients with stroke are at substantial risk of thromboembolic complications and therefore require antithrombotic prophylaxis." | 2.72 | Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. ( Brom, J; Csányi, A; Diener, HC; Harenberg, J; Klingelhöfer, J; Koppenhagen, K; Landgraf, H; Rektor, I; Ringelstein, EB; Schneider, D; von Kummer, R; Weidinger, G, 2006) |
| "Pulmonary embolism was discovered at autopsy in 10 of 63 patients in the nadroparin group and in 17 of 60 in the placebo group [relative risk reduction 0." | 2.71 | Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study. ( Bergmann, JF; Caulin, C; d'Azémar, P; Mahé, I; Vaissie, JJ, 2005) |
| "Ximelagatran was to be initiated within the first two postoperative days." | 2.71 | Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. ( Agnelli, G; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Frison, L; Mouret, P; Nylander, I; Ogren, M; Rosencher, N, 2003) |
| "We randomized 60 symptomatic pulmonary embolism patients in a 2:1 ratio to 90 days of enoxaparin as monotherapy without warfarin (N=40) or to intravenous unfractionated heparin as a "bridge" to warfarin, target INR 2." | 2.71 | Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. ( Beckman, JA; Dunn, K; Goldhaber, SZ; Sasahara, AA, 2003) |
| "Incidences of recurrence of thromboembolism and of severe bleeding were assessed at the end of this period." | 2.71 | [Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism]. ( Baloira Villar, A; Golpe Gómez, R; Pajuelo Fernández, F; Pérez de Llano, LA; Veiga, F; Veres Racamonde, A, 2003) |
| "When there was a suspicion of pulmonary embolism (PE), patients were evaluated with spiral computed tomography." | 2.71 | Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin. ( Bilsel, Y; Buyukkurt, D; Granit, V; Guloglu, R; Kizilirmak, S; Kurtoglu, M; Yanar, H, 2004) |
| "Warfarin dosing with a target international normalized ratio (INR) range of 1." | 2.71 | Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. ( Enyart, JJ; Jones, RJ, 2005) |
| "The incidences of fatal pulmonary embolism and death in surgical patients receiving low-molecular-weight heparin thromboprophylaxis have not been previously determined in large, adequately designed clinical trials and information on the relative efficacy and safety of unfractionated and low-molecular-weight heparin in preventing these clinical endpoints is not available." | 2.71 | Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin. ( Encke, A; Fareed, J; Haas, S; Kakkar, AK; Wolf, H, 2005) |
| "Fatal pulmonary embolism was significantly more frequent in cancer patients (0." | 2.71 | Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. ( Encke, A; Haas, S; Kakkar, AK; Wolf, H, 2005) |
| "DUSG showed deep venous thrombosis (DVT) on the 7th postoperative day in 10 patients in Group 1, in 8 patients in Group 2 and in 3 patients in Group 3." | 2.70 | [Thromboembolic prophylaxis after major abdominal surgery]. ( Adigüzel, H; Balik, AA; Başoğlu, M; Celebi, F; Oren, D; Yildirgan, MI, 2001) |
| "Venous thromboembolism is a frequent complication of total hip replacement." | 2.70 | A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. ( Gallus, AS; Hoek, JA; Turpie, AG, 2001) |
| "To determine the specificity of pulmonary embolism (PE) symptoms and lung scan perfusion defects in patients with deep vein thrombosis (DVT), we analyzed data on 400 patients with phlebography-proven proximal DVT included in a prospective trial." | 2.70 | Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy. ( Buchmuller, A; Decousus, M; Girard, P; Hervé, P; Lamer, C; Laporte, S; Parent, F; Tardy, B, 2001) |
| "Low-molecular-weight heparins are frequently used to treat venous thromboembolism, but optimal dosing regimens and clinical outcomes need further definition." | 2.70 | Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. ( Breddin, HK; Hach-Wunderle, V; Kakkar, VV; Nakov, R, 2001) |
| "The composite endpoint of screened deep vein thrombosis (DVT) and symptomatic pulmonary embolism (PE) during prophylaxis did not differ significantly between patients with or without these mutations." | 2.70 | Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. ( Andersson, C; Bylock, A; Eriksson, BI; Frison, L; Gustafsson, D; Larson, G; Lindahl, TL; Wåhlander, K, 2002) |
| "Bleedings were all minor, mostly during hospital stay." | 2.69 | Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. ( Barsotti, A; Belcaro, G; Cesarone, MR; Christopoulos, D; Corsi, M; De Sanctis, MT; Incandela, L; Laurora, G; Lennox, A; Malouf, M; Nicolaides, AN; Vasdekis, S, 1999) |
| "Both regimens were equally safe and the risk of clinically evident DVT and PE was similar." | 2.69 | Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients. ( Büchler, MW; Egger, B; Naef, M; Schmid, SW; Wildi, S, 2000) |
| " Following is an overview of major insights from the prophylaxis in Medical patients with Enoxaparin (MEDENOX) trial, which was undertaken to evaluate the efficacy of 2 dosage regimens of the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism in acutely ill medical patients." | 2.69 | Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. ( Turpie, AG, 2000) |
| "Bleeding was determined according to pre-defined objective criteria for major and minor episodes." | 2.68 | Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. ( Büller, HR; d'Azemar, P; Gent, M; Haley, S; Henkens, CM; Hoek, JA; Koopman, MM; Nurmohamed, MT; Que, GT; Sicurella, A; ten Cate, JW; Turpie, AG; van der Heul, C; van der Meer, J; van Riel, AM, 1996) |
| "There was only one pulmonary embolism (PE) in a patient belonging to UH-group (1." | 2.68 | Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement. ( Avikainen, V; Hakkinen, S; Kaaja, R; Kaira, P; Partio, E; Usenius, JP; von Bonsdorff, H, 1995) |
| "Distal and proximal thrombosis, pulmonary embolism, and hemorrhage were also recorded, as were deaths." | 2.68 | Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. ( Benoni, G; Bergqvist, D; Björgell, O; Fredin, H; Hedlundh, U; Nicolas, S; Nilsson, P; Nylander, G, 1996) |
| "The incidence of silent pulmonary embolism (PE) (new defect on V/Q scan) was 28% (8 out of 29) in patients with and 5% (2 out of 43) in patients without DVT (chi 2; p < 0." | 2.68 | Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. ( al-Kutoubi, A; Birch, R; Cunningham, DA; Fareed, J; Gill, K; Harris, N; Hoppensteadt, DA; Hunt, D; Johnson, J; Kalodiki, EP; Marx, C; Nicolaides, AN; Regan, F, 1996) |
| "However, its application to pulmonary embolism or previous episodes of thromboembolism has not been studied." | 2.68 | Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. ( Baildon, R; Büller, HR; Gallus, AS; Gent, M; Ginsberg, J; Prins, MH, 1997) |
| "There was no pulmonary embolism recurrence nor major bleeding in either group during the treatment period." | 2.68 | Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. ( Brenot, F; Charbonnier, B; Gillet Juvin, K; Meyer, G; Pacouret, G; Simonneau, G; Sors, H, 1995) |
| "The incidence of DVT and of pulmonary embolism was 4." | 2.67 | An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group. ( Boneu, B, 1993) |
| " In a prospective randomized trial involving 122 consecutive patients, group A (58 patients) received a weight adjusted dose of Fragmin (100 IU/kg) subcutaneously twice a day throughout the treatment period (10 days +/- 1), while in group B (64 patients) the dosage was based on the results of an anti factor Xa (anti Xa) amidolytic assay to obtain a target concentration from 0." | 2.67 | Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group. ( Aiach, M; Alhenc-Gelas, M; Fiessinger, JN; Jestin-Le Guernic, C; Kher, A; Vitoux, JF, 1994) |
| "Patients with immune thrombocytopenia are at risk of both bleeding complications and venous thromboembolism." | 2.66 | Bilateral Pulmonary Embolism With Right Heart Strain in a Patient With Immune Thrombocytopenia-A Case Report and Review of the Literature. ( Brodsky, RA; Haines, C; Hui, C, 2020) |
| "In THA patients, the rate of deep vein thrombosis (DVT) was lower with factor Xa inhibitors than LMWH." | 2.61 | Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. ( Cheng, K; Jia, J; Liang, Q; Sun, G; Wang, Q; Wang, Z; Wu, J, 2019) |
| "No significant increase in major intracranial hemorrhage (p = 0." | 2.58 | Chemical venous thromboembolism prophylaxis in neurosurgical patients: an updated systematic review and meta-analysis. ( Khan, NR; Lee, SL; Patel, PG; Sharpe, JP; Sorenson, J, 2018) |
| "Venous thromboembolism, specifically pulmonary embolism, is a rare complication following elective pediatric orthopedic surgery." | 2.58 | Symptomatic bilateral pulmonary embolism without deep venous thrombosis in an adolescent following arthroscopic anterior cruciate ligament reconstruction: a case report and review of the literature. ( Bourget-Murray, J; Clarke, MA; Gorzitza, S; Phillips, LA, 2018) |
| "Individualised drug dosing has been shown to improve patient outcomes and reduce adverse drug events." | 2.55 | Individualised medicine: why we need Bayesian dosing. ( Barras, MA; Donagher, J; Martin, JH, 2017) |
| " Recently, the use of safe-dose recombinant tissue-type plasminogen activator (rTPA) has been proposed for the treatment of moderate PE demonstrating to be safe and more effective than standard anticoagulation." | 2.50 | [Safe dose rTPA for massive pulmonary embolism associated with high bleeding risk: a case report and review of the literature]. ( Cannone, M; La Torre, PP; Mele, A; Mele, M, 2014) |
| "No major bleeding was observed in the patients treated with LMWH or warfarin and in less than 1% of those treated with aspirin." | 2.50 | Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. ( Di Nisio, M; Otten, HM; Porreca, E; Rutjes, AW, 2014) |
| " Of note, for both filters and augmented pharmacologic dosing strategies, patients at highest risk for VTE were more likely to receive more intensive interventions, limiting our ability to attribute outcomes to prophylactic strategies used." | 2.49 | Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis. ( Brotman, DJ; Chelladurai, Y; Haut, ER; Kebede, S; Prakasa, KR; Segal, JB; Sharma, R; Shermock, K; Shihab, HM; Singh, S, 2013) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 2.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| "The incidence of deep vein thrombosis (DVT) varies from 5 to 63% depending on patients' risk factors, modality of prophylaxis, and methods of detection." | 2.44 | Postinjury thromboprophylaxis. ( Balogh, Z; Bendinelli, C, 2008) |
| "Rivaroxaban (BAY 59-7939) is an oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of venous thromboembolism (VTE)." | 2.44 | Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. ( Bauer, KA; Borris, L; Dahl, OE; Eriksson, BI; Fisher, WD; Gent, M; Haas, S; Homering, M; Huisman, MV; Kakkar, AK; Kälebo, P; Kwong, LM; Misselwitz, F; Turpie, AG, 2007) |
| "Literature review concerning pulmonary embolism of polymethylmethacrylate (PMMA) material following percutaneous vertebroplasty and a report on 2 new cases." | 2.44 | Delayed presentation of pulmonary polymethylmethacrylate emboli after percutaneous vertebroplasty. ( Abdul-Jalil, Y; Alberti, O; Bartels, J; Becker, R, 2007) |
| "Venous thrombosis is a common disease." | 2.44 | Anticoagulant treatment of deep vein thrombosis and pulmonary embolism. ( Ginsberg, J; McRae, S; Tran, H, 2008) |
| "Retroperitoneal hematomas are often fatal, and treatment involves aggressive fluid resuscitation with possible surgical decompression." | 2.43 | Massive retroperitoneal hematoma during enoxaparin treatment of pulmonary embolism after primary total hip arthroplasty: case reports and review of the literature. ( Lee, MC; Limbird, RS; Nickisch, F, 2006) |
| " Due to a longer plasma half life together with high bioavailability and a linear dose-response relationship, the drugs can be safely and effectively administered in the hospital or ambulatory settings without the need to monitor the anticoagulant effect." | 2.42 | Clinical application of enoxaparin. ( Hofmann, T, 2004) |
| "Fondaparinux was also used, with promising results, in prophylaxis in patients undergoing major abdominal surgery and high risk medical patients." | 2.42 | Pentasaccharides. The new anticoagulants. ( Abdel-Razeq, H, 2004) |
| "Guidelines for deep venous thrombosis (DVT) and pulmonary embolism (PE) prophylaxis have been developed for patients undergoing total hip arthroplasty (THA)." | 2.41 | Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty. ( Hawkins, DW; Wade, WE, 2000) |
| "Fondaparinux is a synthetic polysaccharide that selectively binds to antithrombin, the primary endogenous regulator of blood coagulation." | 2.41 | Fondaparinux versus enoxaparin for the prevention of venous thromboembolism. ( Doggrell, SA, 2002) |
| "If patients with pulmonary embolism meet criteria demonstrated to result in a higher risk of death, it is, of course, reasonable to not treat such patients on an outpatient basis." | 2.41 | Outpatient treatment of patients with deep-vein thrombosis or pulmonary embolism. ( Wells, PS, 2001) |
| "The chemistry, pharmacokinetics, pharmacodynamics, clinical efficacy, dosage and administration, adverse effects, and therapeutic role of tinzaparin are reviewed." | 2.41 | Tinzaparin sodium: a low-molecular-weight heparin. ( Carlson, SS; Lenhart, SE; Neely, JL, 2002) |
| "The third pregnancy was established and sintrom was stopped and replaced by fraxiparine 0." | 2.40 | [Successful prophylaxis in a pregnancy with thrombophilic states]. ( Bogdanova, M; Iankova, Z, 1999) |
| " Moreover, subcutaneous parnaparin has a greater bioavailability and longer half-life than heparin, permitting once-daily administration for the prophylaxis of deep venous thrombosis (DVT) or the treatment of established vascular disorders." | 2.39 | Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. ( Faulds, D; Frampton, JE, 1994) |
| "The incidence of pulmonary embolism (2." | 1.91 | Early venous thromboembolism prophylaxis in patients with trauma intracranial hemorrhage: Analysis of the prospective multicenter Consortium of Leaders in Traumatic Thromboembolism study. ( Chien, CY; Inaba, K; Knudson, MM; Martin, MJ; Matsushima, K; Moore, EE; Sauaia, A; Schellenberg, M; Wu, YT, 2023) |
| "The incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) after total joint arthroplasty (TJA) procedures are lower in Asian populations than in Caucasian populations." | 1.91 | Combination of enoxaparin and low-dose aspirin for thromboprophylaxis in selective patients after primary total joint arthroplasty in a Taiwanese population. ( Chang, WL; Chen, CF; Chen, WM; Chou, TA; Pai, FY; Tsai, SW; Wu, PK, 2023) |
| "Pulmonary embolism is a frequent cause of intra-hospital mortality." | 1.91 | "Hospital survival of patients with pulmonary embolism in a country with limited resources case of the city of Kinshasa". ( Brady, MM; Chadrack, B; Erick, KN; Florence, M; Gédéon, D; Marc, TB; Michel, TP; Roly, K; Serge, K; Tousaint, M, 2023) |
| "History of deep vein thrombosis (DVT), location of SVT above the knee, and palpable induration were the only independent factors associated with prolonged treatment duration." | 1.91 | Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin. ( Chatzis, D; Georgiadis, G; Giannoukas, AD; Ioannou, C; Kakkos, SK; Karathanos, C; Latzios, P; Vasdekis, S, 2023) |
| " After observing higher than expected VTE rates within our center's Trauma Quality Improvement Program data, we instituted a change in our VTE prophylaxis protocol, moving to enoxaparin dosing titrated by anti-Xa levels." | 1.72 | Enoxaparin titrated by anti-Xa levels reduces venous thromboembolism in trauma patients. ( Collier, BR; Faulks, ER; Gates, RS; Gillen, JR; Lollar, DI; Smith, J, 2022) |
| "Nonischemic CRVO with cystoid macular edema was diagnosed and an intravitreal injection of ranibizumab was performed." | 1.72 | Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case Report. ( Biskup, M; Kal, M; Krupińska, J; Odrobina, D; Płatkowska-Adamska, B, 2022) |
| "Acute pulmonary embolism and coronavirus disease were diagnosed." | 1.56 | COVID-19 and Acute Pulmonary Embolism in Postpartum Patient. ( Boogar, SS; Khodamoradi, Z; Kouhi, P; Shirazi, FKH, 2020) |
| "We present a late presentation of saddle pulmonary embolism and thrombus-in-transit straddle the patent foramen on patient who successfully recovered from severe acute respiratory syndrome coronavirus-2 (COVID-19) pneumonia." | 1.56 | Saddle pulmonary embolism and thrombus-in-transit straddling the patent foramen ovale 28 days after COVID symptom onset. ( Fontes, JD; Fujikura, K; Taub, CC, 2020) |
| "She was diagnosed with a large pulmonary embolism and was hemodynamically unstable therefore requiring endotracheal intubation and norepinephrine support." | 1.56 | Potential role for furosemide in the treatment of acute respiratory distress syndrome (ARDS) and an unusual presentation of pulmonary embolism in a complex patient. ( Bornstein, G; Zornitzki, L, 2020) |
| "The evidence for outpatient pulmonary embolism (PE) management apart from hospitalization is expanding." | 1.56 | Primary care physicians comprehensively manage acute pulmonary embolism without higher-level-of-care transfer: A report of two cases. ( Hofmann, ER; Isaacs, DJ; Johnson, EJ; Rangarajan, S; Vinson, DR, 2020) |
| "Incidence of postoperative deep venous thrombosis (DVT), pulmonary embolism (PE), bleeding-related complications, postoperative anaemia, and transfusion were identified at 2 weeks, 30 days, 6 weeks, and 90 days." | 1.56 | Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors? ( Amanatullah, DF; Bala, A; Burk, DR; Goodman, SB; Huddleston, JI; Maloney, WJ; Murasko, MJ, 2020) |
| " Given the favourable safety profile of NOACs (especially if a reduced dosage of Apixaban or Rivaroxaban is initiated after at least six months of therapeutic anticoagulation), extended oral anticoagulation of indefinite duration should be considered for all patients with intermediate risk of recurrence." | 1.56 | [Antithrombotic Treatment of Pulmonary Embolism]. ( Ebner, M; Lankeit, M, 2020) |
| "1." | 1.51 | Underdosing of Prophylactic Enoxaparin Is Common in Orthopaedic Trauma and Predicts 90-Day Venous Thromboembolism. ( Fleming, KI; Higgins, TF; Jones, DL; Jones, WA; Pannucci, CJ; Rothberg, DL; Zhang, Y, 2019) |
| "Hypoalbuminemia is a common finding and independent predictor for unfavorable prognosis." | 1.51 | Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. ( Chi, G; Cohen, AT; Gibson, CM; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, RD; Liu, Y, 2019) |
| " If possible, enoxaparin is started, with dosing twice a day." | 1.51 | Significant Reduction of Pulmonary Embolism in Orthopaedic Trauma Patients. ( Au, B; Cripps, MW; Eastman, A; Gebrelul, A; Hu, G; Minei, J; Sanders, D; Sathy, A; Shirley, Z; Starr, AJ; Sutphin, PD, 2019) |
| "Presumptive diagnosis of pulmonary embolism was made and the patient was given 1000IU of antithrombin III and nadroparine (2x90IU/kg/24h s." | 1.48 | [Pulmonary embolism in a girl with nephrotic syndrome and factor V Leiden - case report]. ( Biejat, A; Brzewski, M; Kucińska, B; Kułagowska, J; Mizerska-Wasiak, M; Ofiara, A; Pańczyk-Tomaszewska, M; Skrzypczyk, P; Szyszka, M; Werner, B, 2018) |
| "Dabigatran etexilate is an oral anticoagulant recognized as noninferior to LMWH." | 1.48 | Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada. ( Banica, A; Benoit, B; Delisle, J; Fernandes, JC; Laflamme, GY; Malo, M; Nguyen, H; Ranger, P; Senay, A; Trottier, M, 2018) |
| "Funded studies reported less pulmonary embolisms, fewer events of major bleeding, and significantly less 90-day mortality compared with nonfunded studies." | 1.48 | Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty. ( Azboy, I; Groff, H; Parvizi, J, 2018) |
| ": Lupus anticoagulant hypoprothrombinemia syndrome (LAHS) is a rare disorder characterized by development of lupus anticoagulant and antiprothrombin antibodies." | 1.48 | Fatal pulmonary embolism and pulmonary hemorrhage in lupus anticoagulant hypoprothrombinemia syndrome: a case report and review of literature. ( Chen, X; Cunningham, MT; Nedved, D; Plapp, FV, 2018) |
| "National guidelines have been developed to ensure correct dosing of tinzaparin for women delivered by caesarean delivery (CD) to reduce the risk of venous thromboembolism." | 1.48 | Tinzaparin thromboprophylaxis prescribing practice after caesarean delivery 2009-2014. ( Maguire, PJ; McGuire, M; McNicholl, M; Power, KA; Sheehan, SR; Turner, MJ, 2018) |
| " Once-daily dosing was associated with a lower bleeding risk as compared with twice-daily." | 1.46 | Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis. ( Biedermann, JS; Cannegieter, SC; Kruip, MJHA; Lijfering, WM; Reitsma, PH; van der Meer, FJM; van Rein, N; Vermaas, HW; Wiersma, N, 2017) |
| "A case highlighting challenges with enoxaparin dosage and monitoring in obese patients is presented." | 1.46 | Treatment of suspected pulmonary embolism in a morbidly obese patient. ( Borgstadt, MB; Carlson, L; Heitlage, V, 2017) |
| "BACKGROUND Femoral neuropathy as a result of retroperitoneal hemorrhage most commonly occurs following pelvic and lower extremity trauma, but has been described to develop as a less frequent complication of anticoagulation." | 1.46 | Bilateral Femoral Neuropathy Following Psoas Muscle Hematomas Caused by Enoxaparin Therapy. ( Akkad, I; Bhardwaj, S; Demir, S; Kakar, P; Macauley, P; Shankar, S; Soni, P, 2017) |
| " The changes in anti-factor Xa activity due to plasmapheresis altered the final enoxaparin dosage required to remain in the therapeutic range of 0." | 1.46 | Effect of Plasmapheresis on the Anti-Factor Xa Activity of Enoxaparin in an Obese Adolescent Patient. ( Higgins, KL; Noda, C; Rahawi, KW; Stultz, JS, 2017) |
| " The primary outcome was the incidence of symptomatic pulmonary embolism after surgery, and the secondary outcome was the incidence of bleeding as an adverse effect of enoxaparin injection." | 1.46 | Safety and efficacy of postoperative pharmacologic thromboprophylaxis with enoxaparin after pancreatic surgery. ( Adachi, T; Eguchi, S; Fujita, F; Hidaka, M; Imamura, H; Kitasato, A; Kuroki, T; Soyama, A; Takatsuki, M; Tanaka, T, 2017) |
| "5 mg/kg SC once daily are both FDA-approved dosing regimens for the treatment of pulmonary embolism (PE)." | 1.43 | Once daily versus twice daily enoxaparin for acute pulmonary embolism in cancer patients. ( Chisholm, G; King, AC; Ma, MQ; Toale, KM, 2016) |
| "Workup revealed bilateral submassive pulmonary embolism and proximal right lower extremity deep vein thrombosis." | 1.43 | Inherited antithrombin deficiency and anabolic steroids: a risky combination. ( Choe, H; DeSancho, MT; Elfil, M, 2016) |
| "Apixaban is a new oral anticoagulant with the potential to overcome these limitations." | 1.43 | Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. ( Dickison, DM; King, DA; Pow, RE; Vale, PR, 2016) |
| "Acute pancreatitis is an acute inflammatory process of the pancreas that can trigger a systemic inflammatory response." | 1.43 | Acute pancreatitis complicated with deep vein thrombosis and pulmonary embolism: a case report. ( Herath, HM; Kulatunga, A, 2016) |
| " The VTE rate when enoxaparin sodium is dosed by anti-factor Xa (anti-Xa) trough level is not well described." | 1.43 | Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma. ( Barmparas, G; Chung, K; Dhillon, N; Gewertz, BL; Harada, MY; Ko, A; Ley, EJ; Margulies, DR; Mason, R; Yim, DA, 2016) |
| "BACKGROUND Intraoperative pulmonary embolism (PE) is a rare life-threatening complication in patients undergoing surgical intervention." | 1.43 | Successful Management of Intraoperative Acute Bilateral Pulmonary Embolism in a High Grade Astrocytoma Patient. ( Allouh, MZ; Hiasat, MY; Khraise, WN; Said, RS, 2016) |
| "ESSENTIALS: Does thrombus stability alter the presentation of venous thromboembolism and do anticoagulants alter this? In a murine model, we imaged a femoral vein thrombus and quantified emboli in the pulmonary arteries." | 1.43 | Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. ( Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J, 2016) |
| "We also investigated the occurrence of pulmonary embolism (PE) and its associated risk factors." | 1.42 | Prophylactic effect of fondaparinux and enoxaparin for preventing pulmonary embolism after total hip or knee arthroplasty: A retrospective observational study using the Japanese Diagnosis Procedure Combination database. ( Fushimi, K; Horiguchi, H; Kadono, Y; Matsuda, S; Shoda, N; Tanaka, S; Yasunaga, H, 2015) |
| "Pulmonary tuberculosis was confirmed with positive culture for Mycobacterium tuberculosis." | 1.42 | A rare complication of pulmonary tuberculosis: a case report. ( Jayalath, WA; Kumarihamy, KW; Ralapanawa, DM, 2015) |
| " Adverse events, based on the Common Terminology Criteria for Adverse Events, Version 4, were recorded." | 1.42 | Safety and efficacy of thromboprophylaxis using enoxaparin sodium after cesarean section: A multi-center study in Japan. ( Eguchi, F; Goto, M; Miyamoto, S; Nakahara, H; Ogawa, M; Sanui, A; Satoh, S; Takashima, T; Tatsumura, M; Yoshizato, T, 2015) |
| " In addition we derived defined daily dosage (DDD) of prescribed anticoagulants and the low molecular heparin Enoxaparin for the years 2004-2011 from the statutory health insurance-drug-information system reports." | 1.42 | Prescription of enoxaparin is associated with decreasing pulmonary embolism mortality rate in Germany. ( Kröger, K; Pütter, C; Reinecke, H; Sobik, HM; Stausberg, J; von Beckerath, O, 2015) |
| "Incidences of symptomatic deep vein thrombosis (DVT) and PE, and major or minor bleeding complications were evaluated." | 1.42 | Clinical Performance of the 1st American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism after Total Knee Arthroplasty in Korean Patients. ( Cho, KJ; Fang, R; Kim, TK; Kim, YH; Na, YG, 2015) |
| "He had a history of one isolated seizure 4 years prior, for which he was not prescribed any medication after full evaluation, including a negative electroencephalogram." | 1.40 | Seizure as a presentation of pulmonary embolism. ( Jasani, N; Volz, EE, 2014) |
| "Venous thromboembolism (VTE) (deep vein thrombosis [DVT] and pulmonary embolism [(PE]) represents a substantial economic burden to the healthcare system." | 1.40 | Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. ( Bamber, L; Bookhart, BK; Haskell, L; Mody, SH; Schein, J; Wang, M, 2014) |
| "Iliofemoral deep vein thrombosis is a medical emergency associated with pulmonary embolism, severe postthrombotic morbidity and increased rates of recurrence." | 1.40 | Challenges in the management of iliofemoral deep vein thrombosis in a resource limited setting: a case series. ( Eluehike, S; Isabu, P; Kesieme, EB; Okokhere, P, 2014) |
| "Symptomatic pulmonary embolism constitutes a significant risk following abdominal flap breast reconstruction." | 1.39 | Pulmonary embolism after abdominal flap breast reconstruction: prediction and prevention. ( Damen, THC; Enajat, M; Geenen, A; Mureau, MAM; Timman, R; van der Hulst, RRWJ, 2013) |
| "A patient with a history of intracranial hemorrhage who was hospitalized due to massive pulmonary thromboembolism (PTE) was presented." | 1.39 | [Intracranial hemorrhage due to pulmonary thromboembolism in heparin therapy and therapeutic management of patients hospitalized with massive pulmonary embolism after discharge]. ( Alişir, MF; Beşli, F; Güngören, F; Keçebaş, M, 2013) |
| "Venous thromboembolism and subsequent pulmonary embolism are frequent and sometimes fatal complications in patients after surgical interventions." | 1.39 | [Compliance of patients undergoing thromboprophylaxis with enoxaparin: the COMFORT study]. ( Guschmann, M; Kaiser, J; Rübenacker, S, 2013) |
| "Patients undergoing elective colorectal cancer surgery from 2007 to 2009 at the Royal Adelaide and Queen Elizabeth hospitals were identified from a prospective database." | 1.39 | Is extended thromboprophylaxis necessary in elective colorectal cancer surgery? ( Chandra, R; Hunter, RA; Lawrence, MJ; Melino, G; Moore, J; Thomas, M, 2013) |
| "One fatal pulmonary embolism was recorded (1/1093, 0." | 1.39 | Therapeutic effect of low-molecular weight heparin and incidence of lower limb deep venous thrombosis and pulmonary embolism after laparoscopic bariatric surgery. ( Al-Asfar, F; Al-Bader, I; Al-Mozaini, A; Fingerhut, A; Khoursheed, M; Marouf, R; Sayed, A, 2013) |
| "Acute pulmonary embolism is an important emergency disease which frequently results in life-threatening complication." | 1.39 | Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus. ( Acar, RD; Karakoyun, S; Ozkan, M; Yildiz, M, 2013) |
| "This is a case of bilateral pulmonary embolism in a 16-year-old basketball player whose only risk factor is oral contraceptive medication." | 1.39 | Sixteen-year-old athlete with chest pain and shortness of breath due to pulmonary emboli. ( Tsung, AH; Whitford, AC; Williams, JB, 2013) |
| " There is variable bioavailability of LMWH with standard therapy." | 1.39 | The effects of location and low-molecular-weight heparin administration on deep vein thrombosis outcomes in trauma patients. ( Alonzo, BJ; Differding, J; Hamilton, G; Kremenevskiy, I; Lee, TH; McNamara, S; Schreiber, MA; Underwood, SJ, 2013) |
| "Acute pulmonary embolism (PE) may result in an increase in central venous pressure, which may contribute to pharyngeal narrowing by fluid accumulation in nuchal and peripharyngeal soft tissues and therefore affect obstructive sleep apnoea (OSA)." | 1.38 | Acute pulmonary embolism in patients with obstructive sleep apnoea: does it affect the severity of sleep-disordered breathing? ( Berghaus, TM; Faul, C; Schwaiblmair, M; Thilo, C; Unterer, F; von Scheidt, W, 2012) |
| "Massive pulmonary embolisms were shown by means of the computerized tomography." | 1.37 | Successful administration of a low dose of calcium nadroparin in patients suffering from pulmonary embolism and brain metastases: a report of two cases. ( Antonelli, G; Colina, P; Ferraù, F; Giamo, V; Parisi, A; Rotondo, S; Sessa, E; Vitale, FV, 2011) |
| "In short-term (up to 2 weeks) treatment, bleeding and VTE were more frequent than in long-term treatment." | 1.37 | Prolonged thromboprophylaxis with enoxaparin in early neurological rehabilitation. ( Kienitz, C; Lang, A; Rollnik, JD; Wetzel, P, 2011) |
| "Dependent variables included symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE) within the first 60 postoperative days and time to DVT or PE." | 1.37 | Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. ( Bailey, SH; Dreszer, G; Fisher Wachtman, C; Hamill, JB; Hoxworth, RE; Hume, KM; Jaber, RM; Kalliainen, LK; Neligan, PC; Pannucci, CJ; Pusic, AL; Rubin, JP; Wilkins, EG; Zumsteg, JW, 2011) |
| "We report a case of bilateral pulmonary embolism in a patient of 50 years." | 1.37 | [Pulmonary embolism mimicking acute anterior myocardial infarction: diagnostic trap]. ( Bodian, M; Diack, B; Diao, M; Hakim, R; Kagambèga, LJ; Kane, A; Kane, M; Mbaye, A; Ndiaye, MB; Pessinaba, S; Sow, DD; Yaméogo, NV, 2011) |
| "He was initially diagnosed with a pulmonary thromboembolism." | 1.37 | Metastatic osteosarcoma presenting as a single pulmonary microembolus. ( Chin, C; Midulla, P; Shapiro, M; Wistinghausen, B, 2011) |
| "Eighty percent of deep venous thrombosis resolves spontaneously and less than 15% embolize to pulmonary arteries." | 1.37 | Saddle pulmonary thromboembolism with zero Wells' score. ( Brown, TA; Kangath, RV; Pai, RP, 2011) |
| "Venous thromboembolism is a common and potentially fatal complication in patients with advanced cancer." | 1.36 | Thromboprophylaxis during chemotherapy in patients with advanced cancer. ( Agnelli, G; Verso, M, 2010) |
| "Hospitalized cancer patients are at an increased risk for venous thromboembolism (VTE) and it is recommended they receive pharmacologic prophylaxis unless otherwise contraindicated." | 1.36 | Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population. ( Liu, CY; Reeves, D, 2010) |
| "Given that deep vein thrombosis coincided with obstetric delivery, it was crucial to decide on anesthetic and therapeutic approaches that would assure maternal and fetal safety and prevent such complications as massive pulmonary thromboembolism." | 1.36 | [Parturient at full term with inferior vena cava thrombosis: anesthesia during surgical delivery]. ( Amorós, B; Bermejo, L; Dueñas, N; Fernández, E; Perea, M; Villafranca, A, 2010) |
| " Standard enoxaparin dosing was defined as 0." | 1.36 | Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients. ( Blanc, PD; Boettger, RF; Golden, J; Hoopes, C; Huang, MY; Hui, C; Leard, LE; Singer, JP; Watkins, K, 2010) |
| "The diagnosis of pulmonary embolism was made by computed tomography, which showed the typical changes." | 1.36 | [Pulmonary embolism as a cause of a reduced performance capacity of endurance trained men - report of 2 cases]. ( Dickhuth, HH; König, D; Korsten-Reck, U; Winterer, J, 2010) |
| "The pregnancy was carried to term and she delivered a healthy boy at 38 weeks of gestation." | 1.36 | Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia. ( Corbi, P; Hajj-Chahine, J; Jayle, C; Tomasi, J, 2010) |
| "Acute pulmonary embolism (APE) presents with a broad clinical spectrum ranging from an even asymptomatic course to sudden cardiac death." | 1.36 | [Acute pulmonary embolism]. ( Beyer-Westendorf, J; Braun, S; Halank, M; Höffken, G; Platzek, I, 2010) |
| "To evaluate the rates of deep vein thrombosis (DVT) and pulmonary embolism (PE) in hip fracture patients receiving mechanical thromboprophylaxis." | 1.36 | Mechanical thromboprophylaxis for patients undergoing hip fracture surgery. ( Lee, HC; Loh, JS; Mehta, KV, 2010) |
| "Gastrointestinal stromal tumors are the commonest stromal tumors of the digestive tract." | 1.36 | [Gastrointestinal stromal tumor in pregnancy and control. Case report]. ( Cuerva-González, MJ; de la Calle-Fernández, M; Lacoponi, S; Pozo-Krielinger, J, 2010) |
| "Priapism is a rare disorder defined as a persistent penile erection that continues hours beyond, or is unrelated to, sexual stimulation." | 1.35 | Stuttering priapism complicating warfarin therapy in a patient with protein C deficiency. ( Abu Sham'a, RA; Kufri, FH; Yassin, IH, 2008) |
| "Although the incidence of symptomatic pulmonary thromboembolism did not differ significantly between groups 1 and 2 (1." | 1.35 | The efficacy of prophylactic low-molecular-weight heparin to prevent pulmonary thromboembolism in immediate breast reconstruction using the TRAM flap. ( Ahn, SH; Eom, JS; Kim, EK; Lee, TJ; Son, BH, 2009) |
| "We present three cases who developed deep vein thrombosis (DVT) and subsequent pulmonary thromboembolism (PTE) after transatlantic air travel." | 1.35 | Air travel and pulmonary embolism: "economy class syndrome". ( Arora, P; Bhatia, V; Kaul, U; Mittal, A; Pandey, AK; Parida, AK, 2009) |
| "Major bleedings were reported as secondary endpoints in only two hospitalized patients." | 1.35 | [Prophylaxis of deep vein thrombosis with enoxaparin 40 mg in outpatients compared to hospitalized medically ill patients]. ( Kröger, K, 2009) |
| "This is because pulmonary embolism (PE) is a common cause of mortality postoperatively." | 1.35 | Post discharge prophylactic anticoagulation in gastric bypass patient-how safe? ( Asiyanbola, B; Ojo, P; Reinhold, R; Valin, E, 2008) |
| "The other two patients with history of pulmonary embolism, and one patient having mechanical aortic valve and atrial fibrillation, recovered uneventfully when reduced doses of low molecular weight heparin bridging therapy were administered." | 1.35 | The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases. ( Armstrong, E; Hernesniemi, J; Niemi, T; Silvasti-Lundell, M, 2009) |
| "Dalteparin, an LMWH, was started at a maximum dose of 18,000 units subcutaneously once daily, according to British national prescribing guidelines." | 1.35 | Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin. ( FitzGerald, RJ; Ganguli, A; Pirmohamed, M; Walker, L, 2009) |
| "Low-molecular-weight heparins are effective as initial therapy for pulmonary embolism (PE) in a weight-based dosing regimen up to known body weights of 160 kg." | 1.35 | Treatment of pulmonary embolism in an extremely obese patient. ( Diepstraten, J; Hackeng, CM; Knibbe, CA; Snijder, RJ; van Kralingen, S; van Ramshorst, B, 2009) |
| "Bemiparin has shown to be effective and safe in clinical trials in total knee or hip replacement." | 1.34 | A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery. ( Abad, JI; Gómez-Outes, A; Martínez-González, J; Rocha, E, 2007) |
| "Clinically symptomatic proximal deep vein thrombosis (DVT) or pulmonary embolism (PE) rates were 1." | 1.34 | Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial. ( Chan, E; Chittock, D; de Lemos, J; Gorman, SK; Ho, SG; Simons, RK; Slavik, RS; Wing, PC, 2007) |
| "Clinically symptomatic deep venous thrombosis was detected in association with four (0." | 1.34 | Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. ( Boutary, M; Dorr, LD; Gendelman, V; Long, WT; Maheshwari, AV; Wan, Z, 2007) |
| " The efficacy of daily dosing in critically ill patients is unknown." | 1.33 | Optimal dose of enoxaparin in critically ill trauma and surgical patients. ( Abrams, JE; Rutherford, EJ; Schooler, WG; Skeete, DA; Sredzienski, E, 2005) |
| "Massive pulmonary thromboembolism was defined as thrombotic material seen in main pulmonary arteries." | 1.33 | [Low-molecular-weight heparin for the treatment of acute pulmonary thromboembolism. Comparison with unfractionated intravenous heparin]. ( Abínzano Guillén, ML; Alonso Martínez, JL; Alvarez Frías, MT; Gutiérrez Dubois, J; Munuera García, L; Solano Remírez, M, 2005) |
| "Pulmonary thromboembolism is the leading direct cause of maternal deaths in the UK." | 1.33 | Thromboprophylaxis post vaginal delivery: are we forgetting it? Audit on thromboprophylaxis prescription post vaginal births. ( Tan, EK; Wisdom, SJ, 2006) |
| "Pulmonary thromboembolism is rarely recognized in young children, even in hospital settings." | 1.33 | A six-year old with fatal pulmonary embolism. ( Chakraborty, S; Rao, NK; Sridhar, AV, 2005) |
| "12 patients (2,6%) had pulmonary embolism and 8 of them (1,7%) had died." | 1.32 | [Venous thromboembolism prophylaxis with low molecular weight heparins in polytraumatized patients in intensive care unit (extended serie)]. ( Akar, U; Büyükkurt, CD; Dural, CA; Güloğlu, R; Kurtoğlu, M, 2003) |
| " The rates of minor bleeding complications in the aspirin group, the < 12-hour postoperative dosing of the enoxaparin group, and the 12 to 24-hour postoperative dosing of the enoxaparin group were 3." | 1.32 | Postoperative deep vein thrombosis prophylaxis: a retrospective analysis in 1000 consecutive hip fracture patients treated in a community hospital setting. ( Ennis, RS, 2003) |
| "The early detection of deep venous thrombosis (DVT) and treatment with systemic anticoagulation to prevent pulmonary embolism (PE) are essential in the management of patients undergoing total joint arthroplasty (TJA)." | 1.32 | Surveillance venous duplex is not clinically useful after total joint arthroplasty when effective deep venous thrombosis prophylaxis is used. ( Endean, ED; Hartford, JM; Kwolek, CJ; Matthews, MR; Mentzer, RM; Minion, DJ; Quick, RC; Schwarcz, TH, 2004) |
| " However, emerging evidence suggests that different dosing strategies may be equivalent." | 1.32 | Daily vs twice daily enoxaparin in the prevention of venous thromboembolic disorders during rehabilitation following acute spinal cord injury. ( Chen, D; Crandall, S; Hebbeler, SL; Marciniak, CM; Mendelewski, S; Nussbaum, S, 2004) |
| "To compare the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing gynecological operations without low molecular weight heparin (LMWH) prophylaxis and those receiving such prophylaxis." | 1.31 | Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of low molecular weight heparin. Gynecological ward retrospective analysis. ( Cyrkowicz, A, 2002) |
| " In this report, we describe a woman with primary antiphospholipid antibody syndrome who developed extensive pulmonary embolism despite receiving a proven therapeutic dosage of low molecular weight heparin." | 1.31 | Low-molecular weight heparin: treatment failure in a patient with primary antiphospholipid antibody syndrome. ( Ahmed, S; Karim, A; Mattana, J; Patel, D; Siddiqui, R, 2002) |
| "Patients with clinical suspicion of deep venous thrombosis or pulmonary embolism were investigated as appropriate." | 1.31 | Prophylaxis of thromboembolism in spinal injuries--results of enoxaparin used in 276 patients. ( Deep, K; Fraser, MH; Jigajinni, MV; McLean, AN, 2001) |
| "Thromboprophylaxis with 60 mg enoxaparin daily, in split doses, starting before surgery, is safe and appropriate in patients with hip fractures." | 1.31 | Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery. ( Greiner, N; Korninger, C; Roller, RE; Sim, E; Thaler, HW, 2001) |
| " The treatment protocols for low molecular weight heparin and warfarin, using dosing protocols determined by weight and INR results, are described." | 1.31 | Outpatient treatment of community acquired venous thromboembolism--the Christchurch experience. ( Han, DY; Heaton, D; Inder, A, 2002) |
| "The observed recurrence rate of 0." | 1.31 | Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study. ( Bonet, M; Büller, H; Fraile, M; Lensing, AW; Monreal, M; Muchart, J; Roncales, J, 2002) |
| "Tinzaparin reduced health care costs for pulmonary embolism due to easier administration, less complex laboratory tests, and personnel time savings." | 1.31 | [Economic assessment of the use of tinzaparin in the treatment of acute pulmonary embolism in France]. ( Achkar, A; Allenet, B; Elias, A; Khalifé, K; Lewis, D; Simonneau, G, 2001) |
| "We report a case of acute submassive pulmonary embolism complicating a central venous hemodialysis catheter in a dialysis patient." | 1.30 | Treatment of pulmonary embolism by subcutaneous low-molecular-weight heparin in a hemodialysis patient. ( Lai, KN; Lui, SF; Szeto, CC; Wang, AY; Yu, AW, 1998) |
| "Three patients (0." | 1.30 | The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. ( Geerts, WH; Gent, M; Ginsberg, JS; Hirsh, J; Leclerc, JR, 1998) |
| "The paper deals with fatal pulmonary embolism in patients treated at STOCER after spinal injuries, frequently with neurological impairment." | 1.30 | [Pulmonary embolism as one cause of death after spinal injury--the role of clexane]. ( Jagodziński, K; Kiwerski, JE; Krasuski, M; Krzyzosiak, L, 1998) |
| "We present a case of pulmonary embolism successfully treated with low molecular weight heparin in a woman with a major grade placenta praevia, who required emergency operative delivery." | 1.30 | Thromboembolism treated with low molecular weight heparin in a pregnancy complicated by major placenta praevia: a case report. ( Hertzberg, M; Lahoud, R; Nicholl, M; Rowlands, S, 1997) |
| "Upper extremity deep vein thrombosis (DVT) is now recognized as a major cause of morbidity and mortality." | 1.30 | Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. ( Cruickshank, M; Goudie, D; Kovacs, MJ; Morrow, B; Savage, KJ; Schulz, V; Wells, PS, 1999) |
| "No deep venous thrombosis and no pulmonary embolism were observed." | 1.29 | [General perioperative prevention of thromboembolism in gynecology with low-molecular weight heparin: clinical experiences with enoxaparin over 7 years]. ( Slunsky, R, 1995) |
| " Fourteen children had a deep vein thrombosis or pulmonary embolism, nine had thrombotic complications in the central nervous system, and two had complex congenital heart disease, for which they received prophylaxis at a lower dosage (0." | 1.29 | Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. ( Adams, M; Andrew, M; Brooker, LA; Marzinotto, V; Massicotte, P, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 59 (12.11) | 18.2507 |
| 2000's | 180 (36.96) | 29.6817 |
| 2010's | 190 (39.01) | 24.3611 |
| 2020's | 58 (11.91) | 2.80 |
| Authors | Studies |
|---|---|
| Brüggemann, R | 1 |
| Gietema, H | 1 |
| Jallah, B | 1 |
| Ten Cate, H | 1 |
| Stehouwer, C | 1 |
| Spaetgens, B | 1 |
| Yang, X | 2 |
| Li, N | 1 |
| Guo, T | 1 |
| Guan, X | 1 |
| Tan, J | 1 |
| Gao, X | 1 |
| Wu, Y | 2 |
| Jia, L | 1 |
| Gu, M | 1 |
| Hua, L | 1 |
| Liu, H | 1 |
| van Rein, N | 1 |
| Biedermann, JS | 1 |
| van der Meer, FJM | 1 |
| Cannegieter, SC | 1 |
| Wiersma, N | 1 |
| Vermaas, HW | 1 |
| Reitsma, PH | 1 |
| Kruip, MJHA | 1 |
| Lijfering, WM | 1 |
| Skrzypczyk, P | 1 |
| Mizerska-Wasiak, M | 1 |
| Ofiara, A | 1 |
| Szyszka, M | 1 |
| Kułagowska, J | 1 |
| Biejat, A | 1 |
| Brzewski, M | 1 |
| Kucińska, B | 1 |
| Werner, B | 1 |
| Pańczyk-Tomaszewska, M | 1 |
| Enajat, M | 1 |
| Damen, THC | 1 |
| Geenen, A | 1 |
| Timman, R | 1 |
| van der Hulst, RRWJ | 1 |
| Mureau, MAM | 1 |
| Righini, M | 2 |
| Galanaud, JP | 1 |
| Guenneguez, H | 1 |
| Brisot, D | 2 |
| Diard, A | 1 |
| Faisse, P | 1 |
| Barrellier, MT | 1 |
| Hamel-Desnos, C | 1 |
| Jurus, C | 1 |
| Pichot, O | 1 |
| Martin, M | 1 |
| Mazzolai, L | 1 |
| Choquenet, C | 1 |
| Accassat, S | 1 |
| Robert-Ebadi, H | 1 |
| Carrier, M | 4 |
| Le Gal, G | 1 |
| Mermilllod, B | 1 |
| Laroche, JP | 1 |
| Bounameaux, H | 4 |
| Perrier, A | 2 |
| Kahn, SR | 2 |
| Quere, I | 1 |
| Kistler, U | 1 |
| Kramers-de Quervain, I | 1 |
| Munzinger, U | 1 |
| Kucher, N | 2 |
| Camporese, G | 2 |
| Bernardi, E | 1 |
| Noventa, F | 1 |
| Vitale, FV | 1 |
| Rotondo, S | 1 |
| Sessa, E | 1 |
| Antonelli, G | 1 |
| Colina, P | 1 |
| Parisi, A | 1 |
| Giamo, V | 1 |
| Ferraù, F | 1 |
| Mumoli, N | 1 |
| Cei, M | 1 |
| Agnelli, G | 8 |
| Verso, M | 2 |
| Schwarz, T | 1 |
| Buschmann, L | 1 |
| Beyer, J | 1 |
| Halbritter, K | 1 |
| Rastan, A | 1 |
| Schellong, S | 3 |
| Schindewolf, M | 1 |
| Scheuermann, J | 1 |
| Kroll, H | 1 |
| Garbaraviciene, J | 1 |
| Hecking, C | 1 |
| Marzi, I | 1 |
| Wolter, M | 1 |
| Kaufmann, R | 1 |
| Boehncke, WH | 1 |
| Lindhoff-Last, E | 1 |
| Ludwig, RJ | 1 |
| Zondag, W | 1 |
| Mos, IC | 1 |
| Creemers-Schild, D | 1 |
| Hoogerbrugge, AD | 1 |
| Dekkers, OM | 1 |
| Dolsma, J | 1 |
| Eijsvogel, M | 1 |
| Faber, LM | 1 |
| Hofstee, HM | 1 |
| Hovens, MM | 1 |
| Jonkers, GJ | 1 |
| van Kralingen, KW | 1 |
| Kruip, MJ | 1 |
| Vlasveld, T | 1 |
| de Vreede, MJ | 1 |
| Huisman, MV | 5 |
| Betrosian, AP | 1 |
| Theodossiades, G | 1 |
| Lambroulis, G | 1 |
| Kostantonis, D | 1 |
| Balla, M | 1 |
| Papanikolaou, M | 1 |
| Georgiades, G | 1 |
| Beer, JH | 1 |
| Burger, M | 1 |
| Gretener, S | 1 |
| Bernard-Bagattini, S | 1 |
| Balbay, O | 1 |
| Tuzuner, T | 1 |
| Arbak, P | 1 |
| Orham, Z | 1 |
| Erbas, M | 1 |
| Aydogan, I | 1 |
| Matviĭchuk, BO | 1 |
| Nykolaĭchuk, BIa | 1 |
| Lysovych, BI | 1 |
| Matviĭchuk, OB | 1 |
| Mahé, I | 3 |
| Bergmann, JF | 3 |
| d'Azémar, P | 2 |
| Vaissie, JJ | 1 |
| Caulin, C | 1 |
| Zhu, L | 1 |
| Wang, C | 1 |
| Yang, Y | 1 |
| Zhai, Z | 1 |
| Dai, H | 1 |
| Pang, B | 1 |
| Tong, Z | 1 |
| Pavlović, S | 1 |
| Zivković, S | 1 |
| Koraćević, G | 1 |
| Latacz, P | 1 |
| Rostoff, P | 1 |
| Wyderka, R | 1 |
| Rudnik, A | 1 |
| Kondys, M | 1 |
| Marut, A | 1 |
| Buszman, P | 1 |
| Piwowarska, W | 1 |
| Schapkaitz, E | 1 |
| Jacobson, BF | 2 |
| Tschammler, A | 1 |
| Markert, T | 1 |
| Wittenberg, G | 1 |
| Krahe, T | 1 |
| Bachmann, F | 1 |
| Mironov, SP | 1 |
| Burmakova, GM | 1 |
| Fedotova, TM | 1 |
| Schain, FH | 1 |
| Nurmohamed, MT | 1 |
| van Riel, AM | 1 |
| Henkens, CM | 1 |
| Koopman, MM | 1 |
| Que, GT | 1 |
| Büller, HR | 8 |
| ten Cate, JW | 1 |
| Hoek, JA | 2 |
| van der Meer, J | 1 |
| van der Heul, C | 1 |
| Turpie, AG | 15 |
| Haley, S | 2 |
| Sicurella, A | 1 |
| Gent, M | 9 |
| Haentjens, P | 2 |
| Tomkowski, W | 1 |
| Borowiec, B | 1 |
| Burakowski, J | 1 |
| Hajduk, B | 1 |
| Filipecki, S | 1 |
| Czestochowska, E | 1 |
| Arasimowicz, P | 1 |
| Szücs, G | 1 |
| Mikó, I | 1 |
| Ajzner, E | 1 |
| Póti, L | 1 |
| Szepesi, K | 1 |
| Furka, I | 1 |
| Szeto, CC | 1 |
| Wang, AY | 1 |
| Lui, SF | 1 |
| Lai, KN | 1 |
| Yu, AW | 1 |
| Lloyd, A | 1 |
| Aitken, JA | 1 |
| Hoffmeyer, UK | 1 |
| Kelso, EJ | 1 |
| Wakerly, EC | 1 |
| Barber, ND | 1 |
| Belcaro, G | 1 |
| Nicolaides, AN | 2 |
| Cesarone, MR | 1 |
| Laurora, G | 1 |
| De Sanctis, MT | 1 |
| Incandela, L | 1 |
| Barsotti, A | 1 |
| Corsi, M | 1 |
| Vasdekis, S | 4 |
| Christopoulos, D | 1 |
| Lennox, A | 1 |
| Malouf, M | 1 |
| Iankova, Z | 1 |
| Bogdanova, M | 1 |
| Egger, B | 1 |
| Schmid, SW | 1 |
| Naef, M | 1 |
| Wildi, S | 1 |
| Büchler, MW | 1 |
| Manganaro, A | 1 |
| Giannino, D | 1 |
| Lembo, D | 1 |
| Bruni, F | 1 |
| Consolo, F | 1 |
| Hui, CK | 1 |
| Yuen, MF | 1 |
| Ng, IO | 1 |
| Tsang, KW | 1 |
| Fong, GC | 1 |
| Lai, CL | 1 |
| Couturaud, F | 2 |
| Julian, JA | 3 |
| Kearon, C | 1 |
| Celebi, F | 1 |
| Balik, AA | 1 |
| Yildirgan, MI | 1 |
| Başoğlu, M | 1 |
| Adigüzel, H | 1 |
| Oren, D | 1 |
| Cyrkowicz, A | 1 |
| Petrikov, AS | 1 |
| Cosmi, B | 1 |
| Filippini, M | 1 |
| Tonti, D | 1 |
| Avruscio, G | 1 |
| Ghirarduzzi, A | 1 |
| Bucherini, E | 1 |
| Imberti, D | 1 |
| Palareti, G | 2 |
| Forestieri, P | 1 |
| Quarto, G | 1 |
| De Caterina, M | 1 |
| Cuocolo, A | 1 |
| Pilone, V | 1 |
| Formato, A | 1 |
| Ruocco, A | 1 |
| Ferrari, P | 1 |
| Frampton, JE | 1 |
| Faulds, D | 1 |
| Gioè, FP | 1 |
| Arcara, M | 1 |
| Scaffidi Abbate, F | 1 |
| Mercadante, T | 1 |
| Gao, JH | 1 |
| Chu, XC | 1 |
| Wang, LL | 1 |
| Ning, B | 1 |
| Zhao, CX | 1 |
| Beşli, F | 1 |
| Keçebaş, M | 1 |
| Alişir, MF | 1 |
| Güngören, F | 1 |
| Ciccone, MM | 1 |
| Cortese, F | 1 |
| Corbo, F | 1 |
| Corrales, NE | 1 |
| Al-Momen, AK | 1 |
| Silva, A | 1 |
| Zito, A | 1 |
| Pinto, M | 1 |
| Gesualdo, M | 1 |
| Scicchitano, P | 1 |
| Alalaf, SK | 1 |
| Jawad, AK | 1 |
| Jawad, RK | 1 |
| Ali, MS | 1 |
| Al Tawil, NG | 1 |
| Calderero Aragón, V | 1 |
| de Gregorio Ariza, MA | 1 |
| Pazo Cid, R | 1 |
| Puértolas Hernández, T | 1 |
| Lostalé Latorre, F | 1 |
| Artal Cortés, A | 1 |
| Antón Torres, A | 1 |
| Abad Rico, JI | 1 |
| Lozano Sánchez, FS | 1 |
| Rocha, E | 2 |
| Gallardo Jiménez, P | 1 |
| Guijarro Merino, R | 1 |
| Vallejo Herrera, V | 1 |
| Sánchez Morales, D | 1 |
| Villalobos Sánchez, A | 1 |
| Perelló González-Moreno, JI | 1 |
| Gómez-Huelgas, R | 1 |
| Santamaría, A | 1 |
| Juárez, S | 1 |
| Reche, A | 1 |
| Gómez-Outes, A | 3 |
| Martínez-González, J | 2 |
| Fontcuberta, J | 1 |
| Abad, JI | 1 |
| Kakkar, VV | 4 |
| Howes, J | 1 |
| Sharma, V | 1 |
| Kadziola, Z | 2 |
| Gates, RS | 1 |
| Lollar, DI | 1 |
| Collier, BR | 1 |
| Smith, J | 1 |
| Faulks, ER | 1 |
| Gillen, JR | 1 |
| Marini, CP | 1 |
| Lewis, E | 1 |
| Petrone, P | 1 |
| Zenilman, A | 1 |
| Lu, Z | 1 |
| Rivera, A | 1 |
| McNelis, J | 1 |
| Morici, N | 1 |
| Podda, G | 1 |
| Birocchi, S | 1 |
| Bonacchini, L | 1 |
| Merli, M | 1 |
| Trezzi, M | 1 |
| Massaini, G | 1 |
| Agostinis, M | 1 |
| Carioti, G | 1 |
| Saverio Serino, F | 1 |
| Gazzaniga, G | 1 |
| Barberis, D | 1 |
| Antolini, L | 1 |
| Grazia Valsecchi, M | 1 |
| Cattaneo, M | 2 |
| Verhoeff, K | 1 |
| Raffael, K | 1 |
| Connell, M | 1 |
| Kung, JY | 1 |
| Strickland, M | 1 |
| Parker, A | 1 |
| Anantha, RV | 1 |
| Elikowski, W | 1 |
| Fertała, N | 1 |
| Zawodna-Marszałek, M | 1 |
| Karoń, J | 1 |
| Skrzywanek, P | 1 |
| Mozer-Lisewska, I | 1 |
| Szczęśniewski, P | 1 |
| Łazowski, S | 1 |
| Żytkiewicz, M | 1 |
| Metcalf, KB | 1 |
| Du, JY | 1 |
| Ochenjele, G | 1 |
| Sidhu, VS | 1 |
| Kelly, TL | 1 |
| Pratt, N | 1 |
| Graves, SE | 1 |
| Buchbinder, R | 1 |
| Adie, S | 1 |
| Cashman, K | 1 |
| Ackerman, I | 1 |
| Bastiras, D | 1 |
| Brighton, R | 1 |
| Burns, AWR | 1 |
| Chong, BH | 2 |
| Clavisi, O | 1 |
| Cripps, M | 1 |
| Dekkers, M | 1 |
| de Steiger, R | 1 |
| Dixon, M | 1 |
| Ellis, A | 1 |
| Griffith, EC | 1 |
| Hale, D | 1 |
| Hansen, A | 1 |
| Harris, A | 1 |
| Hau, R | 1 |
| Horsley, M | 1 |
| James, D | 1 |
| Khorshid, O | 1 |
| Kuo, L | 1 |
| Lewis, P | 1 |
| Lieu, D | 1 |
| Lorimer, M | 1 |
| MacDessi, S | 1 |
| McCombe, P | 1 |
| McDougall, C | 1 |
| Mulford, J | 1 |
| Naylor, JM | 1 |
| Page, RS | 1 |
| Radovanovic, J | 1 |
| Solomon, M | 1 |
| Sorial, R | 1 |
| Summersell, P | 1 |
| Tran, P | 1 |
| Walter, WL | 1 |
| Webb, S | 1 |
| Wilson, C | 1 |
| Wysocki, D | 1 |
| Harris, IA | 1 |
| Godat, LN | 1 |
| Haut, ER | 3 |
| Moore, EE | 2 |
| Knudson, MM | 2 |
| Costantini, TW | 1 |
| Płatkowska-Adamska, B | 1 |
| Kal, M | 1 |
| Krupińska, J | 1 |
| Biskup, M | 1 |
| Odrobina, D | 1 |
| Samuel, S | 2 |
| To, C | 1 |
| Ling, Y | 1 |
| Zhang, K | 1 |
| Jiang, X | 1 |
| Bernstam, EV | 1 |
| Elmi, G | 1 |
| Allegri, D | 1 |
| Aluigi, L | 1 |
| Antignani, PL | 1 |
| Aspide, R | 1 |
| Camaggi, V | 1 |
| DI Giulio, R | 1 |
| Domanico, A | 1 |
| Rinaldi, ER | 1 |
| Martignani, A | 1 |
| Li, W | 1 |
| Dunn, K | 2 |
| Cortes, J | 1 |
| Nguyen, T | 1 |
| Moussa, D | 1 |
| Kumar, A | 1 |
| Dao, T | 1 |
| Beeson, J | 1 |
| Choi, HA | 1 |
| McCullough, LD | 1 |
| Wu, YT | 1 |
| Chien, CY | 1 |
| Matsushima, K | 1 |
| Schellenberg, M | 1 |
| Inaba, K | 1 |
| Sauaia, A | 1 |
| Martin, MJ | 1 |
| Tsai, SW | 1 |
| Chang, WL | 1 |
| Pai, FY | 1 |
| Chou, TA | 1 |
| Chen, CF | 1 |
| Wu, PK | 1 |
| Chen, WM | 1 |
| Marc, TB | 1 |
| Michel, TP | 1 |
| Florence, M | 1 |
| Tousaint, M | 1 |
| Serge, K | 1 |
| Chadrack, B | 1 |
| Roly, K | 1 |
| Gédéon, D | 1 |
| Brady, MM | 1 |
| Erick, KN | 1 |
| Peng, S | 1 |
| Zhang, M | 1 |
| Jin, J | 1 |
| MacCormick, AD | 1 |
| Seo, WW | 1 |
| Park, MS | 1 |
| Kim, SE | 1 |
| Lee, JH | 1 |
| Park, DG | 1 |
| Han, KR | 1 |
| Oh, DJ | 1 |
| Hyon, MS | 1 |
| Jarab, AS | 1 |
| Al-Azzam, S | 1 |
| Badaineh, R | 1 |
| Mukattash, TL | 1 |
| Bsoul, R | 1 |
| Jones, DL | 1 |
| Jones, WA | 1 |
| Fleming, KI | 1 |
| Higgins, TF | 1 |
| Rothberg, DL | 1 |
| Zhang, Y | 1 |
| Pannucci, CJ | 2 |
| Yun, R | 1 |
| Sciubba, DM | 1 |
| Lewin, JJ | 1 |
| Streiff, MB | 1 |
| Lau, BD | 1 |
| Shermock, KM | 1 |
| Kraus, PS | 1 |
| Popoola, VO | 1 |
| Dalpoas, SE | 1 |
| Roy, SF | 1 |
| Watson, P | 1 |
| Bouffard, D | 1 |
| Weitz, JI | 6 |
| Bauersachs, R | 4 |
| Becker, B | 1 |
| Berkowitz, SD | 4 |
| Freitas, MCS | 1 |
| Lassen, MR | 5 |
| Metzig, C | 1 |
| Raskob, GE | 7 |
| Krantz, EN | 1 |
| Philpott, CD | 1 |
| Droege, ME | 1 |
| Mueller, EW | 1 |
| Ernst, NE | 1 |
| Garber, PM | 1 |
| Tsuei, BJ | 1 |
| Goodman, MD | 1 |
| Droege, CA | 1 |
| Murphy, RF | 1 |
| Williams, D | 1 |
| Hogue, GD | 1 |
| Spence, DD | 1 |
| Epps, H | 1 |
| Chambers, HG | 1 |
| Shore, BJ | 1 |
| Hui, C | 2 |
| Brodsky, RA | 1 |
| Haines, C | 1 |
| Lee, JK | 1 |
| Koo, JW | 1 |
| Jeong, SY | 1 |
| Choi, S | 1 |
| Park, KC | 1 |
| Hwang, KT | 1 |
| Samama, CM | 3 |
| Laporte, S | 5 |
| Rosencher, N | 4 |
| Girard, P | 4 |
| Llau, J | 1 |
| Mouret, P | 2 |
| Fisher, W | 2 |
| Martínez-Martín, J | 1 |
| Duverger, D | 1 |
| Deygas, B | 1 |
| Presles, E | 1 |
| Cucherat, M | 1 |
| Mismetti, P | 4 |
| Griffin, DO | 1 |
| Jensen, A | 1 |
| Khan, M | 1 |
| Chin, J | 1 |
| Chin, K | 1 |
| Saad, J | 1 |
| Parnell, R | 1 |
| Awwad, C | 1 |
| Patel, D | 2 |
| Khodamoradi, Z | 1 |
| Boogar, SS | 1 |
| Shirazi, FKH | 1 |
| Kouhi, P | 1 |
| Akel, T | 1 |
| Qaqa, F | 1 |
| Abuarqoub, A | 1 |
| Shamoon, F | 1 |
| McConachie, SM | 1 |
| Hanni, CM | 1 |
| Raub, JN | 1 |
| Mohammad, RA | 1 |
| Wilhelm, SM | 1 |
| Kamachi, H | 1 |
| Homma, S | 1 |
| Kawamura, H | 1 |
| Yoshida, T | 1 |
| Ohno, Y | 1 |
| Ichikawa, N | 1 |
| Yokota, R | 1 |
| Funakoshi, T | 1 |
| Maeda, Y | 1 |
| Takahashi, N | 1 |
| Amano, T | 1 |
| Taketomi, A | 1 |
| Moll, M | 1 |
| Zon, RL | 1 |
| Sylvester, KW | 1 |
| Chen, EC | 1 |
| Cheng, V | 1 |
| Connell, NT | 1 |
| Fredenburgh, LE | 1 |
| Baron, RM | 1 |
| Cho, MH | 1 |
| Woolley, AE | 1 |
| Connors, JM | 2 |
| Fujikura, K | 1 |
| Fontes, JD | 1 |
| Taub, CC | 1 |
| Whittemore, P | 1 |
| Macfarlane, L | 1 |
| Herbert, A | 1 |
| Farrant, J | 1 |
| Ferguson, K | 1 |
| Quail, N | 1 |
| Kewin, P | 1 |
| Blyth, KG | 1 |
| Zornitzki, L | 1 |
| Bornstein, G | 1 |
| Russo, V | 1 |
| Cardillo, G | 1 |
| Viggiano, GV | 1 |
| Mangiacapra, S | 1 |
| Cavalli, A | 1 |
| Fontanella, A | 2 |
| Agrusta, F | 1 |
| Bellizzi, A | 1 |
| Amitrano, M | 1 |
| Iannuzzo, M | 1 |
| Sacco, C | 1 |
| Lodigiani, C | 1 |
| Di Micco, P | 1 |
| Bhatt, H | 1 |
| Singh, S | 3 |
| Isaacs, DJ | 1 |
| Johnson, EJ | 1 |
| Hofmann, ER | 1 |
| Rangarajan, S | 1 |
| Vinson, DR | 1 |
| Yamashita, S | 1 |
| Nishi, M | 1 |
| Ikemoto, T | 1 |
| Yoshikawa, K | 1 |
| Higashijima, J | 1 |
| Tokunaga, T | 1 |
| Takasu, C | 1 |
| Kashihara, H | 1 |
| Eto, S | 1 |
| Yoshimoto, T | 1 |
| Shimada, M | 1 |
| Qian, C | 1 |
| Huhtakangas, J | 1 |
| Juvela, S | 1 |
| Bode, MK | 1 |
| Tatlisumak, T | 1 |
| Savolainen, M | 1 |
| Numminen, H | 1 |
| Ollikainen, J | 1 |
| Luostarinen, L | 1 |
| Kupila, L | 1 |
| Tetri, S | 1 |
| Oh, HJ | 1 |
| Ryu, KH | 1 |
| Park, BJ | 1 |
| Yoon, BH | 1 |
| Scarduelli, C | 1 |
| Inglese, F | 1 |
| Beccaria, M | 1 |
| Spreafico, F | 1 |
| Garuti, M | 1 |
| Pecoriello, A | 1 |
| Cervi, G | 1 |
| Greco, G | 1 |
| Scarduelli, S | 1 |
| Lucchini, G | 1 |
| De Donno, G | 1 |
| Borghi, C | 1 |
| Sadeghipour, P | 2 |
| Talasaz, AH | 2 |
| Rashidi, F | 1 |
| Sharif-Kashani, B | 1 |
| Beigmohammadi, MT | 1 |
| Farrokhpour, M | 1 |
| Sezavar, SH | 1 |
| Payandemehr, P | 1 |
| Dabbagh, A | 1 |
| Moghadam, KG | 1 |
| Jamalkhani, S | 1 |
| Khalili, H | 2 |
| Yadollahzadeh, M | 1 |
| Riahi, T | 1 |
| Rezaeifar, P | 1 |
| Tahamtan, O | 1 |
| Matin, S | 1 |
| Abedini, A | 1 |
| Lookzadeh, S | 1 |
| Rahmani, H | 1 |
| Zoghi, E | 1 |
| Mohammadi, K | 1 |
| Abri, H | 1 |
| Tabrizi, S | 1 |
| Mousavian, SM | 1 |
| Shahmirzaei, S | 1 |
| Bakhshandeh, H | 1 |
| Amin, A | 1 |
| Rafiee, F | 1 |
| Baghizadeh, E | 1 |
| Mohebbi, B | 1 |
| Parhizgar, SE | 1 |
| Aliannejad, R | 1 |
| Eslami, V | 1 |
| Kashefizadeh, A | 1 |
| Kakavand, H | 1 |
| Hosseini, SH | 1 |
| Shafaghi, S | 1 |
| Ghazi, SF | 1 |
| Najafi, A | 1 |
| Jimenez, D | 1 |
| Gupta, A | 1 |
| Madhavan, MV | 1 |
| Sethi, SS | 1 |
| Parikh, SA | 1 |
| Monreal, M | 6 |
| Hadavand, N | 1 |
| Hajighasemi, A | 1 |
| Maleki, M | 1 |
| Sadeghian, S | 1 |
| Piazza, G | 3 |
| Kirtane, AJ | 1 |
| Van Tassell, BW | 1 |
| Dobesh, PP | 1 |
| Stone, GW | 1 |
| Lip, GYH | 1 |
| Krumholz, HM | 1 |
| Goldhaber, SZ | 11 |
| Bikdeli, B | 1 |
| Anastas, DC | 1 |
| Farias, A | 1 |
| Runyon, J | 1 |
| Laufer, M | 1 |
| Sendi, P | 1 |
| Totapally, B | 1 |
| Sachdeva, R | 1 |
| Houghton, DE | 2 |
| Vlazny, DT | 2 |
| Casanegra, AI | 2 |
| Brunton, N | 1 |
| Froehling, DA | 2 |
| Meverden, RA | 1 |
| Hodge, DO | 2 |
| Peterson, LG | 2 |
| McBane, RD | 2 |
| Wysokinski, WE | 2 |
| Türk, M | 1 |
| Aldağ, Y | 1 |
| Oğuzülgen, İK | 1 |
| Ekim, N | 1 |
| Fernandez, A | 1 |
| Nair, V | 1 |
| Mckeone, A | 1 |
| Ho, J | 1 |
| Donagher, J | 1 |
| Martin, JH | 1 |
| Barras, MA | 1 |
| Bala, A | 3 |
| Huddleston, JI | 2 |
| Goodman, SB | 2 |
| Maloney, WJ | 2 |
| Amanatullah, DF | 2 |
| Gourzoulidis, G | 1 |
| Kourlaba, G | 1 |
| Kakisis, J | 1 |
| Matsagkas, M | 1 |
| Giannakoulas, G | 1 |
| Gourgoulianis, KI | 1 |
| Vassilakopoulos, T | 1 |
| Maniadakis, N | 1 |
| Clementi, M | 1 |
| Colozzi, S | 1 |
| Guadagni, S | 1 |
| Pessia, B | 1 |
| Sista, F | 1 |
| Schietroma, M | 1 |
| Della Penna, A | 1 |
| Amicucci, G | 1 |
| Cafri, G | 1 |
| Paxton, EW | 1 |
| Chen, Y | 1 |
| Cheetham, CT | 1 |
| Gould, MK | 2 |
| Sluggett, J | 1 |
| Bini, SA | 1 |
| Khatod, M | 1 |
| Heitlage, V | 1 |
| Borgstadt, MB | 1 |
| Carlson, L | 1 |
| Kohn, CG | 1 |
| Fermann, GJ | 1 |
| Peacock, WF | 1 |
| Wells, PS | 5 |
| Baugh, CW | 1 |
| Ashton, V | 1 |
| Crivera, C | 1 |
| Schein, JR | 1 |
| Wildgoose, P | 1 |
| Coleman, CI | 1 |
| Cimminiello, C | 1 |
| Prandoni, P | 2 |
| Di Minno, G | 1 |
| Polo Friz, H | 1 |
| Scaglione, F | 1 |
| Boracchi, P | 1 |
| Marano, G | 1 |
| Harenberg, J | 3 |
| Rottenstreich, A | 1 |
| Kleinstern, G | 1 |
| Spectre, G | 1 |
| Da'as, N | 1 |
| Ziv, E | 1 |
| Kalish, Y | 1 |
| Arbetter, DF | 2 |
| Jain, P | 1 |
| Yee, MK | 2 |
| Michalak, N | 1 |
| Hernandez, AF | 3 |
| Hull, RD | 3 |
| Harrington, RA | 3 |
| Gold, A | 2 |
| Cohen, AT | 14 |
| Gibson, CM | 3 |
| Macauley, P | 1 |
| Soni, P | 1 |
| Akkad, I | 1 |
| Demir, S | 1 |
| Shankar, S | 1 |
| Kakar, P | 1 |
| Bhardwaj, S | 1 |
| Jones, CW | 1 |
| Spasojevic, S | 1 |
| Goh, G | 1 |
| Joseph, Z | 1 |
| Wood, DJ | 1 |
| Yates, PJ | 1 |
| Thind, M | 1 |
| Cohen, DA | 1 |
| Wu, YF | 1 |
| Lai, CC | 1 |
| Chao, CM | 1 |
| Campbell, ST | 1 |
| Jiang, SY | 1 |
| Gardner, MJ | 1 |
| Bishop, JA | 1 |
| Khan, NR | 1 |
| Patel, PG | 1 |
| Sharpe, JP | 1 |
| Lee, SL | 1 |
| Sorenson, J | 1 |
| Grübler, B | 1 |
| de Albuquerque Botura, C | 1 |
| Bersani-Amado, LE | 1 |
| Zacarias-Júnior, AR | 1 |
| Boreli, SD | 1 |
| Stecca, NGG | 1 |
| da Rocha, BA | 1 |
| Cuman, RKN | 1 |
| Bersani-Amado, CA | 1 |
| Jud, P | 1 |
| Watzinger, N | 1 |
| Gary, T | 1 |
| Senay, A | 1 |
| Trottier, M | 1 |
| Delisle, J | 1 |
| Banica, A | 1 |
| Benoit, B | 1 |
| Laflamme, GY | 1 |
| Malo, M | 1 |
| Nguyen, H | 2 |
| Ranger, P | 1 |
| Fernandes, JC | 1 |
| Intiyanaravut, T | 1 |
| Thongpulsawasdi, N | 1 |
| Sinthuvanich, N | 1 |
| Teavirat, S | 1 |
| Kunopart, M | 1 |
| Jandial, A | 1 |
| Mishra, K | 1 |
| Kumar, S | 1 |
| Malhotra, P | 1 |
| Bourget-Murray, J | 1 |
| Clarke, MA | 1 |
| Gorzitza, S | 1 |
| Phillips, LA | 1 |
| Groff, H | 1 |
| Azboy, I | 1 |
| Parvizi, J | 1 |
| Graham, D | 1 |
| Wu, QX | 1 |
| Gilligan, I | 1 |
| Ismail, R | 1 |
| Walker, M | 1 |
| Chi, G | 1 |
| Liu, Y | 1 |
| Chen, X | 2 |
| Nedved, D | 1 |
| Plapp, FV | 1 |
| Cunningham, MT | 1 |
| Martín Guerra, JM | 1 |
| Asenjo, MM | 1 |
| Dueñas Gutiérrez, CJ | 1 |
| Gil González, I | 1 |
| Starr, AJ | 1 |
| Shirley, Z | 1 |
| Sutphin, PD | 1 |
| Sanders, D | 1 |
| Eastman, A | 1 |
| Au, B | 1 |
| Sathy, A | 1 |
| Hu, G | 1 |
| Gebrelul, A | 1 |
| Minei, J | 1 |
| Cripps, MW | 1 |
| Sun, G | 2 |
| Wu, J | 1 |
| Wang, Q | 1 |
| Liang, Q | 1 |
| Jia, J | 1 |
| Cheng, K | 1 |
| Wang, Z | 1 |
| Yoo, HH | 1 |
| Nunes-Nogueira, VS | 1 |
| Fortes Villas Boas, PJ | 1 |
| Broderick, C | 1 |
| Murasko, MJ | 1 |
| Burk, DR | 1 |
| Weithman, ME | 1 |
| Sieber, A | 1 |
| Brewer, J | 1 |
| Sheridan, D | 1 |
| Dalen, JE | 1 |
| Stein, PD | 1 |
| Plitt, JL | 1 |
| Jaswal, N | 1 |
| Alpert, JS | 1 |
| Bott-Kitslaar, DM | 1 |
| Rübenacker, S | 1 |
| Kaiser, J | 1 |
| Guschmann, M | 1 |
| Ruiz-Artacho, P | 1 |
| Pérez Peña, C | 1 |
| Iriarte, A | 1 |
| Martín-Sánchez, FJ | 1 |
| Brotman, DJ | 1 |
| Shihab, HM | 1 |
| Prakasa, KR | 1 |
| Kebede, S | 1 |
| Sharma, R | 1 |
| Shermock, K | 1 |
| Chelladurai, Y | 1 |
| Segal, JB | 1 |
| Ruiz Artacho, P | 1 |
| Merlo Loranca, M | 1 |
| Jiménez Hernández, S | 1 |
| Chandra, R | 1 |
| Melino, G | 1 |
| Thomas, M | 1 |
| Lawrence, MJ | 1 |
| Hunter, RA | 1 |
| Moore, J | 1 |
| Lucania, G | 1 |
| Camiolo, E | 1 |
| Carmina, MG | 1 |
| Fiandaca, T | 1 |
| Indovina, A | 1 |
| Malato, A | 1 |
| Messina, R | 1 |
| Fabbiano, F | 1 |
| Marcenò, R | 1 |
| Cohen, AA | 1 |
| Rider, T | 1 |
| Décousus, H | 7 |
| Grosso, MA | 2 |
| Mercuri, M | 1 |
| Middeldorp, S | 1 |
| Prins, MH | 6 |
| Schellong, SM | 2 |
| Schwocho, L | 2 |
| Segers, A | 5 |
| Shi, M | 2 |
| Verhamme, P | 5 |
| Wells, P | 3 |
| Farooqui, A | 1 |
| Hiser, B | 1 |
| Barnes, SL | 1 |
| Litofsky, NS | 1 |
| Volz, EE | 1 |
| Jasani, N | 1 |
| Khoursheed, M | 1 |
| Al-Bader, I | 1 |
| Al-Asfar, F | 1 |
| Sayed, A | 1 |
| Al-Mozaini, A | 1 |
| Marouf, R | 1 |
| Fingerhut, A | 1 |
| Garcipérez de Vargas, FJ | 1 |
| Marcos, G | 1 |
| Moyano Calvente, SL | 1 |
| van Bellen, B | 1 |
| Bamber, L | 2 |
| Correa de Carvalho, F | 1 |
| Prins, M | 2 |
| Wang, M | 2 |
| Lensing, AW | 5 |
| Gritsiouk, Y | 1 |
| Hegsted, DA | 1 |
| Schlesinger, P | 1 |
| Gardiner, SK | 1 |
| Gubler, KD | 1 |
| Mele, M | 1 |
| Mele, A | 1 |
| La Torre, PP | 1 |
| Cannone, M | 1 |
| Wang, L | 1 |
| Li, L | 1 |
| Sun, Y | 1 |
| Ding, J | 1 |
| Li, J | 1 |
| Duan, X | 1 |
| Li, Y | 1 |
| Junyaprasert, VB | 1 |
| Mao, S | 1 |
| Ishi, SV | 1 |
| Lakshmi, M | 1 |
| Kakde, ST | 1 |
| Sabnis, KC | 1 |
| Jagannati, M | 1 |
| Girish, TS | 1 |
| Jeyaseelan, L | 1 |
| Cherian, AM | 1 |
| Sengodan, P | 1 |
| Grewal, H | 1 |
| Gandhi, S | 1 |
| Bookhart, BK | 1 |
| Haskell, L | 1 |
| Schein, J | 1 |
| Mody, SH | 2 |
| Sebastian, R | 1 |
| Ghanem, O | 1 |
| DiRoma, F | 1 |
| Milner, SM | 1 |
| Price, LA | 1 |
| Barbot, M | 1 |
| Daidone, V | 1 |
| Zilio, M | 1 |
| Albiger, N | 1 |
| Mazzai, L | 1 |
| Sartori, MT | 1 |
| Frigo, AC | 1 |
| Scanarini, M | 1 |
| Denaro, L | 1 |
| Boscaro, M | 1 |
| Casonato, S | 1 |
| Ceccato, F | 1 |
| Scaroni, C | 1 |
| Pavlovic, G | 1 |
| Banfi, C | 1 |
| Tassaux, D | 1 |
| Peter, RE | 1 |
| Licker, MJ | 1 |
| Bendjelid, K | 1 |
| Giraud, R | 1 |
| Kesieme, EB | 1 |
| Okokhere, P | 1 |
| Eluehike, S | 1 |
| Isabu, P | 1 |
| Sengupta, N | 1 |
| Feuerstein, JD | 1 |
| Patwardhan, VR | 1 |
| Tapper, EB | 1 |
| Ketwaroo, GA | 1 |
| Thaker, AM | 1 |
| Leffler, DA | 1 |
| Shoda, N | 1 |
| Yasunaga, H | 1 |
| Horiguchi, H | 1 |
| Fushimi, K | 1 |
| Matsuda, S | 1 |
| Kadono, Y | 1 |
| Tanaka, S | 1 |
| Patel, AA | 1 |
| Ogden, K | 1 |
| Bookhart, B | 1 |
| Ma, G | 1 |
| Zhang, R | 1 |
| Wu, X | 1 |
| Wang, D | 1 |
| Ying, K | 1 |
| Vazquez, FJ | 1 |
| Paulin, P | 1 |
| Rodriguez, P | 1 |
| Lubertino, M | 1 |
| Gándara, E | 1 |
| Holländer, SW | 1 |
| Sifft, A | 1 |
| Hess, S | 1 |
| Klingen, HJ | 1 |
| Djalali, P | 1 |
| Birk, D | 1 |
| Baquero-Salamanca, M | 1 |
| Téllez-Arévalo, AM | 1 |
| Calderon-Ospina, C | 1 |
| King, AC | 1 |
| Ma, MQ | 1 |
| Chisholm, G | 1 |
| Toale, KM | 1 |
| Kumarihamy, KW | 1 |
| Ralapanawa, DM | 1 |
| Jayalath, WA | 1 |
| Squizzato, A | 1 |
| Lussana, F | 1 |
| Rabener, MJ | 1 |
| Howell, C | 1 |
| Shroff, GS | 1 |
| Okwandu, E | 1 |
| Viswanathan, C | 1 |
| Truong, MT | 1 |
| Goto, M | 1 |
| Yoshizato, T | 1 |
| Tatsumura, M | 1 |
| Takashima, T | 1 |
| Ogawa, M | 1 |
| Nakahara, H | 1 |
| Satoh, S | 1 |
| Sanui, A | 1 |
| Eguchi, F | 1 |
| Miyamoto, S | 1 |
| Pütter, C | 1 |
| von Beckerath, O | 1 |
| Sobik, HM | 1 |
| Reinecke, H | 1 |
| Stausberg, J | 1 |
| Kröger, K | 2 |
| Singh, RR | 1 |
| Gupte-Singh, KR | 1 |
| Wilson, JP | 1 |
| Moffett, BS | 1 |
| Triscott, J | 1 |
| Mercer, S | 1 |
| Tian, PG | 1 |
| Dobbs, B | 1 |
| Choe, H | 1 |
| Elfil, M | 1 |
| DeSancho, MT | 1 |
| Liu, X | 1 |
| Johnson, M | 1 |
| Mardekian, J | 1 |
| Phatak, H | 1 |
| Thompson, J | 1 |
| Na, YG | 1 |
| Fang, R | 1 |
| Kim, YH | 1 |
| Cho, KJ | 1 |
| Kim, TK | 1 |
| Ricket, AL | 1 |
| Stewart, DW | 1 |
| Wood, RC | 1 |
| Cornett, L | 1 |
| Odle, B | 1 |
| Cluck, D | 1 |
| Freshour, J | 1 |
| El-Bazouni, H | 1 |
| Campbell, PM | 1 |
| Ippoliti, C | 1 |
| Parmar, S | 1 |
| Brown, TJ | 1 |
| Khan, SA | 1 |
| Duan, L | 1 |
| Zhang, N | 1 |
| Yan, H | 1 |
| Guo, Y | 1 |
| Hong, C | 1 |
| Su, X | 1 |
| Chen, R | 1 |
| Zhou, Y | 1 |
| Zhong, N | 1 |
| Liu, C | 1 |
| Cygan, LD | 1 |
| Weizberg, M | 1 |
| Hahn, B | 1 |
| King, DA | 1 |
| Pow, RE | 1 |
| Dickison, DM | 1 |
| Vale, PR | 1 |
| Herath, HM | 1 |
| Kulatunga, A | 1 |
| Ko, A | 1 |
| Harada, MY | 1 |
| Barmparas, G | 1 |
| Chung, K | 1 |
| Mason, R | 1 |
| Yim, DA | 1 |
| Dhillon, N | 1 |
| Margulies, DR | 1 |
| Gewertz, BL | 1 |
| Ley, EJ | 1 |
| Radzak, KN | 1 |
| Wages, JJ | 1 |
| Hall, KE | 1 |
| Nakasone, CK | 1 |
| Khraise, WN | 1 |
| Allouh, MZ | 1 |
| Hiasat, MY | 1 |
| Said, RS | 1 |
| Raheemullah, A | 1 |
| Laurence, TN | 1 |
| Schmidt-Braekling, T | 1 |
| Pearle, AD | 1 |
| Mayman, DJ | 1 |
| Westrich, GH | 1 |
| Waldstein, W | 1 |
| Boettner, F | 1 |
| Rahawi, KW | 1 |
| Higgins, KL | 1 |
| Noda, C | 1 |
| Stultz, JS | 1 |
| Xie, J | 1 |
| Ma, J | 1 |
| Huang, Q | 1 |
| Yue, C | 1 |
| Pei, F | 1 |
| Imamura, H | 1 |
| Adachi, T | 1 |
| Kitasato, A | 1 |
| Tanaka, T | 1 |
| Soyama, A | 1 |
| Hidaka, M | 1 |
| Fujita, F | 1 |
| Takatsuki, M | 1 |
| Kuroki, T | 1 |
| Eguchi, S | 1 |
| Halaby, R | 1 |
| Korjian, S | 1 |
| Daaboul, Y | 1 |
| Hull, R | 1 |
| Lu, SP | 1 |
| Bandman, O | 1 |
| Leeds, JM | 1 |
| Eriksson, BI | 9 |
| Borris, LC | 3 |
| Friedman, RJ | 1 |
| Haas, S | 8 |
| Kakkar, AK | 7 |
| Bandel, TJ | 2 |
| Beckmann, H | 1 |
| Muehlhofer, E | 1 |
| Misselwitz, F | 6 |
| Geerts, W | 5 |
| Ageno, W | 2 |
| Lieberman, JR | 1 |
| Abu Sham'a, RA | 1 |
| Kufri, FH | 1 |
| Yassin, IH | 1 |
| Alhadad, A | 1 |
| Acosta, S | 1 |
| Sarabi, L | 1 |
| Kölbel, T | 1 |
| Bendinelli, C | 1 |
| Balogh, Z | 1 |
| Lotke, PA | 1 |
| Bozcali, E | 1 |
| Tutpinar, Y | 1 |
| Villalba, JC | 1 |
| Zhang, H | 1 |
| Wu, WD | 1 |
| Kim, EK | 1 |
| Eom, JS | 1 |
| Ahn, SH | 1 |
| Son, BH | 1 |
| Lee, TJ | 1 |
| Bauer, KA | 4 |
| Davidson, BL | 6 |
| Fisher, WD | 2 |
| Huo, MH | 1 |
| Sinha, U | 1 |
| Gretler, DD | 1 |
| Stiefelhagen, P | 1 |
| Baker, EL | 1 |
| Loewenthal, T | 1 |
| Salerno, E | 1 |
| Baker, WL | 1 |
| van Doormaal, FF | 1 |
| Gallus, A | 1 |
| Piovella, F | 3 |
| Reeves, D | 1 |
| Liu, CY | 1 |
| Varela Rois, P | 1 |
| González García, J | 1 |
| Pérez Rodríguez, MT | 1 |
| Paseiro García, MJ | 1 |
| Carcacía Hermilla, ID | 1 |
| Peral, D | 1 |
| Higueras, R | 1 |
| Onrubia, X | 1 |
| Bellver, J | 1 |
| Bhatia, V | 1 |
| Arora, P | 1 |
| Parida, AK | 1 |
| Mittal, A | 1 |
| Pandey, AK | 1 |
| Kaul, U | 1 |
| Bindelglass, DF | 1 |
| Rosenblum, DS | 1 |
| Suárez-Gea, ML | 1 |
| Pozo-Hernández, C | 1 |
| Amin, AN | 1 |
| Lin, J | 1 |
| Johnson, BH | 1 |
| Schulman, KL | 1 |
| Byrne, M | 2 |
| Reynolds, JV | 1 |
| O'Donnell, JS | 1 |
| Keogan, M | 1 |
| White, B | 1 |
| Murphy, S | 1 |
| Maher, SG | 1 |
| Pidgeon, GP | 1 |
| Ouyang, DL | 1 |
| Chow, AY | 1 |
| Daly, TK | 1 |
| Garza, D | 1 |
| Matheson, GO | 1 |
| Axon, RN | 1 |
| Cawley, PJ | 1 |
| Fernández, E | 1 |
| Dueñas, N | 1 |
| Villafranca, A | 1 |
| Perea, M | 1 |
| Amorós, B | 1 |
| Bermejo, L | 1 |
| Lang, A | 1 |
| Kienitz, C | 1 |
| Wetzel, P | 1 |
| Rollnik, JD | 1 |
| Singer, JP | 1 |
| Huang, MY | 1 |
| Blanc, PD | 1 |
| Boettger, RF | 1 |
| Golden, J | 1 |
| Watkins, K | 1 |
| Hoopes, C | 1 |
| Leard, LE | 1 |
| Korsten-Reck, U | 1 |
| Winterer, J | 1 |
| König, D | 1 |
| Dickhuth, HH | 1 |
| Hajj-Chahine, J | 1 |
| Jayle, C | 1 |
| Tomasi, J | 1 |
| Corbi, P | 1 |
| Braun, S | 1 |
| Beyer-Westendorf, J | 2 |
| Platzek, I | 1 |
| Höffken, G | 1 |
| Halank, M | 1 |
| Cao, C | 1 |
| Kupfer, S | 1 |
| Raskob, G | 3 |
| Spaeder, J | 1 |
| Zufferey, PJ | 1 |
| Sachithanandan, A | 1 |
| Tsiridis, E | 1 |
| Gamie, Z | 1 |
| George, MJ | 1 |
| Hamilton-Baille, D | 1 |
| West, RM | 1 |
| Giannoudis, PV | 1 |
| Bailey, SH | 1 |
| Dreszer, G | 1 |
| Fisher Wachtman, C | 1 |
| Zumsteg, JW | 1 |
| Jaber, RM | 1 |
| Hamill, JB | 1 |
| Hume, KM | 1 |
| Rubin, JP | 1 |
| Neligan, PC | 1 |
| Kalliainen, LK | 1 |
| Hoxworth, RE | 1 |
| Pusic, AL | 1 |
| Wilkins, EG | 1 |
| Brenner, B | 2 |
| Gallus, AS | 6 |
| Cohen, A | 3 |
| Mukand, JA | 1 |
| Mukand, NH | 1 |
| Mehta, KV | 1 |
| Lee, HC | 1 |
| Loh, JS | 1 |
| Loke, YK | 1 |
| Kwok, CS | 1 |
| Dempfle, CE | 1 |
| Elmas, E | 1 |
| Link, A | 1 |
| Suvajac, N | 1 |
| Liebe, V | 1 |
| Janes, J | 1 |
| Borggrefe, M | 1 |
| Yaméogo, NV | 1 |
| Mbaye, A | 1 |
| Kagambèga, LJ | 1 |
| Diack, B | 1 |
| Pessinaba, S | 1 |
| Hakim, R | 1 |
| Ndiaye, MB | 1 |
| Bodian, M | 1 |
| Diao, M | 1 |
| Sow, DD | 1 |
| Kane, M | 1 |
| Kane, A | 1 |
| Godier, A | 1 |
| Shapiro, M | 1 |
| Wistinghausen, B | 1 |
| Midulla, P | 1 |
| Chin, C | 1 |
| Landman, GW | 1 |
| Gans, RO | 1 |
| Pai, RP | 1 |
| Kangath, RV | 1 |
| Brown, TA | 1 |
| Dashti-Khavidaki, S | 1 |
| Najmedin, F | 1 |
| Hosseinpoor, R | 1 |
| Stark, JE | 1 |
| Smith, WJ | 1 |
| Adelman, LC | 1 |
| McGillicuddy, DC | 1 |
| Howard, L | 1 |
| Salooja, N | 1 |
| Aujesky, D | 1 |
| Roy, PM | 2 |
| Verschuren, F | 1 |
| Osterwalder, J | 1 |
| Egloff, M | 1 |
| Renaud, B | 1 |
| Stone, RA | 1 |
| Legall, C | 1 |
| Sanchez, O | 2 |
| Pugh, NA | 1 |
| N'gako, A | 1 |
| Cornuz, J | 1 |
| Hugli, O | 1 |
| Beer, HJ | 1 |
| Fine, MJ | 1 |
| Yealy, DM | 1 |
| Minshall, CT | 1 |
| Eriksson, EA | 1 |
| Leon, SM | 1 |
| Doben, AR | 1 |
| McKinzie, BP | 1 |
| Fakhry, SM | 1 |
| Larocca, A | 1 |
| Cavallo, F | 1 |
| Bringhen, S | 1 |
| Di Raimondo, F | 1 |
| Falanga, A | 1 |
| Evangelista, A | 1 |
| Cavalli, M | 1 |
| Stanevsky, A | 1 |
| Corradini, P | 1 |
| Pezzatti, S | 1 |
| Patriarca, F | 1 |
| Cavo, M | 1 |
| Peccatori, J | 1 |
| Catalano, L | 1 |
| Carella, AM | 1 |
| Cafro, AM | 1 |
| Siniscalchi, A | 1 |
| Crippa, C | 1 |
| Petrucci, MT | 1 |
| Yehuda, DB | 1 |
| Beggiato, E | 1 |
| Di Toritto, TC | 1 |
| Boccadoro, M | 1 |
| Nagler, A | 1 |
| Palumbo, A | 1 |
| Vorob'eva, NM | 1 |
| Panchenko, EP | 1 |
| Ermolina, OV | 1 |
| Balakhonova, TV | 1 |
| Dobrovol'skiĭ, AB | 1 |
| Titaeva, EV | 1 |
| Khasanova, ZB | 1 |
| Postnov, AIu | 1 |
| Kirienko, AI | 2 |
| Cuerva-González, MJ | 1 |
| Lacoponi, S | 1 |
| de la Calle-Fernández, M | 1 |
| Pozo-Krielinger, J | 1 |
| Leizorovicz, A | 6 |
| Haas, SK | 1 |
| Merli, G | 3 |
| Knabb, RM | 1 |
| Xia, XY | 1 |
| Tan, YL | 1 |
| Sun, YW | 1 |
| Yan, GD | 1 |
| Rong, YX | 1 |
| Ren, QH | 1 |
| Liu, JY | 1 |
| Xu, XZ | 1 |
| Shan, GP | 1 |
| Jin, L | 1 |
| Fanikos, J | 1 |
| Rao, A | 1 |
| Seger, AC | 1 |
| Catapane, E | 1 |
| Eikelboom, JW | 1 |
| Pillion, G | 1 |
| Berghaus, TM | 1 |
| Faul, C | 1 |
| Unterer, F | 1 |
| Thilo, C | 1 |
| von Scheidt, W | 1 |
| Schwaiblmair, M | 1 |
| Lensin, AW | 1 |
| Minar, E | 1 |
| Chlumsky, J | 2 |
| Hamilton, SC | 1 |
| Whang, WW | 1 |
| Anderson, BJ | 1 |
| Bradbury, TL | 1 |
| Erens, GA | 1 |
| Roberson, JR | 1 |
| Shin, JH | 1 |
| Kim, GN | 1 |
| Kil, HR | 1 |
| Chang, MY | 1 |
| Aispuru, GR | 1 |
| Clavier, MM | 1 |
| Cardone, AJ | 1 |
| Gilberto, DO | 1 |
| Barousse, AP | 1 |
| Chick, JF | 1 |
| Chauhan, NR | 1 |
| Mullen, KM | 1 |
| Bair, RJ | 1 |
| Khurana, B | 1 |
| Yildiz, M | 1 |
| Karakoyun, S | 1 |
| Acar, RD | 1 |
| Ozkan, M | 1 |
| Gómez Arrayas, I | 1 |
| Suárez Fernández, C | 1 |
| Gómez Cerezo, JF | 1 |
| Betegón Nicolás, L | 1 |
| de Salas-Cansado, M | 1 |
| Rubio-Terrés, C | 1 |
| Tsung, AH | 1 |
| Williams, JB | 1 |
| Whitford, AC | 1 |
| Lee, TH | 1 |
| Alonzo, BJ | 1 |
| Differding, J | 1 |
| Underwood, SJ | 1 |
| Hamilton, G | 1 |
| Kremenevskiy, I | 1 |
| McNamara, S | 1 |
| Schreiber, MA | 1 |
| Thumbikat, P | 1 |
| Poonnoose, PM | 1 |
| Balasubrahmaniam, P | 1 |
| Ravichandran, G | 1 |
| McClelland, MR | 1 |
| Mrug, M | 1 |
| Mishra, PV | 1 |
| Lusane, HC | 1 |
| Cunningham, JM | 1 |
| Alpert, MA | 1 |
| Findik, S | 1 |
| Erkan, ML | 1 |
| Selçuk, MB | 1 |
| Albayrak, S | 1 |
| Atici, AG | 1 |
| Doru, F | 1 |
| Mouly, S | 1 |
| Kaaja, RJ | 1 |
| Ulander, VM | 1 |
| Ahmed, S | 1 |
| Karim, A | 1 |
| Siddiqui, R | 1 |
| Mattana, J | 1 |
| Dahl, OE | 3 |
| Eskilson, C | 1 |
| Nylander, I | 1 |
| Frison, L | 2 |
| Ogren, M | 1 |
| Kurtoğlu, M | 3 |
| Büyükkurt, CD | 1 |
| Dural, CA | 1 |
| Güloğlu, R | 2 |
| Akar, U | 1 |
| Ennis, RS | 1 |
| Beckman, JA | 1 |
| Sasahara, AA | 2 |
| Pérez de Llano, LA | 1 |
| Baloira Villar, A | 1 |
| Veres Racamonde, A | 1 |
| Veiga, F | 1 |
| Golpe Gómez, R | 1 |
| Pajuelo Fernández, F | 1 |
| Ibrahim, A | 1 |
| Ashkan, K | 1 |
| Smith, M | 1 |
| Watkins, L | 1 |
| Desjardins, L | 3 |
| Bara, L | 1 |
| Boutitie, F | 1 |
| Samama, MM | 2 |
| Combe, S | 1 |
| Janbon, C | 2 |
| Olsson, CG | 6 |
| McGarry, LJ | 1 |
| Thompson, D | 1 |
| Hofmann, T | 2 |
| De Blanche, LE | 1 |
| Schmitz, ML | 1 |
| Johnson, CE | 1 |
| Best, TH | 1 |
| Drummond-Webb, JJ | 1 |
| Schwarcz, TH | 1 |
| Matthews, MR | 1 |
| Hartford, JM | 1 |
| Quick, RC | 1 |
| Kwolek, CJ | 1 |
| Minion, DJ | 1 |
| Endean, ED | 1 |
| Mentzer, RM | 1 |
| Bird, H | 1 |
| Kapoor, V | 1 |
| Vallance, H | 1 |
| Abdel-Razeq, H | 1 |
| De Groote, K | 1 |
| Annemans, L | 1 |
| Yanar, H | 1 |
| Bilsel, Y | 1 |
| Kizilirmak, S | 1 |
| Buyukkurt, D | 1 |
| Granit, V | 1 |
| Hebbeler, SL | 1 |
| Marciniak, CM | 1 |
| Crandall, S | 1 |
| Chen, D | 1 |
| Nussbaum, S | 1 |
| Mendelewski, S | 1 |
| Topgül, K | 1 |
| Uzun, O | 1 |
| Anadol, AZ | 1 |
| Gök, A | 1 |
| Enyart, JJ | 1 |
| Jones, RJ | 1 |
| Olsen, J | 1 |
| Gundgaard, J | 1 |
| Stannard, JP | 1 |
| Singhania, AK | 1 |
| Lopez-Ben, RR | 1 |
| Anderson, ER | 1 |
| Farris, RC | 1 |
| Volgas, DA | 1 |
| McGwin, GR | 1 |
| Alonso, JE | 1 |
| Rutherford, EJ | 1 |
| Schooler, WG | 1 |
| Sredzienski, E | 1 |
| Abrams, JE | 1 |
| Skeete, DA | 1 |
| Alonso Martínez, JL | 1 |
| Abínzano Guillén, ML | 1 |
| Solano Remírez, M | 1 |
| Alvarez Frías, MT | 1 |
| Gutiérrez Dubois, J | 1 |
| Munuera García, L | 1 |
| Brighton, TA | 1 |
| Baker, RI | 2 |
| Thurlow, P | 1 |
| Lee, CH | 1 |
| Quenet, S | 1 |
| Levine, M | 1 |
| Derobert, E | 1 |
| Potdar, N | 1 |
| Jabbar, B | 1 |
| Burrell, SJ | 1 |
| Tan, EK | 1 |
| Wisdom, SJ | 1 |
| Borris, L | 2 |
| Kälebo, P | 2 |
| Patel, RK | 1 |
| Ramasamy, K | 1 |
| Goss, D | 1 |
| Deane, C | 1 |
| Bonner, L | 1 |
| Arya, R | 1 |
| Quiroz, R | 1 |
| McKean, S | 1 |
| Bischoff, A | 1 |
| Kaluza, V | 1 |
| Rao, DS | 1 |
| Said, JW | 1 |
| de Vos, S | 1 |
| Myers, J | 1 |
| Lee, MC | 1 |
| Nickisch, F | 1 |
| Limbird, RS | 1 |
| Castro, DJ | 1 |
| Díaz, G | 1 |
| Martí, D | 1 |
| Escobar, C | 1 |
| Ortega, J | 1 |
| García-Rull, S | 1 |
| Picher, J | 1 |
| Sueiro, A | 1 |
| Crooke, B | 1 |
| Callaway, LK | 1 |
| Schulz, SL | 1 |
| Kesselring, C | 1 |
| Seeberger, U | 1 |
| Andresen, D | 1 |
| Jeong, GK | 1 |
| Gruson, KI | 1 |
| Egol, KA | 1 |
| Aharonoff, GB | 1 |
| Karp, AH | 1 |
| Zuckerman, JD | 1 |
| Koval, KJ | 1 |
| Slavik, RS | 1 |
| Chan, E | 1 |
| Gorman, SK | 1 |
| de Lemos, J | 1 |
| Chittock, D | 1 |
| Simons, RK | 1 |
| Wing, PC | 1 |
| Ho, SG | 1 |
| Homering, M | 1 |
| Kwong, LM | 1 |
| Lynd, LD | 1 |
| Goeree, R | 1 |
| Crowther, MA | 2 |
| O'Brien, BJ | 1 |
| Martins, HS | 1 |
| Scalabrini-Neto, A | 1 |
| Velasco, IT | 1 |
| Abdul-Jalil, Y | 1 |
| Bartels, J | 1 |
| Alberti, O | 1 |
| Becker, R | 1 |
| Benjamin, SP | 1 |
| Saravanan, K | 1 |
| Jayanth, JJ | 1 |
| Thirugnanam, P | 1 |
| Premkumar, R | 1 |
| Kenny, B | 1 |
| Volobuev, V | 1 |
| Dorr, LD | 1 |
| Gendelman, V | 1 |
| Maheshwari, AV | 1 |
| Boutary, M | 1 |
| Wan, Z | 1 |
| Long, WT | 1 |
| Doboszyńska, A | 2 |
| Koć, M | 1 |
| Koć, K | 1 |
| Swietlik, E | 2 |
| Sosnowska, E | 1 |
| Tomaszewska, I | 2 |
| Rozek, M | 1 |
| Jerjes-Sánchez, C | 1 |
| Villarreal-Umaña, S | 1 |
| Ramírez-Rivera, A | 1 |
| Garcia-Sosa, A | 1 |
| Miguel-Canseco, L | 1 |
| Archondo, T | 1 |
| Reyes, E | 1 |
| Garza, A | 1 |
| Arriaga, R | 1 |
| Castillo, F | 1 |
| Jasso, O | 1 |
| Garcia, H | 1 |
| Bermudez, M | 1 |
| Hernandez, JM | 1 |
| Garcia, J | 1 |
| Martinez, P | 1 |
| Rangel, F | 1 |
| Gutierrez, J | 1 |
| Comparan-Nuñez, A | 1 |
| Ojo, P | 1 |
| Asiyanbola, B | 1 |
| Valin, E | 1 |
| Reinhold, R | 1 |
| Dahl, O | 1 |
| Zielske, D | 1 |
| Tran, H | 1 |
| McRae, S | 1 |
| Ginsberg, J | 2 |
| Flosbach, CW | 1 |
| Avikainen, V | 1 |
| von Bonsdorff, H | 1 |
| Partio, E | 1 |
| Kaira, P | 1 |
| Hakkinen, S | 1 |
| Usenius, JP | 1 |
| Kaaja, R | 1 |
| Menzin, J | 1 |
| Colditz, GA | 1 |
| Regan, MM | 1 |
| Richner, RE | 1 |
| Oster, G | 1 |
| Boneu, B | 3 |
| Slunsky, R | 1 |
| Leclerc, JR | 3 |
| Geerts, WH | 3 |
| Laflamme, GH | 1 |
| L'Espérance, B | 1 |
| Demers, C | 1 |
| Kassis, J | 1 |
| Cruickshank, M | 2 |
| Whitman, L | 1 |
| Delorme, F | 1 |
| Bergqvist, D | 3 |
| Benoni, G | 1 |
| Björgell, O | 1 |
| Fredin, H | 1 |
| Hedlundh, U | 1 |
| Nicolas, S | 1 |
| Nilsson, P | 1 |
| Nylander, G | 1 |
| Massicotte, P | 2 |
| Adams, M | 1 |
| Marzinotto, V | 2 |
| Brooker, LA | 1 |
| Andrew, M | 2 |
| Kalodiki, EP | 1 |
| Hoppensteadt, DA | 1 |
| Fareed, J | 3 |
| Gill, K | 1 |
| Regan, F | 1 |
| al-Kutoubi, A | 1 |
| Cunningham, DA | 1 |
| Birch, R | 1 |
| Harris, N | 1 |
| Hunt, D | 2 |
| Johnson, J | 1 |
| Marx, C | 1 |
| Neuhart, E | 1 |
| Gallay, S | 1 |
| Waddell, JP | 1 |
| Cardella, P | 1 |
| Morton, J | 1 |
| Eskander, MB | 1 |
| Limb, D | 1 |
| Stone, MH | 1 |
| Furlong, AJ | 1 |
| Shardlow, D | 1 |
| Stead, D | 1 |
| Culleton, G | 1 |
| Parent, F | 2 |
| Page, Y | 2 |
| Tardy, B | 2 |
| Faivre, R | 1 |
| Charbonnier, B | 3 |
| Barral, FG | 1 |
| Huet, Y | 1 |
| Simonneau, G | 4 |
| Hirsh, J | 3 |
| Ginsberg, JS | 3 |
| Buoncristiani, P | 1 |
| Severi, P | 1 |
| Pini, M | 1 |
| D'Angelo, A | 1 |
| Beltrametti, C | 1 |
| Damiani, M | 1 |
| Andrioli, GC | 1 |
| Pugliese, R | 1 |
| Iorio, A | 1 |
| Brambilla, G | 1 |
| Krasuski, M | 1 |
| Jagodziński, K | 1 |
| Kiwerski, JE | 1 |
| Krzyzosiak, L | 1 |
| Planes, A | 1 |
| Vochelle, N | 1 |
| Darmon, JY | 2 |
| Zolotukhin, IA | 1 |
| Porterfield, LM | 1 |
| Colwell, CW | 2 |
| Collis, DK | 1 |
| Paulson, R | 1 |
| McCutchen, JW | 1 |
| Bigler, GT | 1 |
| Lutz, S | 1 |
| Hardwick, ME | 1 |
| Cereza, G | 1 |
| Danés, I | 1 |
| Eldor, A | 3 |
| Weisslinger, N | 1 |
| Rybachuk, OI | 1 |
| Besiedyns'kyĭ, SM | 1 |
| Huliaiev, DV | 1 |
| Tseng, CW | 1 |
| Huntington, J | 1 |
| Calderon, EJ | 1 |
| Varela, JM | 1 |
| Gonzalez de la Puente, MA | 1 |
| Stratton, MA | 1 |
| Anderson, FA | 1 |
| Bussey, HI | 2 |
| Caprini, J | 1 |
| Comerota, A | 1 |
| Haines, ST | 1 |
| Hawkins, DW | 3 |
| O'Connell, MB | 2 |
| Smith, RC | 1 |
| Stringer, KA | 1 |
| Bollinger, KA | 1 |
| Vermeulen, LC | 1 |
| Davis, SN | 1 |
| Geurkink, EA | 1 |
| Wade, WE | 2 |
| Groce, JB | 1 |
| Spiro, TE | 2 |
| Abildgaard, U | 1 |
| Elias, D | 1 |
| Grigg, A | 1 |
| Musset, D | 1 |
| Rodgers, GM | 1 |
| Trowbridge, AA | 3 |
| Yusen, RD | 1 |
| Zawilska, K | 1 |
| Norwood, SH | 1 |
| McAuley, CE | 1 |
| Berne, JD | 1 |
| Vallina, VL | 1 |
| Kerns, DB | 1 |
| Grahm, TW | 1 |
| McLarty, JW | 1 |
| Lopez, LM | 1 |
| Deep, K | 1 |
| Jigajinni, MV | 1 |
| McLean, AN | 1 |
| Fraser, MH | 1 |
| Fitzgerald, RH | 1 |
| Gardiner, GA | 1 |
| Whitsett, TL | 1 |
| Ohar, JA | 1 |
| Young, TR | 1 |
| Marietta, M | 1 |
| Bertesi, M | 1 |
| Simoni, L | 1 |
| Castelli, I | 1 |
| Cappi, C | 1 |
| Torelli, G | 1 |
| Thaler, HW | 1 |
| Roller, RE | 1 |
| Greiner, N | 1 |
| Sim, E | 1 |
| Korninger, C | 1 |
| Wilson, MD | 1 |
| Harrison, K | 1 |
| Heit, JA | 2 |
| Francis, CW | 1 |
| Whipple, J | 1 |
| Peters, G | 1 |
| Alikhan, R | 1 |
| Decousus, M | 1 |
| Buchmuller, A | 1 |
| Hervé, P | 1 |
| Lamer, C | 1 |
| Spruill, WJ | 1 |
| Diuguid, DL | 1 |
| Perry, DJ | 1 |
| Nilsson, PE | 1 |
| Le Moigne-Amrani, A | 1 |
| Dietrich-Neto, F | 1 |
| Doggrell, SA | 1 |
| Stellbrink, C | 1 |
| Hanrath, P | 1 |
| Nixdorff, U | 1 |
| Lehmacher, W | 1 |
| Kühle, K | 1 |
| Fetsch, T | 1 |
| Grewe, R | 1 |
| Schmidt-Lucke, JA | 1 |
| Manninen, I | 1 |
| Counsell, C | 1 |
| Sandercock, P | 1 |
| Shields, K | 1 |
| Szechtman, B | 1 |
| Boeckl, O | 1 |
| Bordenave, L | 1 |
| Brehm, OA | 1 |
| Brücke, P | 1 |
| Coccheri, S | 1 |
| Galland, F | 1 |
| Jarrige, J | 1 |
| Koppenhagen, K | 2 |
| LeQuerrec, A | 1 |
| Parraguette, E | 1 |
| Roder, JD | 1 |
| Roos, M | 1 |
| Rüschemeyer, C | 1 |
| Siewert, JR | 1 |
| Vinazzer, H | 1 |
| Wenzel, E | 1 |
| Baildon, R | 1 |
| Breddin, HK | 2 |
| Hach-Wunderle, V | 1 |
| Nakov, R | 2 |
| Hoppenstead, DA | 1 |
| Scully, M | 1 |
| Riess, H | 2 |
| Becker, LK | 1 |
| Melzer, N | 1 |
| Greinacher, A | 1 |
| Schwanebeck, U | 1 |
| Sieder, C | 1 |
| Abletshauser, C | 1 |
| Bramlage, P | 1 |
| Diener, HC | 2 |
| Wolf, H | 2 |
| Encke, A | 2 |
| Ringelstein, EB | 1 |
| von Kummer, R | 1 |
| Landgraf, H | 1 |
| Rektor, I | 1 |
| Csányi, A | 1 |
| Schneider, D | 1 |
| Klingelhöfer, J | 1 |
| Brom, J | 1 |
| Weidinger, G | 1 |
| Planquette, B | 1 |
| Bertoletti, L | 1 |
| Charles-Nelson, A | 1 |
| Grange, C | 1 |
| Pernod, G | 1 |
| Elias, A | 2 |
| Falvo, N | 1 |
| Sevestre, MA | 1 |
| Ray, V | 1 |
| Burnod, A | 1 |
| Brebion, N | 1 |
| Timar-David, M | 1 |
| Aquilanti, S | 1 |
| Constans, J | 1 |
| Bura-Rivière, A | 1 |
| Chatellier, G | 1 |
| Meyer, G | 5 |
| Burns, KEA | 1 |
| Heels-Ansdell, D | 6 |
| Thabane, L | 2 |
| Lauzier, F | 1 |
| Mehta, S | 2 |
| Ostermann, M | 1 |
| Bhuptani, P | 1 |
| Finfer, S | 3 |
| Cook, DJ | 2 |
| Becattini, C | 1 |
| Muñoz, A | 1 |
| Torbicki, A | 1 |
| Sueiro, MR | 1 |
| Lambert, C | 1 |
| Gussoni, G | 1 |
| Campanini, M | 1 |
| Vescovo, G | 1 |
| Ebner, M | 1 |
| Lankeit, M | 1 |
| Aho, T | 1 |
| Al-Hayek, S | 1 |
| Winterbottom, A | 1 |
| Koo, B | 1 |
| Warren, A | 1 |
| Khorana, AA | 3 |
| Noble, S | 1 |
| Lee, AYY | 2 |
| Soff, G | 1 |
| O'Connell, C | 1 |
| Di Nisio, M | 3 |
| van Es, N | 2 |
| Wang, TF | 1 |
| Garcia, D | 2 |
| Weitz, J | 1 |
| Buller, H | 2 |
| Liang, JJ | 1 |
| Goldberg, AD | 1 |
| Afessa, B | 1 |
| Fowler, RA | 1 |
| Mittmann, N | 1 |
| Guyatt, G | 5 |
| Krahn, M | 1 |
| Pinto, R | 1 |
| Chan, B | 1 |
| Ormanidhi, O | 1 |
| Arabi, Y | 1 |
| Qushmaq, I | 3 |
| Rocha, MG | 1 |
| Dodek, P | 1 |
| McIntyre, L | 1 |
| Hall, R | 1 |
| Ferguson, ND | 2 |
| Marshall, JC | 1 |
| Doig, CJ | 1 |
| Muscedere, J | 1 |
| Jacka, MJ | 1 |
| Klinger, JR | 1 |
| Vlahakis, N | 1 |
| Orford, N | 1 |
| Seppelt, I | 1 |
| Skrobik, YK | 1 |
| Sud, S | 1 |
| Cade, JF | 1 |
| Cooper, J | 1 |
| Cook, D | 4 |
| Larsen, AC | 1 |
| Brøndum Frøkjaer, J | 1 |
| Wishwanath Iyer, V | 1 |
| Vincents Fisker, R | 1 |
| Sall, M | 1 |
| Yilmaz, MK | 1 |
| Kuno Møller, B | 1 |
| Kristensen, SR | 1 |
| Thorlacius-Ussing, O | 1 |
| Bleker, SM | 1 |
| Mercuri, MF | 1 |
| Kakkar, A | 1 |
| Boda, Z | 1 |
| Gibbs, H | 1 |
| Kamphuisen, PW | 2 |
| Ockelford, P | 1 |
| Pabinger, I | 1 |
| Li, G | 1 |
| Levine, MAH | 1 |
| Crowther, M | 4 |
| Holbrook, A | 1 |
| Lamontagne, F | 1 |
| Walter, SD | 2 |
| Arabi, YM | 1 |
| Bellomo, R | 1 |
| Cooper, DJ | 3 |
| Shaya, SA | 1 |
| Saldanha, LJ | 1 |
| Vaezzadeh, N | 1 |
| Zhou, J | 1 |
| Ni, R | 1 |
| Gross, PL | 1 |
| Bobinskas, A | 1 |
| Dunbar, E | 1 |
| Koppel, D | 1 |
| Plante, S | 1 |
| Belzile, EL | 1 |
| Fréchette, D | 1 |
| Lefebvre, J | 1 |
| Dindo, D | 1 |
| Breitenstein, S | 1 |
| Hahnloser, D | 1 |
| Seifert, B | 1 |
| Yakarisik, S | 1 |
| Asmis, LM | 1 |
| Muller, MK | 1 |
| Clavien, PA | 1 |
| Niemi, T | 1 |
| Silvasti-Lundell, M | 1 |
| Armstrong, E | 1 |
| Hernesniemi, J | 1 |
| Ganguli, A | 1 |
| Walker, L | 1 |
| FitzGerald, RJ | 1 |
| Pirmohamed, M | 1 |
| Kerr, J | 1 |
| Linkins, LA | 1 |
| Puskas, D | 1 |
| Bocanegra, T | 1 |
| Meade, M | 3 |
| Walter, S | 1 |
| Warkentin, TE | 2 |
| Zytaruk, N | 3 |
| Vallance, S | 2 |
| Rocha, M | 2 |
| Berwanger, O | 2 |
| Vlahakis, NE | 1 |
| Esterbrook, G | 1 |
| Hart, S | 1 |
| Heaton, D | 1 |
| Han, DY | 1 |
| Inder, A | 1 |
| Bonet, M | 1 |
| Roncales, J | 2 |
| Muchart, J | 1 |
| Fraile, M | 1 |
| Bick, RL | 1 |
| Lee, AY | 1 |
| Levine, MN | 1 |
| Bowden, C | 1 |
| Rickles, FR | 1 |
| Kovacs, MJ | 4 |
| Vaitkus, PT | 2 |
| Zacharski, L | 1 |
| Jiménez, JA | 1 |
| Vilaseca, B | 1 |
| Pokrovskaia, EV | 1 |
| Many, A | 1 |
| Koren, G | 1 |
| Anderson, DR | 1 |
| Rodger, MA | 1 |
| Forgie, MA | 1 |
| Florack, P | 1 |
| Touchie, D | 2 |
| Morrow, B | 3 |
| Gray, L | 2 |
| O'Rourke, K | 1 |
| Wells, G | 1 |
| Kovacs, J | 1 |
| DeBernardo, RL | 1 |
| Perkins, RB | 1 |
| Littell, RD | 1 |
| Krasner, CN | 1 |
| Duska, LR | 1 |
| Moore, A | 1 |
| Lau, E | 1 |
| Yang, C | 1 |
| Mackool, B | 1 |
| Kuter, DJ | 1 |
| Douketis, J | 1 |
| Granton, J | 1 |
| Skrobik, Y | 1 |
| Albert, M | 1 |
| Fowler, R | 1 |
| Hebert, P | 1 |
| Pagliarello, G | 1 |
| Friedrich, J | 1 |
| Freitag, A | 1 |
| Karachi, T | 1 |
| Rabbat, C | 1 |
| Walden, A | 1 |
| Levison, R | 1 |
| Keeling, D | 1 |
| Alhenc-Gelas, M | 1 |
| Jestin-Le Guernic, C | 1 |
| Vitoux, JF | 1 |
| Kher, A | 1 |
| Aiach, M | 1 |
| Fiessinger, JN | 1 |
| Lafoz, E | 1 |
| Olive, A | 1 |
| del Rio, L | 1 |
| Vedia, C | 1 |
| Brenot, F | 1 |
| Pacouret, G | 1 |
| Gillet Juvin, K | 1 |
| Sors, H | 2 |
| Partsch, H | 1 |
| Kechavarz, B | 1 |
| Mostbeck, A | 1 |
| Köhn, H | 1 |
| Lipp, C | 1 |
| Flordal, PA | 1 |
| Berggvist, D | 1 |
| Burmark, US | 1 |
| Ljungström, KG | 1 |
| Törngren, S | 1 |
| Howard, PA | 1 |
| Rowlands, S | 1 |
| Lahoud, R | 1 |
| Hertzberg, M | 1 |
| Nicholl, M | 1 |
| Chillag, KJ | 1 |
| Hoek, KJ | 1 |
| Obernosterer, A | 1 |
| Schippinger, G | 1 |
| Lipp, RW | 1 |
| Wirnsberger, G | 1 |
| Roller, R | 1 |
| Pilger, E | 1 |
| Savage, KJ | 1 |
| Schulz, V | 1 |
| Goudie, D | 1 |
| Anderson, D | 1 |
| Frostick, SP | 1 |
| Khinev, S | 1 |
| Tsoneva, D | 1 |
| Darfinova, K | 1 |
| Kamenova, B | 1 |
| Yar'mov, N | 1 |
| Borja, J | 1 |
| Olivella, P | 1 |
| Wåhlander, K | 1 |
| Larson, G | 1 |
| Lindahl, TL | 1 |
| Andersson, C | 1 |
| Gustafsson, D | 1 |
| Bylock, A | 1 |
| Xynogalos, S | 1 |
| Simeonidis, D | 1 |
| Papageorgiou, G | 1 |
| Pouliakis, A | 1 |
| Charalambakis, N | 1 |
| Lianos, E | 1 |
| Mazlimoglou, E | 1 |
| Liatsos, AN | 1 |
| Kosmas, C | 1 |
| Ziras, N | 1 |
| Karathanos, C | 3 |
| Kakkos, SK | 3 |
| Georgiadis, G | 3 |
| Ioannou, C | 3 |
| Chatzis, D | 3 |
| Latzios, P | 3 |
| Giannoukas, AD | 3 |
| Maguire, PJ | 1 |
| McGuire, M | 1 |
| Power, KA | 1 |
| McNicholl, M | 1 |
| Sheehan, SR | 1 |
| Turner, MJ | 1 |
| Østergaard, S | 1 |
| Hvas, AM | 1 |
| Medrud, L | 1 |
| Fuglsang, J | 1 |
| Khalifeh, A | 1 |
| Grantham, J | 1 |
| Byrne, J | 1 |
| Murphy, K | 1 |
| McAuliffe, F | 1 |
| Byrne, B | 1 |
| Janas, MS | 1 |
| Jarner, MF | 1 |
| Perry, SL | 1 |
| Bohlin, C | 1 |
| Reardon, DA | 1 |
| Desjardins, A | 1 |
| Friedman, AH | 1 |
| Friedman, HS | 1 |
| Vredenburgh, JJ | 1 |
| Jensen, HH | 1 |
| Søgaard, K | 1 |
| Grande, P | 1 |
| Langhoff-Roos, J | 1 |
| Diepstraten, J | 1 |
| van Kralingen, S | 1 |
| Snijder, RJ | 1 |
| Hackeng, CM | 1 |
| van Ramshorst, B | 1 |
| Knibbe, CA | 1 |
| Hoy, SM | 1 |
| Scott, LJ | 1 |
| Plosker, GL | 1 |
| Pérez-de-Llano, LA | 1 |
| Leiro-Fernández, V | 1 |
| Golpe, R | 1 |
| Núñez-Delgado, JM | 1 |
| Palacios-Bartolomé, A | 1 |
| Méndez-Marote, L | 1 |
| Colomé-Nafria, E | 1 |
| Neely, JL | 1 |
| Carlson, SS | 1 |
| Lenhart, SE | 1 |
| Taccone, FS | 1 |
| Starc, JM | 1 |
| Sculier, JP | 1 |
| Pineo, GF | 1 |
| Daskalopoulos, ME | 1 |
| Daskalopoulou, SS | 1 |
| Tzortzis, E | 1 |
| Sfiridis, P | 1 |
| Nikolaou, A | 1 |
| Dimitroulis, D | 1 |
| Kakissis, I | 1 |
| Liapis, CD | 1 |
| Sridhar, AV | 1 |
| Rao, NK | 1 |
| Chakraborty, S | 1 |
| Bitzén, U | 1 |
| Olsson, B | 1 |
| Magnusson, P | 1 |
| Carlsson, MS | 1 |
| Jonson, B | 1 |
| Bajc, M | 1 |
| Amathieu, R | 1 |
| Tual, L | 1 |
| Fessenmeyer, C | 1 |
| Dhonneur, G | 1 |
| Hyers, TM | 1 |
| Spyropoulos, AC | 1 |
| Davies, CW | 1 |
| Wimperis, J | 1 |
| Green, ES | 1 |
| Pendry, K | 1 |
| Killen, J | 1 |
| Mehdi, I | 1 |
| Tiplady, C | 1 |
| Kesteven, P | 1 |
| Rose, P | 1 |
| Oldfield, W | 1 |
| Wille-Jørgensen, P | 1 |
| Lausen, I | 1 |
| Jørgensen, LN | 1 |
| Laaban, JP | 1 |
| Azarian, R | 1 |
| Laurent, M | 1 |
| Hirsch, JL | 1 |
| Ferrari, E | 1 |
| Bosson, JL | 1 |
| Mottier, D | 1 |
| Beau, B | 1 |
| Fegan, CD | 1 |
| Wartski, M | 1 |
| Collignon, MA | 1 |
| Lewis, D | 1 |
| Allenet, B | 1 |
| Achkar, A | 1 |
| Khalifé, K | 1 |
| Elliott, CG | 1 |
| Morrey, BF | 1 |
| Heller, S | 1 |
| Krause, M | 1 |
| Porreca, E | 1 |
| Otten, HM | 1 |
| Rutjes, AW | 1 |
| Chen, YW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Contention Alone Versus Anticoagulation for Symptomatic Calf Vein Thrombosis Diagnosed by Ultrasonography[NCT00421538] | Phase 3 | 260 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis[NCT04981327] | Phase 3 | 1,300 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| Inzidenz Und Art Heparin-induzierter Hautveränderungen[NCT00510432] | 500 participants (Anticipated) | Observational | 2007-04-30 | Recruiting | |||
| Criteria for Hospitalization or Outpatient Management of Patients With Pulmonary Embolism, Hestia Rule Versus Simplified PESI Score : an Open-label Controlled Randomized International Trial (HOME-PE)[NCT02811237] | 1,975 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| Efficacy and Safety Evaluation of Recombinant Streptokinase and Urokinase in the Treatment of Pulmonary Embolism: A Multi-Center, Randomized Controlled Trial in China[NCT00968929] | Phase 4 | 83 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Efficacy and Safety Evaluation of Low Dosage of Recombinant Tissue Plasminogen Activator (rt-PA) in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China[NCT00781378] | Phase 4 | 118 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| Efficacy and Safety of Body Weight Adjusted Nadroparin vs Standard Unfractionated Heparin for the Initial Treatment of Pulmonary Thromboembolism：a Multi-Centre, Randomised Controlled Trial in China[NCT00796692] | Phase 4 | 274 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| Efficacy and Safety Evaluation of 12-h and 2-h Urokinase Regimes in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China[NCT00799968] | Phase 4 | 129 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| A Randomized, Active-comparator-controlled, Multicenter Study to Assess the Safety and Efficacy of Different Doses of BAY1213790 for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Total Knee Arthroplasty, Open-label to Tr[NCT03276143] | Phase 2 | 813 participants (Actual) | Interventional | 2017-09-21 | Completed | ||
| A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery[NCT02401594] | Phase 3 | 3,608 participants (Actual) | Interventional | 2015-12-08 | Terminated (stopped due to Remaining outdated treatments and additional costs too high for new manufacturing) | ||
| Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19[NCT04486508] | Phase 3 | 600 participants (Actual) | Interventional | 2020-07-30 | Completed | ||
| Evaluation of the Effect of Exogenous Surfactant Through Nebulizer Mask on Clinical Outcomes in Covid-19 Patients[NCT04847375] | 60 participants (Anticipated) | Interventional | 2021-04-20 | Not yet recruiting | |||
| Standardized, Guidelines Directed But Patients Oriented Clinical Practice Prospectively Registered[NCT03504007] | 10,000 participants (Anticipated) | Observational | 2013-03-01 | Recruiting | |||
| (Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients[NCT01583218] | Phase 3 | 7,513 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF)[NCT02942576] | Phase 3 | 632 participants (Actual) | Interventional | 2017-03-21 | Completed | ||
| Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism (VTE) in Korea and Taiwan[NCT02952599] | 352 participants (Actual) | Observational | 2017-03-27 | Completed | |||
| The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)[NCT03977363] | 25 participants (Actual) | Observational [Patient Registry] | 2020-01-27 | Terminated (stopped due to Halted Prematurely) | |||
| Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe[NCT02943993] | 2,809 participants (Actual) | Observational | 2016-04-06 | Completed | |||
| A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From B[NCT02798471] | Phase 3 | 290 participants (Actual) | Interventional | 2017-03-27 | Completed | ||
| Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease[NCT05122455] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism ([NCT00986154] | Phase 3 | 8,292 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism[NCT00439777] | Phase 3 | 4,833 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism[NCT00440193] | Phase 3 | 3,449 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients[NCT02774265] | Phase 3 | 329 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism[NCT00643201] | Phase 3 | 5,614 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?[NCT02900170] | 8 participants (Actual) | Observational | 2016-07-31 | Completed | |||
| RECORD 1 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement[NCT00329628] | Phase 3 | 4,541 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis[NCT02458729] | Phase 4 | 294 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| An Efficacy and Safety Study of New Oral Anticoagulants and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters: A Prospective Randomized Controlled Trial[NCT04066764] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-05-08 | Recruiting | ||
| Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome[NCT02295475] | Phase 4 | 48 participants (Actual) | Interventional | 2014-12-10 | Completed | ||
| Comparison of Topical and Infusion Tranexamic Acid on Blood Loss and Risk of Deep Vein Thrombosis After Total Knee Arthroplasty[NCT02453802] | Phase 4 | 90 participants (Anticipated) | Interventional | 2015-06-30 | Not yet recruiting | ||
| RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled., Double-blind, Randomized Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.[NCT00361894] | Phase 3 | 2,531 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| A Phase 2, Randomized, Active Comparator-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement[NCT00641732] | Phase 2 | 1,045 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women[NCT02829957] | Phase 2/Phase 3 | 19 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Once-daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism. The Einstein-Extension Study[NCT00439725] | Phase 3 | 1,197 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis[NCT03191305] | 50 participants (Anticipated) | Interventional | 2017-08-31 | Not yet recruiting | |||
| Drotrecogin Alfa (Activated) (LY203638)] Exploratory, Safety Study, Multi-Center, Randomized, Placebo-Controlled, Dose Escalating Study Design, Comparing a Standard Therapy (Enoxaparin Sodium) for Submassive Pulmonary Embolism to a Combined Therapy of Dro[NCT00191724] | Phase 2 | 47 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Outpatient Treatment of Low-risk Patients With Pulmonary Embolism: a Randomized-controlled Trial[NCT00425542] | Phase 3 | 343 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978] | 140 participants (Actual) | Observational | 2022-09-01 | Completed | |||
| A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS[NCT00551928] | Phase 3 | 402 participants (Actual) | Interventional | 2007-06-30 | Active, not recruiting | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Incidence and Characteristics of Pulmonary Embolism in COVID-19 Patients Hospitalized for Acute Respiratory Syndrome[NCT04420312] | 1,024 participants (Actual) | Observational | 2020-03-01 | Completed | |||
| A Phase 3 Randomized, Double-Blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization.[NCT00457002] | Phase 3 | 6,758 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| An International, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Study of 3-month or 6-month Treatment With SSR126517E (3.0 mg s.c. Once-weekly) Versus Oral INR-adjusted Warfarin in the Treatment of Patients With Symptomatic Pulmonar[NCT00345618] | Phase 3 | 3,202 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion[NCT03630055] | Phase 3 | 1,800 participants (Anticipated) | Interventional | 2018-10-03 | Recruiting | ||
| Multi-center、Randomize、Open、Non-inferiority Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD[NCT03277001] | 438 participants (Anticipated) | Interventional | 2017-10-01 | Not yet recruiting | |||
| Once Daily Enoxaparin for Outpatient Treatment of Acute Deep Venous Thrombosis and/or Pulmonary Embolism[NCT00413374] | 40 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| [NCT01956955] | Phase 4 | 150 participants (Anticipated) | Interventional | 2011-01-31 | Recruiting | ||
| A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group, Dose Ranging Study of Subcutaneous SR123781A With an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery[NCT00338897] | Phase 2/Phase 3 | 1,090 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against Deep Venous Thrombosis and Pulmonary Embolus in Patients Undergoing Major Lung Resection: A Pilot Study to Evaluate the Incidence of DVT and PE After Major Lung Resection[NCT02258958] | 150 participants (Actual) | Observational | 2014-01-31 | Completed | |||
| PREPIC 2 : Interruption of Inferior Vena Cava by a Retrievable Filter for the Prevention of Recurrent Pulmonary Embolism : a Randomised, Open Label Study[NCT00457158] | Phase 4 | 399 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Retrievable Inferior Vena Cava Filter for Primary Pulmonary Embolism Prophylaxis in At-Risk Trauma Patients: RIPT Feasibility Trial[NCT03070834] | 42 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
| Phase 1 Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-Like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide in 12 Patients With Recurre[NCT01550523] | Phase 1 | 13 participants (Actual) | Interventional | 2012-02-09 | Completed | ||
| Norwegian Intensive Care Unit Dalteparin Effect Study[NCT01721928] | 70 participants (Actual) | Observational | 2012-12-03 | Completed | |||
| Weight Based Enoxaparin for Venous Thromboembolism Prophylaxis in Trauma Patients[NCT01916707] | Phase 4 | 1,200 participants (Anticipated) | Interventional | 2013-07-31 | Active, not recruiting | ||
| The Use of Low Molecular Weight Heparin in Traumatic Brain Injury[NCT00170378] | Phase 4 | 300 participants | Interventional | 2002-12-31 | Completed | ||
| The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients[NCT00531843] | Phase 2/Phase 3 | 105 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy in a High-volume Center. A Cohort Study.[NCT02597218] | 350 participants (Anticipated) | Observational | 2015-10-31 | Recruiting | |||
| Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698[NCT00769873] | Phase 2 | 35 participants (Actual) | Interventional | 2006-10-31 | Terminated (stopped due to Recruitment was slower than anticipated. Insufficient funding to expand to multi-centered trial.) | ||
| Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer[NCT00718354] | Phase 3 | 740 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| An Open-label Comparison of the Efficacy and Safety of the Low-molecular-weight Heparin (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-surgical Patients[NCT00311753] | Phase 3 | 342 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| Efficacy and Safety of Oral Rivaroxaban for the Treatment of Venous Thromboembolism in Patients With Active Cancer. A Pilot Study.[NCT02746185] | Phase 3 | 159 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study[NCT03045406] | Phase 3 | 1,168 participants (Actual) | Interventional | 2017-04-13 | Active, not recruiting | ||
| A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer[NCT02073682] | Phase 3 | 1,046 participants (Actual) | Interventional | 2015-07-16 | Completed | ||
| PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)[NCT00182143] | Phase 3 | 3,659 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses[NCT02719418] | 28 participants (Actual) | Observational | 2016-02-01 | Completed | |||
| Analysis of Pro-coagulant and Thrombin-generation Markers for the Prediction of Therapeutic Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism: A Pilot Study[NCT01602445] | 700 participants (Anticipated) | Observational | 2012-07-31 | Completed | |||
| Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism[NCT02898051] | 370 participants (Actual) | Observational | 2011-08-31 | Active, not recruiting | |||
| Safety and Efficacy of Switching From Direct Oral Anticoagulants to Low Molecular Weight Heparin in Cancer Patients With Atrial Fibrillation During Antineoplastic Therapy[NCT04508855] | 240 participants (Anticipated) | Observational | 2020-08-01 | Recruiting | |||
| Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism[NCT01164046] | Phase 3 | 56 participants (Actual) | Interventional | 2010-08-31 | Terminated (stopped due to Due to slow inclusion of patients) | ||
| Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients[NCT01602432] | 0 participants (Actual) | Observational | 2012-11-30 | Withdrawn (stopped due to Project did not meet criteria of a research study and was confirmed as a Quality Initiative Project) | |||
| Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)[NCT00138099] | 140 participants (Actual) | Observational | 2004-07-31 | Completed | |||
| A Pilot Study of Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis of the Upper Extremity[NCT00216866] | Phase 2 | 70 participants | Interventional | 2002-09-30 | Completed | ||
| Metaxa's Thromboprophylaxis Program in Oncological & Surgical Patients[NCT04248348] | 600 participants (Anticipated) | Observational | 2018-12-01 | Recruiting | |||
| Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT[NCT01130025] | Phase 3 | 900 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Intensive Dose Tinzaparin in Hospitalized COVID19 Patients[NCT05036824] | 300 participants (Anticipated) | Observational | 2021-10-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.30 |
| Enoxaparin | 1.90 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.03 |
| Enoxaparin | 1.45 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.70 |
| Enoxaparin | 6.02 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.94 |
| Enoxaparin | 1.45 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.43 |
| Enoxaparin | 5.99 |
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, venous thromboembolism (VTE) related death adjudicated by a blinded independent Clinical Events Committee (CEC) between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 5.70 |
| Enoxaparin | 7.18 |
Percentage of participants experiencing at least one major bleeding adjudicated by a blinded independent CEC between randomization (day 1) and up to seven days after discontinuation of all study medication. (NCT01583218)
Timeframe: Between randomization and Day 49 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.67 |
| Enoxaparin | 0.57 |
Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability. (NCT02942576)
Timeframe: Day 1 to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban-based Regimen | 10 |
| VKA-based Regimen | 3 |
"An alternative definition characterized stroke (ischemic, hemorrhagic, or undetermined) as an abrupt onset, over minutes to hours, of a focal neurological deficit in the distribution of a single brain artery that was not due to an identifiable nonvascular cause (ie, brain tumor or trauma), and that either lasted at least 24 hours or resulted in death within 24 hours of onset.~Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability." (NCT02942576)
Timeframe: Day 1 to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban-based Regimen | 1 |
| VKA-based Regimen | 2 |
"Stroke (ischemic, hemorrhagic, or undetermined) was defined by Valve Academic Research Consortium-2 (VARC-2) as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury following hemorrhage or infarction. A stroke event was based on any of the following: duration of neurological dysfunction >24 hours (h), duration of neurological dysfunction <24 h in case of imaging-documented new hemorrhage or infarction, and a neurological dysfunction resulting in death.~Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability." (NCT02942576)
Timeframe: Day 1 to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban-based Regimen | 1 |
| VKA-based Regimen | 2 |
"Stroke (ischemic, hemorrhagic, or undetermined) was defined by Valve Academic Research Consortium-2 (VARC-2) as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury following hemorrhage or infarction. A stroke event was based on any of the following: duration of neurological dysfunction >24 hours (h), duration of neurological dysfunction <24 h in case of imaging-documented new hemorrhage or infarction, and a neurological dysfunction resulting in death.~SEE was defined as an arterial embolism resulting in clinical ischemia, excluding the central nervous system, coronary, and pulmonary arterial circulation.~CV mortality was defined as cardiac or vascular death according to Academic Research Consortium." (NCT02942576)
Timeframe: Day 1 to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban-based Regimen | 1 |
| VKA-based Regimen | 0 |
Descriptive statistics were used to report the number of participants with at least 1 symptomatic VTE recurrence. Recurrent VTE events were based on adjudicated events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| ETNA-VTE | 100 |
Descriptive statistics were used to report the duration of edoxaban treatment. (NCT02943993)
Timeframe: Baseline up to end of observational period (18 months)
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Month 1 ongoing | Month 3 ongoing | Month 6 ongoing | Month 12 ongoing | Month 18 ongoing | Participants off edoxaban treatment at 18 months | |
| ETNA-VTE | 2527 | 2346 | 1842 | 1272 | 713 | 1910 |
Descriptive statistics were used to assess the duration of VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | days (Median) | |||
|---|---|---|---|---|
| Total number of VTE recurrences | Deep vein thrombosis (DVT) only | Pulmonary embolism with DVT | Pulmonary embolism only | |
| ETNA-VTE | 11.0 | 9.5 | 0 | 15.0 |
Descriptive statistics were used to assess the duration of VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | days (Median) | |||
|---|---|---|---|---|
| Total number of VTE recurrences | Deep vein thrombosis (DVT) only | Pulmonary embolism with DVT | Pulmonary embolism only | |
| ETNA-VTE | 18.0 | 44.5 | 8.0 | 16.0 |
Descriptive statistics were used to report the number of participants experiencing recurrent VTE and at least 1 real world safety event. VTE recurrence data were reported by recurrent deep vein thrombosis (DVT), recurrent pulmonary embolism (PE) with DVT, and recurrent PE only. Recurrent VTE events were based on adjudicated events. Real world safety events included all-cause death, cardiovascular (CV)-related death, VTE-related death, stroke, systemic embolic event, and hospitalization related to CV. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Recurrent DVT only | Recurrent PE with DVT | Recurrent PE only | All-cause death | Cardiovascular-related death | Venous thromboembolism-related death | Stroke | Systemic embolic event | Hospitalization related to CV | |
| ETNA-VTE | 61 | 7 | 31 | 95 | 23 | 1 | 26 | 2 | 253 |
Adverse drug reactions were reported and coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. (NCT02943993)
Timeframe: Baseline up to end of observational period (18 months)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Haemorrhage | Gastrointestinal haemorrhage | Menorrhagia | Epistaxis | Fatigue | Nausea | Dizziness | Rash | Headache | Pruritus | |
| ETNA-VTE | 35 | 12 | 12 | 11 | 8 | 8 | 7 | 7 | 5 | 5 |
Descriptive statistics were used to report the number of participants with overall symptomatic VTE recurrence. VTE recurrence data were further reported by recurrent deep venous thrombosis (DVT), recurrent pulmonary embolism (PE) with deep venous thrombosis (DVT), and recurrent PE only. Recurrent VTE events were based on adjudicated events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Recurrent VTE | Recurrent DVT only | Recurrent PE with DVT | Recurrent PE only | All-cause death | CV-related death | VTE-related death | Stroke | Systemic embolic event | Hospitalization-related to cardiovascular | |
| ETNA-VTE | 37 | 27 | 1 | 9 | 50 | 11 | 1 | 15 | 1 | 167 |
Descriptive statistics were used to report the number of participants with bleeding events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Participants with any bleeding events | At least 1 major bleeding event | Clinically relevant non-major bleeding event | Minor | Gastrointestinal bleeding event | Epidural or subdural haematoma bleeding event | Intra-ocular bleeding event | Intra-articular bleeding event | Pleural bleeding event | Other bleeding event | Spontaneous bleeding | Provoked bleeding | Unknown bleeding | |
| ETNA-VTE | 304 | 38 | 82 | 300 | 77 | 4 | 5 | 3 | 1 | 319 | 287 | 115 | 18 |
Descriptive statistics were used to report the number of participants with pre-defined adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Stroke | Bleeding events | Systemic embolic events | Non-valvular atrial fibrillation | Malignancy | Others | |
| ETNA-VTE | 2 | 75 | 0 | 0 | 0 | 4 |
Descriptive statistics were used to assess the number of participants with risk factors for thromboembolic events. (NCT02943993)
Timeframe: at Baseline
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Puerperium | Prolonged immobilisation | >5 days in bed | History of major surgery trauma | Known thrombophilic conditions | |
| ETNA-VTE | 9 | 401 | 218 | 359 | 111 |
Descriptive statistics were used to report the number of stroke events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | events (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Overall treatment: Total number of stroke events | Overall treatment: Ischemic events | Overall treatment: Haemorrhagic events | Overall treatment: Unknown events | On treatment: Total number of stroke events | On treatment: Ischemic events | On treatment: Haemorrhagic events | On treatment: Unknown events | |
| ETNA-VTE | 27 | 17 | 5 | 5 | 16 | 12 | 3 | 1 |
Descriptive statistics were used to report the number of systemic embolic events (SEE). (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Systemic embolic events (Number) | |
|---|---|---|
| Upper/lower extremity | Renal | |
| ETNA-VTE | 1 | 1 |
Descriptive statistics were used to report an overview of participants with adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Death due to ADR | Participants with at least 1 ADR | Participants with at least 1 serious ADR | Study discontinuation due to ADR | |
| ETNA-VTE | 2 | 142 | 59 | 0 |
Descriptive statistics were used to assess the number of recurrent VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | VTE recurrences (Number) | |||
|---|---|---|---|---|
| Total number of VTE recurrences | Deep vein thrombosis (DVT) only | Pulmonary embolism with DVT | Pulmonary embolism only | |
| ETNA-VTE | 39 | 28 | 1 | 9 |
Descriptive statistics were used to describe the number of VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | VTE recurrences (Number) | |||
|---|---|---|---|---|
| Total number of VTE recurrences | Deep vein thrombosis (DVT) only | Pulmonary embolism with DVT | Pulmonary embolism only | |
| ETNA-VTE | 105 | 64 | 7 | 32 |
All bleeding events included major bleeding defined as a composite of any of the following: fatal bleeding; and/or symptomatic bleeding in critical area or organ such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, pulmonary, or pericardial, or intramuscular with compartment syndrome; and/or bleeding that causes a decrease in hemoglobin of at least 2 g/dL or more, or leading to transfusion of the equivalent of two or more units of whole blood or red blood cells (RBCs), clinically relevant non-major bleeding defined as acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding; a physician-guided medical or surgical treatment for bleeding or a change in antithrombotic therapy (including interruption or discontinuation of study drug), nuisance bleeding, or a combination of bleeding events. (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 25 |
| Standard of Care | 24 |
Any bleeding event defined as major and clinically relevant non-major bleeding (CRNM) events was reported. Major bleeding was defined as defined as a composite of any of the following: fatal bleeding; and/or symptomatic bleeding in critical area or organ such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, pulmonary, or pericardial, or intramuscular with compartment syndrome; and/or bleeding that causes a decrease in hemoglobin of at least 2 g/dL or more, or leading to transfusion of the equivalent of two or more units of whole blood or red blood cells. CRNM was defined as acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding; a physician-guided medical or surgical treatment for bleeding or a change in antithrombotic therapy (including interruption or discontinuation of study drug). (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 3 |
| Standard of Care | 5 |
Any bleeding event defined as major and clinically relevant non-major bleeding (CRNM) events was reported. Major bleeding was defined as defined as a composite of any of the following: fatal bleeding; and/or symptomatic bleeding in critical area or organ such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, pulmonary, or pericardial, or intramuscular with compartment syndrome; and/or bleeding that causes a decrease in hemoglobin of at least 2 g/dL or more, or leading to transfusion of the equivalent of two or more units of whole blood or red blood cells. CRNM was defined as acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding; a physician-guided medical or surgical treatment for bleeding or a change in antithrombotic therapy (including interruption or discontinuation of study drug). (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 8 |
| Standard of Care | 5 |
No change or extension of thrombotic burden as assessed by quantitative diagnostic imaging of the index qualifying VTE thrombus at baseline and at Month 3. Imaging criteria for VTE included: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA). (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 21 |
| Standard of Care | 29 |
No change or extension of thrombotic burden as assessed by quantitative diagnostic imaging of the index qualifying VTE thrombus. Imaging criteria for VTE included: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA). (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 35 |
| Standard of Care | 47 |
Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis. (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 5 |
| Standard of Care | 2 |
Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis. (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 7 |
| Standard of Care | 2 |
All-cause mortality is defined as death due to any cause. Adjudicated data are reported for overall all-cause mortality, all-cause mortality by the primary cause of death, and primary cause of death further described by additional specifications. (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Participants with adjudicated all-cause mortality | Venous thromboembolism (VTE)-related death | Venous thromboembolism (VTE)-related death: Unexplained death which VTE cannot be ruled out | Other known causes of death | Other known causes of death: Cancer | Other known causes of death: Infectious disease | Other known causes of death: Other | |
| Edoxaban | 2 | 1 | 1 | 1 | 0 | 0 | 1 |
| Standard of Care | 3 | 1 | 1 | 2 | 1 | 1 | 0 |
Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Pulmonary embolism (PE) with or without deep vein thrombosis (DVT) | Fatal PE | Non-fatal PE | Deep vein thrombosis (DVT) only | Fatal DVT | Non-fatal DVT | Unexplained death which VTE cannot be ruled out | |
| Edoxaban | 0 | 0 | 0 | 5 | 0 | 4 | 1 |
| Standard of Care | 1 | 0 | 1 | 1 | 0 | 0 | 1 |
Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Death as a result of VTE | Unexplained death which VTE cannot be ruled out | |
| Edoxaban | 1 | 1 |
| Standard of Care | 1 | 1 |
Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Pulmonary embolism (PE) with or without deep vein thrombosis (DVT) | Fatal PE | Non-fatal PE | Deep vein thrombosis (DVT) only | Fatal DVT | Non-fatal DVT | Unexplained death which VTE cannot be ruled out | |
| Edoxaban | 1 | 0 | 1 | 6 | 0 | 5 | 1 |
| Standard of Care | 1 | 0 | 1 | 1 | 0 | 0 | 1 |
Diagnosis of recurrent VTE requires the confirmation imaging and ≥1 symptom of VTE. Death from VTE is based on diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. No change or extension of thrombotic burden (quantitative diagnostic imaging) of the index qualifying VTE thrombus. Imaging criteria for VTE: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA). (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Symptomatic recurrent VTE | PE with or without DVT | DVT only | Death as a result of VTE | Unexplained death which VTE cannot be ruled out | No change or extension of thrombotic burden | |
| Edoxaban | 4 | 0 | 4 | 1 | 1 | 21 |
| Standard of Care | 1 | 1 | 0 | 1 | 1 | 29 |
Deep vein thrombosis was assessed by ultrasonography or magnetic resonance venography (MRV), catheter-related thrombosis was assessed by ultrasonography or echocardiography, sino-venous thrombosis was assessed by brain MRI, and pulmonary embolism was assessed by nuclear ventilation/perfusion (V/Q) scanning. (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Main Treatment: Participants with DVT only | Main Treatment: Participants with catheter-related thrombosis | Main Treatment: Participants with cerebral sino-venous DVT thrombosis | Main Treatment: Participants with PE with or without DVT | Extension Treatment: Participants with DVT | Extension Treatment: Participants with catheter-related thrombosis | Extension Treatment: Participants with sino-venous DVT thrombosis | Extension Treatment: Participants with PE | Overall Treatment: Participants with DVT | Overall Treatment: Participants with catheter-related thrombosis | Overall Treatment: Participants with sino-venous DVT thrombosis | Overall Treatment: Participants with PE | |
| Edoxaban | 4 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 5 | 1 | 1 | 1 |
| Standard of Care | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis. (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Symptomatic VTE | Pulmonary embolism (PE) with or without deep vein thrombosis (DVT) | Deep vein thrombosis (DVT) only | |
| Edoxaban | 4 | 0 | 4 |
| Standard of Care | 1 | 1 | 0 |
Clinically relevant bleeding (i.e., major or clinically relevant non-major bleeding) occurring during treatment plus 3 days after their last dose for that time period. (NCT00986154)
Timeframe: 12 months from time of randomization
| Intervention | participants with an event (Number) |
|---|---|
| Heparin/Edoxaban Tosylate | 349 |
| Heparin/Warfarin | 423 |
"Symptomatic recurrent Venous Thromboembolism (VTE), i.e., the composite of deep Vein Thrombosis (DVT), non-fatal Pulmonary Embolism (PE), and fatal PE occurring during the Overall Study Period.~Overall Study Period defined as The time from the reference date (randomization date/initial dose of study drug date) to the last study follow-up visit." (NCT00986154)
Timeframe: 12 months from time of randomization
| Intervention | number or participants with an event (Number) |
|---|---|
| Heparin/Edoxaban Tosylate | 130 |
| Heparin/Warfarin | 146 |
(NCT00986154)
Timeframe: 12 months from time of randomization
| Intervention | number of participants with event (Number) |
|---|---|
| Heparin/Edoxaban Tosylate | 228 |
| Heparin/Warfarin | 228 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Enoxaparin/VKA | 1.2 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 3.4 |
| Enoxaparin/VKA | 4.0 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.5 |
| Enoxaparin/VKA | 1.4 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.5 |
| Enoxaparin/VKA | 4.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 10.3 |
| Enoxaparin/VKA | 11.4 |
All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.5 |
| Enoxaparin/VKA | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 |
| Enoxaparin/VKA | 0.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 |
| Enoxaparin/VKA | 0.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.4 |
| Enoxaparin/VKA | 1.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.1 |
| Enoxaparin/VKA | 1.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.9 |
| Enoxaparin/VKA | 0.7 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.1 |
| Enoxaparin/VKA | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.0 |
| Enoxaparin/VKA | 3.4 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| All post-randomization | Treatment-emergent (time window: 2 days) | Treatment-emergent (time window: 7 days) | |
| Enoxaparin/VKA | 2.1 | 0.8 | 1.1 |
| Rivaroxaban (Xarelto, BAY59-7939) | 2.6 | 1.2 | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0 | 0.05 | 0 | 0.5 | 0.1 | 0.09 | 0.05 | 0.7 | 0.5 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.09 | 0 | 0.09 | 0.5 | 0.2 | 0.09 | 0.3 | 0.8 | 0.3 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0.04 | 0.2 | 0.1 | 0.8 | 0.7 | 0.2 | 0.1 | 1.5 | 2.4 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.1 | 0.3 | 0.0 | 1.0 | 0.7 | 0.2 | 0.4 | 1.3 | 1.4 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE or major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.1 |
| Enoxaparin/VKA | 1.1 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.9 |
| Enoxaparin/VKA | 4.2 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding, cardiovascular death, myocardial infarctions, stroke, or non CNS systemic embolism. Major bleeding was associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography ( PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Enoxaparin/VKA | 1.3 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death, cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events confirmed by independent committee blinded to treatment, based on compression ultrasound, venography, spiral CT scan, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy, results/films/images of confirmatory testing and/or case summaries (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 3.6 |
| Enoxaparin/VKA | 4.7 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 8.1 |
| Enoxaparin/VKA | 8.1 |
All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 |
| Enoxaparin/VKA | 0.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.6 |
| Enoxaparin/VKA | 0.3 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.9 |
| Enoxaparin/VKA | 1.6 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.8 |
| Enoxaparin/VKA | 0.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.1 |
| Enoxaparin/VKA | 3.0 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.2 |
| Enoxaparin/VKA | 1.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.0 |
| Enoxaparin/VKA | 5.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| All post-randomization | Treatment-emergent (time window: 2 days) | Treatment-emergent (time window: 7 days) | |
| Enoxaparin/VKA | 3.0 | 1.1 | 1.5 |
| Rivaroxaban (Xarelto, BAY59-7939) | 2.4 | 1.0 | 1.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0 | 0.07 | 0 | 0.1 | 0.3 | 0.1 | 0.3 | 0.8 | 0.6 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0 | 0.07 | 0 | 0.3 | 0.6 | 0.07 | 0.07 | 1.3 | 0.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0 | 0.3 | 0 | 1.0 | 1.6 | 0.3 | 0.2 | 2.0 | 1.3 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.06 | 0.2 | 0.06 | 1.2 | 0.8 | 0.06 | 0.1 | 1.8 | 0.9 |
DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 5 |
| VTE Prophylaxis With Aspirin 81mg BID | 9 |
Bases on imaging obtained for symptoms. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 6 |
| VTE Prophylaxis With Aspirin 81mg BID | 2 |
Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 52 |
| VTE Prophylaxis With Aspirin 81mg BID | 53 |
Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0385 |
| Enoxaparin + Warfarin | 0.0800 |
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded. (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0322 |
| Enoxaparin + Warfarin | 0.0395 |
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite. (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0234 |
| Enoxaparin + Warfarin | 0.0292 |
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0280 |
| Enoxaparin + Warfarin | 0.0448 |
VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT). (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0699 |
| Enoxaparin + Warfarin | 0.1261 |
VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0226 |
| Enoxaparin + Warfarin | 0.0269 |
All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0056 |
| Enoxaparin + Warfarin | 0.0182 |
Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0430 |
| Enoxaparin + Warfarin | 0.0971 |
Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.1170 |
| Enoxaparin + Warfarin | 0.1878 |
DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0084 |
| Enoxaparin + Warfarin | 0.0133 |
PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). (NCT00643201)
Timeframe: Day 1 to Week 24 + + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0104 |
| Enoxaparin + Warfarin | 0.0095 |
Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.1502 |
| Enoxaparin + Warfarin | 0.2514 |
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0046 |
| Enoxaparin + Warfarin | 0.0061 |
Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0157 |
| Enoxaparin + Warfarin | 0.0198 |
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0058 |
| Enoxaparin + Warfarin | 0.0087 |
Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00643201)
Timeframe: First dose to last dose of 24 Weeks + 2 days (AEs) or + 30 days (SAEs) or until drug discontinued
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| AE | SAE | Bleeding AE or SAE | Discontinued Due to AE or SAE | Death | |
| Apixaban | 1795 | 417 | 415 | 162 | 37 |
| Enoxaparin + Warfarin | 1923 | 410 | 695 | 199 | 44 |
Creatine kinase High: >5*ULN Units/Liter (U/L); Total Protein High/Low: < 0.9 *LLN or > 1.1*ULN, or if pre-dose < LLN then use 0.9* pre-dose or > ULN if pre-dose > ULN then use 1.1 *pre-dose or
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Creatine Kinase High (N=2601, 2596) | Uric Acid High (N=2601, 2596) | Total Protein Low (N=2601, 2596) | Total Protein High (N=2601, 2596) | |
| Apixaban | 20 | 6 | 15 | 0 |
| Enoxaparin + Warfarin | 24 | 3 | 16 | 0 |
Bicarbonate milliequivalents/Liter (mEq/L) Low/High: < 0.75*LLN or > 1.25*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Calcium mg/dL Low/High: < 0.8*LLN or > 1.2*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Chloride mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Potassium mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Sodium mEq/L: < 0.95*LLN or > 1.05*ULN, or if pre-dose < LLN then use < 0.95*pre-dose or > ULN if pre-dose > ULN then use > 1.05*pre-dose or < LLN. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Bicarbonate Low (N=2600,2593) | Bicarbonate High (N=2600,2593) | Total Calcium Low (N=2601,2596) | Total Calcium High (N=2601,2596) | Chloride Low Total Calcium Low (N=2601,2596) | Chloride Low Total Calcium High (N=2601,2596) | Potassium Low (N=2601,2596) | Potassium High (N=2601,2596) | Sodium Low (N=2601,2596) | ||
| Apixaban | 44 | 17 | 3 | 12 | 5 | 0 | 26 | 19 | 10 | 4 |
| Enoxaparin + Warfarin | 31 | 11 | 10 | 11 | 3 | 1 | 22 | 22 | 6 | 4 |
Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: < 0.75*LLN, > 1.25*ULN; Hemoglobin: <= 11.5 g/dL (males), <= 9.5 g/dL (females); Hematocrit: <= 37% (males), <= 32% (females); Erythrocytes: <0.75*10^6 c/µL*PreRx; Platelet count: < 75*10^9 c/L, > 700*10^9 c/L; ANC: < 1.00*10^3 c/µL; Abs eosinophils: > 0.750*10^3 c/µL; Abs Basophils: > 400/MM^3; Abs Monocytes> 2000/MM^3; Abs Lymphocytes: < 0.750*10*3 c/ µL, > 7.5*10^3 c/ µL. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erthrocytes Low (N=2599, 2593) | Hematocrit Low (N=2588, 2587) | Hemoglobin Low (N=2599, 2593) | Platelet Count Low (N=2594, 2589) | Leukocytes Low (N=2528, 2519) | Leukocytes High (N=2528, 2519) | Absolute Basophils High (N=2594,2589) | Absolute Eosinophils High (N=2594,2589) | Absolute Lyphocytes Low (N=2594,2589) | Absolute Lyphocytes High (N=2594,2589) | Absolute Monocytes High (N=2594,2589) | Absolute Neutrophils Low (N=2594,2589) | |
| Apixaban | 23 | 26 | 96 | 23 | 41 | 26 | 1 | 84 | 94 | 4 | 1 | 9 |
| Enoxaparin + Warfarin | 17 | 20 | 101 | 13 | 41 | 15 | 2 | 79 | 76 | 3 | 2 | 20 |
Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: > 1.5*ULN; Creatinine mg/dL: > 1.5*ULN; Alanine aminotransferase (ALT) U/L: > 3*ULN; Aspartate aminotransferase (AST) U/L: > 3*ULN; Alkaline phosphatase U/L: > 2*ULN; Bilirubin Direct mg/dL: > 1.5*ULN; Bilirubin Total mg/dL: > 2*ULN. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| BUN High (N=517, 523) | Creatinine High (N=2601, 2596) | ALT High (N=2601, 2598) | ALP High (N=2601, 2598) | AST High (N=2601, 2598) | Direct Bilirubin High (N=2601, 2593) | Total Bilirubin High (N=2601, 2597) | |
| Apixaban | 2 | 47 | 52 | 35 | 40 | 28 | 8 |
| Enoxaparin + Warfarin | 7 | 37 | 145 | 27 | 40 | 21 | 7 |
All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Blood in Urine High (N=2289, 2273) | Glucose in Urine High (N=2289, 2273) | Leukocyte Esterase in Urine High (N=2289, 2273) | Protein in Urine High (N=2289, 2273) | RBC + WBC in Urine High (N=1685, 1719) | RBC in Urine High (N=1293, 1389) | WBC in Urine High (N=1354, 1361) | |
| Apixaban | 85 | 46 | 105 | 41 | 359 | 111 | 274 |
| Enoxaparin + Warfarin | 127 | 31 | 102 | 50 | 361 | 140 | 263 |
Primary endpoint - Incidence of ARN is the primary outcome of this study and this is based on a documentation of AKI (defined as an increase in baseline serum creatinine ≥ 0.3 mg/dL), in the absence of any other obvious etiology for the AKI identified after a standard clinical evaluation and work up by the patient's primary care physician, cardiologist or nephrologist. This incidence will be expressed as a percentage. (NCT02900170)
Timeframe: 6 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Participants | 0 |
Measure Description: Normal hemoglobin range for adult women - 12 - 16 g/dL. Lower levels indicate worse outcomes. (NCT02829957)
Timeframe: 3 months
| Intervention | g/dl (Median) |
|---|---|
| Rivaroxaban | 12.8 |
| Apixaban | 13.25 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 3 |
| Apixaban | 1 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 4 |
| Apixaban | 2 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 3 |
| Apixaban | 0 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 0 |
| Apixaban | 0 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 0 |
| Apixaban | 0 |
(NCT02829957)
Timeframe: 1, 2, and 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 0 |
| Apixaban | 0 |
"Measure Description: A PBAC Score of < 100 indicates a normal menstrual cycle. The lowest possible score would be zero. Higher values indicate worse outcomes. The higher theoretical range value cannot be calculated. The scoring mechanism is as follows;~Towels~1 point for each lightly stained towel~5 points or each moderately soiled towel~20 points if the towel is completely saturated with blood~Tampons~1 point for each lightly stained tampon~5 points for each moderately soiled tampon~10 points if the tampon is completely saturated with blood~Clots~1 point for small clots~5 points for large clots" (NCT02829957)
Timeframe: 3 months
| Intervention | score on a scale (Median) |
|---|---|
| Rivaroxaban | 292 |
| Apixaban | 146 |
The RAND 36-Item Health Survey (Version 1.0) taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. All items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. (NCT02829957)
Timeframe: 3 months
| Intervention | Score (Median) |
|---|---|
| Rivaroxaban | 55.5 |
| Apixaban | 45.6 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.2 |
| Placebo | 0.0 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.0 |
| Placebo | 0.2 |
Events were adjudicated/confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral CT scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units, occurring in a critical site or contributing to death. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 0.9 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.0 |
| Placebo | 7.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound or venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.9 |
| Placebo | 0.7 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.8 |
| Placebo | 5.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 0.9 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 7.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either spiral computed tomography (CT) scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 |
| Placebo | 0.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either spiral computed tomography (CT) scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 |
| Placebo | 2.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 0.9 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. For definition of DVT/PE, kindly refer to the link in the Protocol section. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.3 |
| Placebo | 7.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 1.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), or lung scintigraphy (for PE), and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.3 |
| Placebo | 7.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.4 |
| Placebo | 1.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.5 |
| Placebo | 7.4 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. Treatment-emergent events and all events post randomization were reported. Treatment-emergent: after intake of first tablet of study medication as randomized but not more than 2 days after stop of study medication (referred to as time window: 2 days) (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Treatment-emergent (time window: 2 days) | All post-randomization | |
| Placebo | 0.2 | 0.3 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.2 | 0.2 |
All events adjudicated/confirmed by CIAC blinded to treatment. Clinically relevant bleeding included major bleeding (definition: see outcome 7) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of daily life activities. Treatment-emergent events (after intake of 1st study medication tablet as randomized up to 2 days after stop of study medication ['time window: 2 days']) and all events post randomization were reported (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Treatment-emergent (time window: 2 days) | All post-randomization | |
| Placebo | 1.2 | 1.9 |
| Rivaroxaban (Xarelto, BAY59-7939) | 6.0 | 6.0 |
All events were adjudicated and confirmed by a central independent adjudication committee (CIAC) blinded to treatment. Major bleeding event was overt bleeding associated with a 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death. Treatment-emergent [after intake of first tablet of study medication as randomized but not more than 2 days after stop of study medication (referred to as time window: 2 days)] events and all events post randomization were reported. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Treatment-emergent (time window: 2 days) | All post-randomization | |
| Placebo | 0.0 | 0.2 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 | 0.7 |
All pre-defined vascular events (acute coronary syndromes, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism and vascular death) were adjudicated/confirmed by a central independent adjudication committee blinded to treatment, based on results/films/images of confirmatory testing, and/or case summaries. On treatment events and all events post randomization were reported. On treatment: after intake of first tablet of study medication as randomized but not more than 1 day after stop of study medication (referred to as time window: 1 day) (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| On treatment (time window: 1 day) | All post-randomization | |
| Placebo | 0.7 | 0.7 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.5 | 0.8 |
Scores in each of the 4 domains (dyspnea, fatigue, emotional, and mastery) ranged from 1 (maximum impairment) to 7 (no impairment). (NCT00191724)
Timeframe: baseline and day 90 (follow-up)
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Dyspnea - Baseline | Dyspnea - 90 Day Follow-Up | Fatigue - Baseline | Fatigue - 90 Day Follow-Up | Emotional - Baseline | Emotional - 90 Day Follow-Up | Mastery - Baseline | Mastery - 90 Day Follow-Up | |
| Drotrecogin Alfa (Activated) - 12 | 4.5 | 5.1 | 3.6 | 4.1 | 4.1 | 4.8 | 4.1 | 4.9 |
| Drotrecogin Alfa (Activated) - 18 | 4.8 | 6.7 | 4.2 | 5.2 | 4.8 | 5.5 | 4.7 | 6.1 |
| Drotrecogin Alfa (Activated) - 24 | 5.0 | 4.8 | 4.7 | 4.0 | 6.1 | 4.4 | 5.8 | 4.9 |
| Drotrecogin Alfa (Activated) - 6 | 5.0 | 4.8 | 4.5 | 4.8 | 4.0 | 4.7 | 5.1 | 5.0 |
| Placebo | 4.8 | 6.5 | 4.1 | 5.0 | 4.4 | 5.2 | 4.8 | 6.1 |
Number of patients with major bleeding events, defined as: Reduction in hemoglobin of 2 to 5 grams per deciliter (g/dL) within 24 hours; Transfusion of 2 to 4 units of packed red blood cells within 24 hours; Hematoma requiring prolonged hospitalization or surgical intervention; Intracranial or retroperitoneal hemorrhage. (NCT00191724)
Timeframe: baseline through day 6
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Intracranial Hemorrhage | Reduction in Hemoglobin | Transfusion | Hematoma | |
| Drotrecogin Alfa (Activated) - 12 | 0 | 0 | 0 | 0 |
| Drotrecogin Alfa (Activated) - 18 | 0 | 0 | 0 | 0 |
| Drotrecogin Alfa (Activated) - 24 | 0 | 0 | 0 | 0 |
| Drotrecogin Alfa (Activated) - 6 | 1 | 0 | 0 | 0 |
| Placebo | 0 | 1 | 0 | 0 |
Change of right ventricular function measured as difference of right ventricular enddiastolic area/left ventricular enddiastolic area (RVEDA/LVEDA) ratios by echocardiography (NCT00191724)
Timeframe: baseline, day 6, day 90
| Intervention | ratio (Mean) | ||
|---|---|---|---|
| RVEDA/LVEDA at Day 0 | RVEDA/LVEDA at Day 6 | RVEDA/LVEDA at Day 90 | |
| Drotrecogin Alfa (Activated) - 12 | 1.0 | 0.7 | 0.5 |
| Drotrecogin Alfa (Activated) - 18 | 1.0 | 0.8 | 0.6 |
| Drotrecogin Alfa (Activated) - 24 | 0.9 | 0.6 | 0.5 |
| Drotrecogin Alfa (Activated) - 6 | 0.8 | 0.7 | 0.5 |
| Placebo | 1.1 | 0.7 | 0.6 |
A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 2.36 |
| Enoxaparin 40 mg | 2.12 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.22 |
| Enoxaparin 40 mg | 0.24 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. PE: non-fatal or fatal. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.22 |
| Enoxaparin 40 mg | 0.24 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 2.40 |
| Enoxaparin 40 mg | 2.50 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 6.44 |
| Enoxaparin 40 mg | 6.50 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 2.71 |
| Enoxaparin 40 mg | 2.93 |
Events were adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.00 |
| Enoxaparin 40 mg | 0.15 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.15 |
| Enoxaparin 40 mg | 0.49 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.15 |
| Enoxaparin 40 mg | 0.37 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 3.11 |
| Enoxaparin 40 mg | 3.46 |
Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Key Secondary Efficacy population: all who received at least 1 dose of parenteral study drug and: (those without suspected VTE events during Parenteral Treatment) had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or (those with suspected VTE events during Parenteral Treatment) had those suspected VTE events adjudicated as non-events, and had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or had an adjudicated total VTE during Parenteral Treatment; or had an adjudicated VTE-related death during Parenteral Treatment. Event rate (%): n/N*100 (n=number with observation; N=total secondary efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1 to last dose of parenteral study drug plus 1 day
| Intervention | Event rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 1.73 |
| Enoxaparin 40 mg | 1.61 |
Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Secondary Efficacy Evaluable includes those who had an adjudicated, evaluable ultrasound at end of parenteral treatment and for those with a suspected symptomatic event, the result of the adjudication for the symptomatic event was not inadequate; or those with an adjudicated event that was part of the composite endpoint.. Event rate (%): n/N*100 (n=number with observation; N=total secondary efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1 to last dose of parenteral study drug plus 1 day
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 1.66 |
| Enoxaparin 40 mg | 1.51 |
Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal (N-F) PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. All-Cause Death (A-C Death). Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 6.44 |
| Enoxaparin 40 mg | 6.63 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.06 |
| Enoxaparin 40 mg | 0.09 |
Bleeding was adjudicated by an ICAC using criteria from the ISTH. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs, for bleeding endpoints. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of drug to last dose of drug plus 2 days
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 7.73 |
| Enoxaparin 40 mg | 6.81 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 7.16 |
| Enoxaparin 40 mg | 6.83 |
Bleeding was adjudicated by an ICAC using criteria from the ISTH. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis, if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for bleeding endpoints. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days
| Intervention | Event Rate (%): (Number) |
|---|---|
| Apixaban 2.5 mg | 2.26 |
| Enoxaparin 40 mg | 1.90 |
VTE: nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE could not be excluded as a cause. Intended Treatment Period=period that started on day of randomization: period ended (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; period ended (for not treated) 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. All efficacy events were adjudicated by the Independent Central Adjudication Committee (ICAC). Event rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 2.71 |
| Enoxaparin 40 mg | 3.06 |
Bleeding was adjudicated by an ICAC using criteria from the ISTH. Major bleeding: acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or bleeding in a critical site or bleeding which is fatal. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage; rectal blood loss. Treatment Period=onset from first dose of study drug through 2 days after last dose of study drugs. Incidence: Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 2.67 |
| Enoxaparin 40 mg | 2.08 |
Major bleeding was adjudicated by an ICAC using criteria from the International Society on Thrombosis and Hemostasis (ISTH) and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or bleeding in a critical site or bleeding which is fatal. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.47 |
| Enoxaparin 40 mg | 0.19 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.40 |
| Enoxaparin 40 mg | 0.80 |
Events of Special Interest include: adjudicated thrombocytopenia, adjudicated myocardial infarction (MI), adjudicated stroke, and adjudicated MI or stroke. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | Event Rate (%) (Number) | |||
|---|---|---|---|---|
| MI or stoke (N=3183, 3216) | MI (N=3184, 3217) | Stroke (N=3183, 3216) | Thrombocytopenia (N=3184, 3217) | |
| Apixaban 2.5 mg | 0.38 | 0.22 | 0.16 | 0.19 |
| Enoxaparin 40 mg | 0.37 | 0.12 | 0.25 | 0.09 |
Diastolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken with the participant either sitting, standing, or supine. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | mmHg (Mean) | |
|---|---|---|
| Day of Discharge from Hospital (N=1607, 1625) | Day 30 of Treatment + 2 (N=2227,2301) | |
| Apixaban 2.5 mg | -1.0 | 0.0 |
| Enoxaparin 40 mg | -0.4 | -0.5 |
Heart Rate was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Heart rate was measured in beats per minute (bpm) and could have been taken with participants either sitting, standing, or supine. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | bpm (Mean) | |
|---|---|---|
| Hospital Discharge (N=1606,1622) | Day 30 of treatment (N=2225,2299) | |
| Apixaban 2.5 mg | -5.4 | -4.0 |
| Enoxaparin 40 mg | -5.1 | -4.3 |
Systolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken either sitting, standing, or supine. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | mmHg (Mean) | |
|---|---|---|
| Discharge from Hospital (N=1607, 1625) | Day 30 of Treatment + 2 (N=2227, 2301) | |
| Apixaban 2.5 mg | -3.0 | -2.3 |
| Enoxaparin 40 mg | -2.4 | -2.9 |
Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for AEs, and 30 days after last dose of study drugs for SAEs and deaths. (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days (AEs), plus 30 days (SAEs, Deaths)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| AEs | SAEs | Bleeding AEs | Discontinuations Due to AE | Deaths | |
| Apixaban 2.5 mg | 1871 | 611 | 244 | 290 | 131 |
| Enoxaparin 40 mg | 1910 | 601 | 221 | 262 | 133 |
Special interest include: liver function test increases, AEs related to liver function, and neurologic AEs. Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drug when summarizing AEs and through 30 days after the last dose when summarizing SAEs. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days (AEs) and plus 30 days (SAEs)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Neurologic AEs | Neurologic SAEs | Liver-related AEs | Liver-related SAEs | |
| Apixaban 2.5 mg | 45 | 5 | 127 | 9 |
| Enoxaparin 40 mg | 42 | 1 | 142 | 12 |
Liver function tests: Alanine aminotransferase (ALT) U/L; Aspartate aminotransferase (AST) U/L; Alkaline phosphatase U/L; Total Bilirubin (TBili) mg/dL. Elevations consist of >3*Upper Limit of Normal (ULN) for ALT and AST and elevation of >2*ULN for Bilirubin. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST Elevation >3*ULN (N=2831, 2863) | ALT Elevation >3*ULN (N=2827, 2861) | AST + ALT >3*ULN on same date (N= 2827, 2861) | TBili >2*ULN (N= 2853, 2884) | ALT or AST >3*ULN + TBili >2*ULN (N=2818,2855) | ALT>3*ULN + TBili >2*ULN (N=2817, 2853) | |
| Apixaban 2.5 mg | 23 | 22 | 14 | 13 | 2 | 0 |
| Enoxaparin 40 mg | 28 | 32 | 13 | 14 | 2 | 2 |
Bicarbonate milliequivalents/Liter (mEq/L) Low/High: < 0.75*LLN or > 1.25*ULN, or if PreRx < LLN then use < 0.75* PreRx or > ULN if PreRx > ULN then use > 1.25*PreRx or < LLN; Serum Calcium mg/dL Low/High: < 0.8*LLN or > 1.2*ULN, or if PreRx < LLN then use < 0.75*PreRx or > ULN if PreRx > ULN then use > 1.25*PreRx or < LLN; Serum Chloride mEq/L: < 0.9*LLN or > 1.1*ULN, or if PreRx < LLN then use < 0.9*PreRx or > ULN if PreRx > ULN then use > 1.1*PreRx or < LLN; Serum Potassium mEq/L: < 0.9*LLN or > 1.1*ULN, or if PreRx < LLN then use < 0.9*PreRx or > ULN if PreRx > ULN then use > 1.1*PreRx or < LLN; Serum Sodium mEq/L: < 0.95*LLN or > 1.05*ULN, or if PreRx < LLN then use < 0.95*PreRx or > ULN if PreRx > ULN then use > 1.05*PreRx or < LLN. Samples obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Calcium < 0.8*LLN (N=2861, 2893) | Calcium > 1.2*ULN (N=2861, 2893) | Chloride < 0.9*LLN (N=2861, 2886) | Chloride > 1.1*ULN (N=2861, 2886) | Bicarbonate < 0.75*LLN (N=2831, 2855) | Bicarbonate > 1.25*ULN (N=2831, 2855) | Potassium < 0.9*LLN (N=2851, 2878) | Potassium > 1.1*ULN (N=2851, 2878) | Sodium < 0.95*LLN (N=2862, 2888) | Sodium > 1.05*ULN (N=2862, 2888) | |
| Apixaban 2.5 mg | 6 | 3 | 25 | 5 | 5 | 6 | 61 | 140 | 23 | 9 |
| Enoxaparin 40 mg | 8 | 3 | 25 | 1 | 6 | 4 | 58 | 137 | 25 | 6 |
Creatine kinase High: >5*ULN Units/Liter (U/L); Total Protein High/Low: < 0.9 *LLN or > 1.1*ULN, or if PreRx < LLN then use 0.9* PreRx or > ULN if PreRx > ULN then use 1.1 *PreRx or
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Glucose Fasting <0.9*LLN (N=284,287) | Glucose Fasting > 1.5*ULN (N=284,287) | Total Protein < 0.9 *LLN (N=2864, 2890) | Total Protein > 1.1*ULN (N=2864, 2890) | Creatine kinase >5*ULN U/L(N=2856, 2888) | Uric acid > 1.5* ULN (N=2862, 2889) | |
| Apixaban 2.5 mg | 5 | 39 | 78 | 16 | 8 | 47 |
| Enoxaparin 40 mg | 3 | 30 | 51 | 8 | 10 | 44 |
Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). Absolute (Abs). Hemoglobin: >2 g/dL decrease compared to PreRx value or value <=8 g/dL; Hematocrit: <0.75*PreRx; Erythrocytes: <0.75*PreRx c/µL; Leukocytes: <0.75*LLN or > 1.25*ULN, if PreRx
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin >2 g/dL decrease (N=2835, 2871) | Hematocrit <0.75*PreRx (N=2688, 2722) | Platelet Count < 100*10^9 c/L (N=2761, 2799) | Erythrocytes <0.75*PreRx c/µL (N=2697, 2730) | Leukocytes <0.75*LLN (N= 2835, 2869) | Leukocytes > 1.25*ULN (N=2835, 2869) | Abs Eosinophils > 0.75*10^3 c/µL (N=20, 24) | Abs Lymphocytes < 0.750*10*3 c/ µL (N=20, 24) | Abs Monocytes > 2000/MM^3 (N= 19, 25) | |
| Apixaban 2.5 mg | 133 | 23 | 9 | 28 | 64 | 331 | 1 | 4 | 1 |
| Enoxaparin 40 mg | 98 | 17 | 7 | 16 | 55 | 283 | 1 | 2 | 0 |
Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL > 1.5*ULN; Creatinine mg/dL: > 1.5*ULN; Alanine aminotransferase (ALT) U/L: > 3*ULN; Aspartate aminotransferase (AST) U/L: > 3*ULN; Alkaline phosphatase U/L: > 2*ULN; Bilirubin Direct mg/dL: > 1.5*ULN; Bilirubin Total mg/dL: > 2*ULN. Samples for laboratories obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Alkaline phosphatase U/L > 2*ULN(N=2866, 2895) | ALT U/L > 3*ULN (N=2827, 2861) | AST U/L > 3*ULN (N=2831, 2863) | Bilirubin Direct mg/dL > 1.5*ULN (N=2782, 2821) | Bilirubin Total mg/dL > 2*ULN (N=2853, 2884) | BUN mg/dL > 1.5*ULN (N=2864, 2891) | Creatinine mg/dL > 1.5*ULN (N=2862, 2892) | |
| Apixaban 2.5 mg | 35 | 23 | 24 | 123 | 17 | 194 | 150 |
| Enoxaparin 40 mg | 47 | 33 | 29 | 106 | 15 | 188 | 156 |
All-cause mortality (NCT00413374)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Enoxaparin 1.5 mg/kg Once Daily | 0 |
| Enoxaparin 1 mg/kg Twice Daily | 0 |
Major bleeding complication as defined as spinal, retroperitoneal, or intracranial bleeding; drop in hemoglobin ≥2g/dl or transfusion ≥2U or surgical or medical intervention, death related to bleeding. (NCT00413374)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Enoxaparin 1.5 mg/kg Daily | 0 |
| Enoxaparin 1 mg/kg Twice Daily | 3 |
Major clotting complication (recurrent VTE) as defined as recurrent acute pulmonary embolism confirmed on chest CT or recurrent deep vein thrombosis in the contralateral extremity confirmed with venous ultrasound or CT scan while on once daily enoxaparin therapy. (NCT00413374)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Enoxaparin 1.5 mg/kg Daily | 1 |
| Enoxaparin 1 mg/kg Twice Daily | 3 |
Coagulopathic bleeding due to fondaparinux was suspected in patients requiring packed red cell transfusions after initiation of fondaparinux therapy only if the change in hematocrit prompting transfusion was not clinically commensurate with the degree of injuries that the patient had sustained (primarily orthopaedic) and/or the hematocrit did not respond appropriately post-transfusion. (NCT00531843)
Timeframe: 3 weeks post injury
| Intervention | participants (Number) |
|---|---|
| Fondaparinux Sodium | 0 |
Serum samples were collected 30 minutes before (trough) and 2 hours after (peak) the third dose of fondaparinux. Normative data plots comparing study participants with healthy volunteers were supplied by the company outsourced to analyze samples. (NCT00531843)
Timeframe: Day 3
| Intervention | Participants (Number) | |
|---|---|---|
| Trough values outside normative range | Peak values outside normative range | |
| Fondaparinux Sodium | 0 | 0 |
Color-flow duplex venous ultrasonography examinations of upper and lower extremities were performed within 48 hours of injury, and then weekly until discharge or 3 weeks. DVT was defined as any clot occurring in the subclavian, iliac, femoral, or popliteal location. Patients were examined daily for clinical signs and symptoms of venous thromboembolism (VTE) and PE. Small, nonocclusive clots discovered in other locations were observed for progression on sequential ultrasonography examinations. (NCT00531843)
Timeframe: within 3 weeks post injury
| Intervention | participants (Number) | ||
|---|---|---|---|
| DVT | DVT after fondaparinux | PE | |
| Fondaparinux Sodium | 2 | 1 | 0 |
| No Fondaparinux | 2 | NA | 0 |
The primary safety endpoint was major bleeding events during the On-Treatment Study Period (defined as on-study drug or up to 3 days after the last dose of study drug). (NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 32 |
| Dalteparin Group | 16 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 67 |
| Dalteparin Group | 71 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 19 |
| Dalteparin Group | 35 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 21 |
| Dalteparin Group | 24 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 41 |
| Dalteparin Group | 59 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 235 |
| Dalteparin Group | 228 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 6 |
| Dalteparin Group | 4 |
67 reviews available for dalteparin and Embolism, Pulmonary
| Article | Year |
|---|---|
[Prevention of deep venous thrombosis after knee arthroscopy. Recent advances].
Topics: Anticoagulants; Arthroscopy; Combined Modality Therapy; Follow-Up Studies; Hemorrhage; Humans; Incid | 2009 |
[Recurrent pulmonary embolism in the functional loss of an LGM cava filter after the recanalization of a caval thrombosis].
Topics: Aged; Combined Modality Therapy; Equipment Failure; Femoral Vein; Heparin; Humans; Iliac Vein; Male; | 1994 |
[The treatment of deep venous thrombosis using low-molecular heparin. Swiss Consensus Conference for the Application of Low-molecular Heparin].
Topics: Animals; Biological Availability; Dalteparin; Enoxaparin; Fibrinolytic Agents; Heparin; Heparin, Low | 1994 |
[Successful prophylaxis in a pregnancy with thrombophilic states].
Topics: Acenocoumarol; Adult; Anticoagulants; Drug Therapy, Combination; Female; Gravidity; Humans; Nadropar | 1999 |
[Evolution in the pharmacological treatment of venous thrombosis according to evidence-based medicine].
Topics: Acute Disease; Administration, Oral; Anticoagulants; Clinical Trials as Topic; Dalteparin; Enoxapari | 2000 |
Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Topics: Acute Disease; Anticoagulants; Dalteparin; Drug Administration Schedule; Enoxaparin; Hemorrhage; Hep | 2001 |
Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders.
Topics: Absorption; Animals; Biological Availability; Blood Coagulation; Half-Life; Heparin; Heparin, Low-Mo | 1994 |
Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis.
Topics: Anticoagulants; Arthroplasty; Azetidines; Benzylamines; Dabigatran; Enoxaparin; Heparin; Heparin, Lo | 2017 |
Bemiparin, an effective and safe low molecular weight heparin: a review.
Topics: Anticoagulants; Clinical Trials as Topic; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; | 2014 |
Clinical experience with bemiparin.
Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Surgical Procedures, Oper | 2010 |
Relationship between anti-Xa level achieved with prophylactic low-molecular weight heparin and venous thromboembolism in trauma patients: A systematic review and meta-analysis.
Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Molecular Weight; Prospective Stu | 2022 |
The effectiveness of venous thromboembolism prophylaxis interventions in trauma patients: A systematic review and network meta-analysis.
Topics: Adult; Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Multiple Trauma; Network Meta-A | 2023 |
Bilateral Pulmonary Embolism With Right Heart Strain in a Patient With Immune Thrombocytopenia-A Case Report and Review of the Literature.
Topics: Adolescent; Anticoagulants; Computed Tomography Angiography; Dyspnea; Echocardiography; Enoxaparin; | 2020 |
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Fema | 2021 |
Individualised medicine: why we need Bayesian dosing.
Topics: Aged; Bayes Theorem; Dose-Response Relationship, Drug; Enoxaparin; Humans; Male; Precision Medicine; | 2017 |
Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies.
Topics: Anticoagulants; Enoxaparin; Health Care Costs; Hemorrhage; Humans; Length of Stay; Pulmonary Embolis | 2017 |
Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Drug-Related Side Effects | 2017 |
Chemical venous thromboembolism prophylaxis in neurosurgical patients: an updated systematic review and meta-analysis.
Topics: Anticoagulants; Enoxaparin; Evidence-Based Medicine; Hemorrhage; Heparin, Low-Molecular-Weight; Intr | 2018 |
Symptomatic bilateral pulmonary embolism without deep venous thrombosis in an adolescent following arthroscopic anterior cruciate ligament reconstruction: a case report and review of the literature.
Topics: Adolescent; Anterior Cruciate Ligament Reconstruction; Anticoagulants; Arthroscopy; Elective Surgica | 2018 |
Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enox | 2019 |
Outpatient versus inpatient treatment for acute pulmonary embolism.
Topics: Acute Disease; Adult; Ambulatory Care; Anticoagulants; Confidence Intervals; Enoxaparin; Hemorrhage; | 2019 |
Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis.
Topics: Anticoagulants; Bariatric Surgery; Comparative Effectiveness Research; Enoxaparin; Heparin, Low-Mole | 2013 |
NOACs for thromboprophylaxis in medical patients.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administr | 2013 |
[Safe dose rTPA for massive pulmonary embolism associated with high bleeding risk: a case report and review of the literature].
Topics: Aged, 80 and over; Anemia, Hypochromic; Anticoagulants; Bundle-Branch Block; Diabetes Complications; | 2014 |
Pulmonary embolism in burns, is there an evidence based prophylactic recommendation? Case report and review of literature.
Topics: Adult; Anticoagulants; Burns; Enoxaparin; Evidence-Based Medicine; Female; Humans; Obesity; Pulmonar | 2015 |
Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Human | 2015 |
The outcome of pulmonary vein thrombosis in non-surgical patients. A systematic review and case report.
Topics: Adult; Aged; Aged, 80 and over; Enoxaparin; Fatal Outcome; Female; Hemorrhage; Humans; Male; Middle | 2015 |
Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Brain Ischemi | 2015 |
Retroperitoneal haematoma associated with enoxaparin use in an elderly woman with chronic kidney disease.
Topics: Aged, 80 and over; Anticoagulants; Aspirin; Enoxaparin; Erythrocyte Transfusion; Female; Hematoma; H | 2015 |
Spontaneous, resolving S1Q3T3 in pulmonary embolism: A case report and literature review on prognostic value of electrocardiography score for pulmonary embolism.
Topics: Adult; Electrocardiography; Emergency Service, Hospital; Enoxaparin; Humans; Male; Myocardial Ischem | 2016 |
Postinjury thromboprophylaxis.
Topics: Anticoagulants; Critical Illness; Enoxaparin; Factor Xa Inhibitors; Fondaparinux; Humans; Incidence; | 2008 |
[Venous thromboembolism and immobilization for medical reason].
Topics: Age Factors; Aged; Anticoagulants; Dalteparin; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux | 2008 |
Early postoperative bleeding in polytrauma patients treated with fondaparinux: literature review and institutional experience.
Topics: Acetabulum; Adult; Anticoagulants; Enoxaparin; Female; Fondaparinux; Fractures, Bone; Humans; Male; | 2011 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhib | 2011 |
Standard or extended-duration prophylaxis in medical patients? A review of the evidence.
Topics: Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Male; Pulmonary Embolism; Randomized Control | 2011 |
Discoveries in thrombosis care for medical patients.
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Critical Care; Drug Costs; Enoxaparin; Fibrinolytic | 2002 |
Thromboprophylaxis in medical patients: focus on France.
Topics: Acute Disease; Adult; Aged; Attitude of Health Personnel; Cardiovascular Diseases; Double-Blind Meth | 2002 |
Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely III medical inpatients in community practice.
Topics: Acute Disease; Aged; Anticoagulants; Databases, Factual; Enoxaparin; Humans; Inpatients; Pulmonary E | 2004 |
Clinical application of enoxaparin.
Topics: Anticoagulants; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Enoxaparin; Fibrinolytic Ag | 2004 |
Successful surgical management of a neonate with a saddle pulmonary embolus.
Topics: Anticoagulants; Arm; Cardiopulmonary Bypass; Ductus Arteriosus, Patent; Embolectomy; Enoxaparin; Fem | 2004 |
Pentasaccharides. The new anticoagulants.
Topics: Anticoagulants; Enoxaparin; Female; Fondaparinux; Humans; Male; Orthopedic Procedures; Polysaccharid | 2004 |
Surgical management of enoxaparin- and/or warfarin-induced massive retroperitoneal bleeding: report of a case and review of the literature.
Topics: Aged; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Laparotomy; Male; Pulmonary Embolism; Retroper | 2005 |
Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Pulmona | 2005 |
Clinical trials of deep vein thrombosis prophylaxis in medical patients.
Topics: Aged; Anticoagulants; Dalteparin; Enoxaparin; Fondaparinux; Humans; Middle Aged; Polysaccharides; Pu | 2005 |
Massive retroperitoneal hematoma during enoxaparin treatment of pulmonary embolism after primary total hip arthroplasty: case reports and review of the literature.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Female; Hematoma; Humans; Postoper | 2006 |
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dos | 2007 |
Delayed presentation of pulmonary polymethylmethacrylate emboli after percutaneous vertebroplasty.
Topics: Anticoagulants; Bone Cements; Enoxaparin; Female; Fractures, Compression; Humans; Lumbar Vertebrae; | 2007 |
Anticoagulant treatment of deep vein thrombosis and pulmonary embolism.
Topics: Anticoagulants; Antithrombin III; Enoxaparin; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; P | 2008 |
Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
Topics: Cost-Benefit Analysis; Decision Trees; Enoxaparin; Hip Prosthesis; Humans; Pulmonary Embolism; Sensi | 1995 |
Prolonged prophylaxis against postoperative venous thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Disease Susceptibility; Double-Blind Method; Drug Ad | 1996 |
Low-molecular-weight heparins in clinical practice.
Topics: Anticoagulants; Cardiovascular Diseases; Clinical Trials as Topic; Dalteparin; Enoxaparin; Fibrinoly | 1998 |
[Clexane in prevention of acute venous thrombosis and pulmonary thromboembolism].
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Cost-Benefit Analysis; Drug Administration Schedule; | 1998 |
Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty.
Topics: Adult; Ambulatory Care; Anticoagulants; Arthroplasty, Replacement, Hip; Clinical Trials as Topic; Co | 2000 |
Preventing venous thromboembolism in general medical inpatients and after an ischaemic stroke.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as | 2000 |
Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism.
Topics: Clinical Trials as Topic; Dalteparin; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Pulmonary E | 2001 |
Prophylaxis of venous thromboembolism in medical patients.
Topics: Anticoagulants; Bandages; Brain Ischemia; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Myocard | 2001 |
Treating venous thromboembolism: enoxaparin.
Topics: Ambulatory Care; Anticoagulants; Contraindications; Cost-Benefit Analysis; Drug Costs; Enoxaparin; H | 2001 |
Fondaparinux versus enoxaparin for the prevention of venous thromboembolism.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Fondaparinux; Humans; P | 2002 |
Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke (Cochrane review).
Topics: Acute Disease; Anticoagulants; Brain Ischemia; Chondroitin Sulfates; Databases, Factual; Dermatan Su | 2002 |
Low-molecular-weight heparins during pregnancy.
Topics: Anticoagulants; Dalteparin; Female; Heparin, Low-Molecular-Weight; Humans; Maternal-Fetal Exchange; | 2005 |
Dalteparin: a low-molecular-weight heparin.
Topics: Abdomen; Adult; Aged; Anticoagulants; Biological Availability; Dalteparin; Drug Costs; Female; Hepar | 1997 |
Death after joint replacement.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; | 2000 |
Outpatient treatment of patients with deep-vein thrombosis or pulmonary embolism.
Topics: Administration, Oral; Ambulatory Care; Anticoagulants; Dalteparin; Feasibility Studies; Heparin, Low | 2001 |
Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis.
Topics: Blood Coagulation; Clinical Trials as Topic; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hum | 2010 |
Tinzaparin sodium: a low-molecular-weight heparin.
Topics: Biological Availability; Economics, Pharmaceutical; Fibrinolytic Agents; Half-Life; Heparin, Low-Mol | 2002 |
Is there a need for long-term thromboprophylaxis following general surgery?
Topics: Bandages; Clinical Trials as Topic; Combined Modality Therapy; Double-Blind Method; Follow-Up Studie | 1993 |
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Topics: Adult; Ambulatory Care; Anticoagulants; Antineoplastic Agents; Antithrombins; Child; Hemorrhage; Hep | 2014 |
137 trials available for dalteparin and Embolism, Pulmonary
| Article | Year |
|---|---|
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study.
Topics: Adult; Aged; Anticoagulants; Combined Modality Therapy; Compression Bandages; Disease Progression; D | 2010 |
Low allergenic potential with fondaparinux: results of a prospective investigation.
Topics: Anticoagulants; Biopsy; Dose-Response Relationship, Drug; Drug Hypersensitivity; Factor X; Female; F | 2010 |
Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study.
Topics: Acute Disease; Adult; Aged; Ambulatory Care; Anticoagulants; Female; Hemorrhage; Humans; Male; Middl | 2011 |
Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Feasibility Studies; He | 2003 |
Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Autopsy; Double-Blind Method; Female; | 2005 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Humans | 2008 |
Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.
Topics: Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Hemorrhage; Humans; Nadrop | 1996 |
Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium)
Topics: Aged; Anticoagulants; Drug Administration Schedule; Female; Hip Fractures; Humans; Leg Injuries; Mal | 1996 |
[Clinically silent pulmonary embolism in patients with proximal deep venous thrombosis].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Humans; Incidence; Male; Middle Aged; Nadrop | 1996 |
Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
Topics: Ambulatory Care; Anticoagulants; Female; Fibrinolytic Agents; Follow-Up Studies; Health Care Costs; | 1999 |
Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients.
Topics: Anticoagulants; Digestive System Surgical Procedures; Female; Heparin; Humans; Male; Middle Aged; Na | 2000 |
[Thromboembolic prophylaxis after major abdominal surgery].
Topics: Abdomen; Bandages; Female; Fibrinolytic Agents; Hematoma; Humans; Injections, Subcutaneous; Male; Mi | 2001 |
A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum).
Topics: Aged; Analysis of Variance; Anticoagulants; Chi-Square Distribution; Dose-Response Relationship, Dru | 2012 |
Prophylaxis of thromboembolism in bariatric surgery with parnaparin.
Topics: Adult; Anticoagulants; Bariatric Surgery; Blood Coagulation Tests; Body Mass Index; Combined Modalit | 2007 |
[Low molecular weight heparin (parnaparin) versus calcium heparin in the prevention of thromboembolic disease in general surgery].
Topics: Adult; Aged; Aged, 80 and over; Female; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; | 1994 |
Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Gynecologic Surgical Procedures; | 2015 |
Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study.
Topics: Aged; Anticoagulants; Female; Health Care Costs; Heparin, Low-Molecular-Weight; Humans; Male; Middle | 2006 |
A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Female | 2000 |
Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial.
Topics: Anticoagulants; COVID-19; Enoxaparin; Hemorrhage; Humans; Pulmonary Embolism; Venous Thromboembolism | 2022 |
Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Aust | 2022 |
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Replacement, Knee; Dose-Respo | 2020 |
Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
Topics: Administration, Oral; Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Hu | 2020 |
The Impact of Multiple Renal Estimates on Pharmacist Dosing Recommendations: A Randomized Trial.
Topics: Acute Disease; Aged; Clinical Decision-Making; Creatinine; Electronic Health Records; Enoxaparin; Fe | 2021 |
Intermittent pneumatic compression versus additional prophylaxis with enoxaparin for prevention of venous thromboembolism after laparoscopic surgery for gastric and colorectal malignancies: multicentre randomized clinical trial.
Topics: Aged; Anticoagulants; Colorectal Neoplasms; Enoxaparin; Female; Hemorrhage; Humans; Intermittent Pne | 2020 |
Early vs. late enoxaparin for the prevention of venous thromboembolism in patients with ICH: A double blind placebo controlled multicenter study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cerebral Hemorrhage; Disease Progression; Double-Blind Meth | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy.
Topics: Aged; Anticoagulants; Benzamides; Delayed-Action Preparations; Double-Blind Method; Enoxaparin; Fact | 2017 |
Enoxaparin versus No Anticoagulation Prophylaxis after Total Knee Arthroplasty in Thai Patients: A Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxa | 2017 |
Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Human | 2019 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Safety and efficacy of early thromboembolism chemoprophylaxis after intracranial hemorrhage from traumatic brain injury.
Topics: Adult; Aged; Anticoagulants; Brain Injuries; Chemoprevention; Clinical Protocols; Cohort Studies; En | 2013 |
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Pulmonar | 2014 |
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Pulmonar | 2014 |
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Pulmonar | 2014 |
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Pulmonar | 2014 |
Randomised controlled trial for efficacy of unfractionated heparin (UFH) versus low molecular weight heparin (LMWH) in thrombo-prophylaxis.
Topics: Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Heparin; Humans; Intention to Treat | 2013 |
Identifying the Bariatric Patient at Risk for Pulmonary Embolism: Prospective Clinical Trial Using Duplex Sonography and Blood Screening.
Topics: Adult; Bariatric Surgery; Blood Chemical Analysis; Blood Coagulation Tests; Enoxaparin; Female; Huma | 2015 |
Adherence to Anticoagulant Therapy in Pediatric Patients Hospitalized With Pulmonary Embolism or Deep Vein Thrombosis: A Retrospective Cohort Study.
Topics: Adolescent; Anticoagulants; Child; Enoxaparin; Female; Hospitalization; Humans; Male; Medicaid; Medi | 2016 |
Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibito | 2015 |
Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism.
Topics: Administration, Oral; Anticoagulants; Cytochrome P-450 CYP2C9; Enoxaparin; Genotype; Humans; Pulmona | 2016 |
Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2017 |
Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Coagulation; Drug Interactions; Enoxapa | 2017 |
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzamides; Double-Blind Method; Enoxaparin; Factor Xa Inhi | 2017 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-B | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-B | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-B | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-B | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
Topics: Administration, Oral; Adult; Aged; Arthroplasty, Replacement, Knee; Canada; Dose-Response Relationsh | 2009 |
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Kne | 2010 |
Early postoperative bleeding in polytrauma patients treated with fondaparinux: literature review and institutional experience.
Topics: Acetabulum; Adult; Anticoagulants; Enoxaparin; Female; Fondaparinux; Fractures, Bone; Humans; Male; | 2011 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Coagulation; Dose-Response Relationshi | 2011 |
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res | 2011 |
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res | 2011 |
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res | 2011 |
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res | 2011 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
[Prolongation of enoxaparin therapy to one month promotes recanalization of the occlusively thrombosed deep veins].
Topics: Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combin | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
[Enoxaparin for the prevention of post surgical pulmonary embolism].
Topics: Adult; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Postoperative C | 2011 |
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Biotin; Double-Blind Meth | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Injections | 2002 |
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip | 2003 |
Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism.
Topics: Acute Disease; Adult; Aged; Enoxaparin; Feasibility Studies; Female; Hemorrhage; Heparin; Humans; Le | 2003 |
[Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism].
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Prospectiv | 2003 |
Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study.
Topics: Aged; Blood Coagulation Factors; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Human | 2004 |
Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Concussion; Cerebral Hemorrhage, Traumatic; Cervic | 2004 |
Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
Topics: Angiography; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort | 2005 |
Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.
Topics: Adult; Aged; Ambulatory Care; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Heparin; | 2005 |
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Response Relati | 2006 |
Ambulatory therapy of patients with free-floating proximal deep vein thrombosis is safe.
Topics: Adult; Aged; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Pulmona | 2005 |
Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism.
Topics: Acute Disease; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Humans; Male; Middl | 2005 |
Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Enoxaparin; Female; Hemorrhage; Humans; In Vitro Techniques; | 2007 |
Improving adjunctive treatment in pulmonary embolism and fibrinolytic therapy. The role of enoxaparin and weight-adjusted unfractionated heparin.
Topics: Adult; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Heparin; Hospital Mortal | 2009 |
SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Response Relati | 2008 |
Antithromboembolic efficacy and safety of enoxaparin in general surgery. German multicentre trial.
Topics: Adult; Aged; Enoxaparin; Female; Hematologic Tests; Hemorrhage; Humans; Incidence; Male; Middle Aged | 1994 |
Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement.
Topics: Aged; Drug Administration Schedule; Enoxaparin; Female; Heparin; Hip Prosthesis; Humans; Male; Posto | 1995 |
Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
Topics: Cost-Benefit Analysis; Decision Trees; Enoxaparin; Hip Prosthesis; Humans; Pulmonary Embolism; Sensi | 1995 |
Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin.
Topics: Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans | 1996 |
Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administration Schedule; E | 1996 |
Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial.
Topics: Aged; Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Enoxaparin; Female; | 1996 |
A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Chi-Square Distribution; Double-Blind Method | 1996 |
Prolonged prophylaxis against postoperative venous thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Disease Susceptibility; Double-Blind Method; Drug Ad | 1996 |
Sequential mechanical and pharmacological thromboprophylaxis in the surgery of hip fractures. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Femor | 1997 |
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma | 1998 |
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma | 1998 |
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma | 1998 |
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma | 1998 |
Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.
Topics: Adult; Aged; Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Elective Surg | 1998 |
The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1,984 patients. Canadian Collaborative Group.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort Studie | 1998 |
Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery: the French study--venographic outcome at 35 days.
Topics: Aged; Anti-Bacterial Agents; Arthroplasty, Replacement, Hip; Enoxaparin; Female; Follow-Up Studies; | 1998 |
Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug A | 1999 |
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hospitalization; Human | 1999 |
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hospitalization; Human | 1999 |
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hospitalization; Human | 1999 |
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hospitalization; Human | 1999 |
[The prevention of postoperative deep venous thrombosis in orthopedic surgery].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Ortho | 1999 |
Comparative effectiveness of low-molecular-weight heparins after therapeutic interchange.
Topics: Aged; Anticoagulants; Dalteparin; Economics, Pharmaceutical; Enoxaparin; Female; Formularies as Topi | 2000 |
[Médenox study].
Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Hospitalization; Humans; Prospective S | 2000 |
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Administ | 2001 |
Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial.
Topics: Aged; Anticoagulants; Critical Illness; Enoxaparin; Female; Humans; Male; Multicenter Studies as Top | 2000 |
A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Res | 2001 |
Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Female; | 2001 |
Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Azetidines; Benz | 2001 |
Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiography; Anticoagulants; Enoxaparin; Hepar | 2001 |
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
Topics: Aged; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Hip Fr | 2001 |
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Enoxaparin; F | 2001 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Low molecular weight heparin for prevention of thromboembolic complications in cardioversion--rationale and design of the ACE study (Anticoagulation in Cardioversion using Enoxaparin).
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Atrial Fibrillation; Dose-Response Relationship, | 2002 |
An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Drug Therapy, Combination; Heparin; Hepar | 2003 |
An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group.
Topics: Adult; Aged; Double-Blind Method; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Inciden | 1993 |
Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial.
Topics: Adult; Aged; Anticoagulants; Double-Blind Method; Female; Hemorrhage; Heparin; Heparin, Low-Molecula | 1997 |
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.
Topics: Anticoagulants; Death, Sudden; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; M | 1997 |
Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
Topics: Acute Disease; Anticoagulants; Drug Administration Schedule; Female; Hemorrhage; Heparin; Heparin, L | 2001 |
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis.
Topics: Acute Disease; Anticoagulants; Biomarkers; Blood Coagulation Factors; Heparin; Heparin, Low-Molecula | 2002 |
Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin.
Topics: Aged; Anticoagulants; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Injections, Intravenou | 2014 |
An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Female; Follow-Up Studies; Hemorrhage; Hepar | 2010 |
Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin.
Topics: Adult; Aged; Anticoagulants; Double-Blind Method; Female; Heparin; Heparin, Low-Molecular-Weight; Hu | 2005 |
Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy.
Topics: Anticoagulants; Cause of Death; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle | 2005 |
Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Heparin; Heparin, Low-Molecular-Wei | 2006 |
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
Topics: Aged; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pulm | 2022 |
Sex differences in thromboprophylaxis of the critically ill: a secondary analysis of a randomized trial.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Heparin; Humans; Male; Pulmonary Embolism; Sex | 2023 |
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Topics: Administration, Oral; Aged; Anticoagulants; Dalteparin; Female; Hemorrhage; Humans; Incidence; Injec | 2020 |
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Topics: Aged; Blood Coagulation; Dalteparin; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hem | 2019 |
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
Topics: Adult; Anticoagulants; Dalteparin; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Ne | 2015 |
Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients.
Topics: Aged; Anticoagulants; APACHE; Critical Illness; Dalteparin; Female; Heparin; Humans; Intensive Care | 2015 |
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Canada; Dalteparin; Doub | 2010 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
Topics: Acute Disease; Adult; Aged; Ambulatory Care; Dalteparin; Female; Fibrinolytic Agents; Follow-Up Stud | 2005 |
Thromboprophylaxis with dalteparin in medical patients: which patients benefit?
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Double-Blind Method; Fema | 2007 |
Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group.
Topics: Acute Disease; Adult; Aged; Dalteparin; Dose-Response Relationship, Drug; Female; Humans; Male; Midd | 1994 |
Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
Topics: Adult; Aged; Aged, 80 and over; Contraindications; Coumarins; Dalteparin; Female; Fractures, Spontan | 1994 |
Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Female; Follow-Up Studies; Heparin; Huma | 1995 |
Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin.
Topics: Aged; Aged, 80 and over; Bandages; Chi-Square Distribution; Dalteparin; Female; Femoral Vein; Fibrin | 1996 |
Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. The Fragmin Multicentre Study Group.
Topics: Abdomen; Anticoagulants; Dalteparin; Elective Surgical Procedures; Hemorrhagic Disorders; Humans; Mu | 1996 |
Outpatient treatment of pulmonary embolism with dalteparin.
Topics: Adult; Aged; Ambulatory Care; Anticoagulants; Cohort Studies; Dalteparin; Disease-Free Survival; Fib | 2000 |
Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.
Topics: Activated Protein C Resistance; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthropl | 2002 |
Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study.
Topics: Aged; Anticoagulants; Cohort Studies; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Prospective | 2022 |
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Norma | 2015 |
Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.
Topics: Adult; Aged; Brain Neoplasms; Drug Administration Schedule; Female; Fibrinolytic Agents; Follow-Up S | 2009 |
Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Fibrinolytic Agents; Heparin, | 2010 |
Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial.
Topics: Acenocoumarol; Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Fema | 2005 |
Is there a need for long-term thromboprophylaxis following general surgery?
Topics: Bandages; Clinical Trials as Topic; Combined Modality Therapy; Double-Blind Method; Follow-Up Studie | 1993 |
A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.
Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Hepari | 1997 |
Incomplete recovery of lung perfusion after 3 months in patients with acute pulmonary embolism treated with antithrombotic agents. THESEE Study Group. Tinzaparin ou Heparin Standard: Evaluation dans l'Embolie Pulmonaire Study.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Fib | 2000 |
Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Ambulatory Care; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cause | 2000 |
[Low molecular weight heparin decreases thrombosis risk in patients receiving chemotherapy for cancer].
Topics: Double-Blind Method; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weig | 2013 |
287 other studies available for dalteparin and Embolism, Pulmonary
| Article | Year |
|---|---|
Arterial and venous thromboembolic disease in a patient with COVID-19: A case report.
Topics: Anticoagulants; Cerebral Infarction; Clopidogrel; Computed Tomography Angiography; Coronavirus Infec | 2020 |
Comparison of the Effects of Low-Molecular-Weight Heparin and Fondaparinux on Liver Function in Patients With Pulmonary Embolism.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Asian People; Chemical and Drug Induced Liver Injury | 2020 |
Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Cohort Studies; Drug Administration Schedule; Female; He | 2017 |
[Pulmonary embolism in a girl with nephrotic syndrome and factor V Leiden - case report].
Topics: Adolescent; Anticoagulants; Antithrombin III; Factor V; Female; Humans; Mycophenolic Acid; Nadropari | 2018 |
Pulmonary embolism after abdominal flap breast reconstruction: prediction and prevention.
Topics: Adult; Aged; Anticoagulants; Body Mass Index; BRCA1 Protein; BRCA2 Protein; DNA Mutational Analysis; | 2013 |
Bleeding complications after systematic switch of routine thromboprophylaxis for major orthopaedic surgery.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Middle Aged; Nadropari | 2008 |
Successful administration of a low dose of calcium nadroparin in patients suffering from pulmonary embolism and brain metastases: a report of two cases.
Topics: Anticoagulants; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cerebellar Neoplasms; Dyspnea; Fem | 2011 |
Heparin-induced thrombocytopenia associated with pulmonary embolism.
Topics: Aged; Antibodies; Female; Fibrinolytic Agents; Fractures, Bone; Hirudins; Humans; Nadroparin; Orthop | 2010 |
Thromboprophylaxis during chemotherapy in patients with advanced cancer.
Topics: Anticoagulants; Antineoplastic Agents; Humans; Nadroparin; Neoplasms; Pulmonary Embolism; Randomized | 2010 |
Heparin-induced thrombocytopenia with pulmonary embolism and disseminated intravascular coagulation associated with low-molecular-weight heparin.
Topics: Arthroplasty, Replacement, Hip; Disseminated Intravascular Coagulation; Female; Humans; Immunoglobul | 2003 |
Spontaneous leg hematoma in a patient anticoagulated with nadroparin for suspected pulmonary thromboembolism.
Topics: Aged; Aged, 80 and over; Anticoagulants; Female; Hematoma; Humans; Leg; Nadroparin; Pulmonary Emboli | 2004 |
[Peculiarities of occurrence and prophylaxis of pulmonary thromboembolism in an urgent abdominal surgery].
Topics: Abdominal Cavity; Adolescent; Adult; Aged; Aged, 80 and over; Female; Fibrinolytic Agents; Humans; M | 2004 |
[Determination of factor Xa inhibition doses of low-molecular heparin, nadroparin and reviparin in urological patients].
Topics: Anticoagulants; Body Mass Index; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Nadrop | 2007 |
[Massive pulmonary embolism mimicking ST-elevation acute coronary syndrome successfully treated with hybrid therapy in a trauma patient receiving nadroparin: diagnostic and therapeutic dilemmas].
Topics: Acute Coronary Syndrome; Angiocardiography; Angioplasty, Balloon; Diagnosis, Differential; Drug Ther | 2007 |
Delayed hypersensitivity to low-molecular-weight heparin (LMWH) in pregnancy.
Topics: Adult; Anticoagulants; Cortisone; Drug Eruptions; Female; Fibrinolytic Agents; Follow-Up Studies; Fo | 2007 |
[The use of fraxiparin in orthopedic trauma patients to prevent and treat pulmonary embolism and deep venous thrombosis of the extremities].
Topics: Adult; Drug Evaluation; Female; Fractures, Bone; Humans; Knee Injuries; Male; Middle Aged; Nadropari | 1993 |
[Prevention of thrombosis with fraxiparin 0.3 after ambulatory surgery].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Surgical Procedures; Anticoagulants; Dose-Res | 1996 |
[Long-term prophylaxis of thromboembolism and fraxiparin].
Topics: Anticoagulants; Contraindications; Drug Administration Schedule; Heart Valve Prosthesis; Humans; Nad | 1997 |
Efficacy of prevention of thromboembolic complications with LMW-heparin in experiment.
Topics: Animals; Anticoagulants; Arthroplasty, Replacement, Hip; Disease Models, Animal; Dogs; Factor Xa Inh | 1997 |
Treatment of pulmonary embolism by subcutaneous low-molecular-weight heparin in a hemodialysis patient.
Topics: Adult; Anticoagulants; Catheterization, Central Venous; Humans; Jugular Veins; Male; Nadroparin; Pul | 1998 |
Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy.
Topics: Fibrinolytic Agents; Humans; Italy; Nadroparin; Postoperative Complications; Pulmonary Embolism; Thr | 1997 |
Low molecular weight heparin-induced liver toxicity.
Topics: Adult; Anticoagulants; Cerebral Infarction; Chemical and Drug Induced Liver Injury; Complement C3; E | 2001 |
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of low molecular weight heparin. Gynecological ward retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Electrocardiography; Female; Gynecologic Surgical Procedures; Hepari | 2002 |
[Parnaparin sodium - modern therapy options and prevention of venous thromboembolic complications].
Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Venous Thromboembolism | 2020 |
[Intracranial hemorrhage due to pulmonary thromboembolism in heparin therapy and therapeutic management of patients hospitalized with massive pulmonary embolism after discharge].
Topics: Angiography; Anticoagulants; Embolectomy; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; In | 2013 |
[Role of low molecular weight heparins in prophylaxis of thromboembolic events on oncological patients with indwelling central venous catheter].
Topics: Adult; Aged; Anticoagulants; Catheterization, Central Venous; Catheters, Indwelling; Data Interpreta | 2009 |
[Assessment of venous thromboembolism risk in hospitalized medical patients. Concordance between PRETEMED guide and the recommendations of the viii conference of the American College of Chest Physicians].
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Decision Support Techniques; Enoxaparin; Fe | 2012 |
A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Administ | 2007 |
Enoxaparin titrated by anti-Xa levels reduces venous thromboembolism in trauma patients.
Topics: Blood Coagulation Tests; Chemoprevention; Dose-Response Relationship, Drug; Drug Dosage Calculations | 2022 |
Incidence and effects of deep vein thrombosis on the outcome of patients with coronavirus disease 2019 infection.
Topics: Adult; Aged; Anticoagulants; COVID-19; Enoxaparin; Female; Humans; Incidence; Male; Middle Aged; Pul | 2022 |
Retroperitoneal hematoma in COVID-19 patients - case series.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; COVID-19; Enoxaparin; Female; Hematoma; Heparin, Low | 2022 |
Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular Fractures?
Topics: Anticoagulants; Aspirin; Chemoprevention; Enoxaparin; Hematoma; Heparin; Hip Fractures; Humans; Pelv | 2022 |
Venous thromboembolism risk after spinal cord injury: A secondary analysis of the CLOTT study.
Topics: Anticoagulants; Enoxaparin; Female; Heparin; Humans; Male; Prospective Studies; Pulmonary Embolism; | 2023 |
Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case Report.
Topics: Adult; Angiogenesis Inhibitors; COVID-19; COVID-19 Serotherapy; Enoxaparin; Glucocorticoids; Humans; | 2022 |
Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients.
Topics: Anticoagulants; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Retr | 2023 |
Management and outcomes of calf deep vein thrombosis in patients with contraindication to full anticoagulation due to bleeding.
Topics: Anticoagulants; Contraindications; Enoxaparin; Hemorrhage; Humans; Mesenteric Ischemia; Pulmonary Em | 2023 |
Unfractionated heparin versus enoxaparin for venous thromboembolism prophylaxis in intensive care units: a propensity score adjusted analysis.
Topics: Anticoagulants; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Pr | 2023 |
Early venous thromboembolism prophylaxis in patients with trauma intracranial hemorrhage: Analysis of the prospective multicenter Consortium of Leaders in Traumatic Thromboembolism study.
Topics: Anticoagulants; Enoxaparin; Heparin; Humans; Intracranial Hemorrhage, Traumatic; Intracranial Hemorr | 2023 |
Combination of enoxaparin and low-dose aspirin for thromboprophylaxis in selective patients after primary total joint arthroplasty in a Taiwanese population.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; Humans; Postoperative Complicat | 2023 |
"Hospital survival of patients with pulmonary embolism in a country with limited resources case of the city of Kinshasa".
Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Democratic Republic of the Congo; Enoxaparin; Fema | 2023 |
Neutrophil-Lymphocyte Ratio as a Predictor of Venous Thromboembolism after Total Knee Replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Biomarkers; Chemoprevention; Enoxaparin; Fema | 2021 |
Awareness and Perception of Thromboembolism and Thromboprophylaxis among Hospitalized Patients in Jordan.
Topics: Adult; Aged; Cross-Sectional Studies; Educational Status; Enoxaparin; Female; Fibrinolytic Agents; H | 2020 |
Underdosing of Prophylactic Enoxaparin Is Common in Orthopaedic Trauma and Predicts 90-Day Venous Thromboembolism.
Topics: Academic Medical Centers; Adult; Aged; Anticoagulants; Cohort Studies; Dose-Response Relationship, D | 2019 |
Defects in Processes of Care for Pharmacologic Prophylaxis Are Common Among Neurosurgery Patients Who Develop In-Hospital Postoperative Venous Thromboembolism.
Topics: Aged; Algorithms; Anticoagulants; Chemoprevention; Enoxaparin; Female; Guideline Adherence; Heparin; | 2020 |
Bullous hemorrhagic dermatosis.
Topics: Anticoagulants; Diagnosis, Differential; Enoxaparin; Fatal Outcome; Female; Hemorrhage; Humans; Midd | 2020 |
Retrospective Evaluation of Venous Thromboembolism Prophylaxis in Elderly, High-Risk Trauma Patients.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Anticoagulants; Enoxaparin; Female; Humans; Incidence; | 2020 |
Prophylaxis for Pediatric Venous Thromboembolism: Current Status and Changes Across Pediatric Orthopaedic Society of North America From 2011.
Topics: Aspirin; Enoxaparin; Guideline Adherence; Humans; North America; Orthopedic Procedures; Pediatrics; | 2020 |
Perioperative symptomatic venous thromboembolism after immediate chemoprophylaxis in patients with pelvic and lower-extremity fractures.
Topics: Adult; Aged; Anticoagulants; Bones of Lower Extremity; Chemoprevention; Dabigatran; Enoxaparin; Fema | 2020 |
Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease.
Topics: Acute Disease; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Betacoronavirus; Biomarkers; | 2020 |
COVID-19 and Acute Pulmonary Embolism in Postpartum Patient.
Topics: Acute Disease; Adult; Anticoagulants; Betacoronavirus; Cesarean Section; Clinical Laboratory Techniq | 2020 |
Pulmonary embolism: A complication of COVID 19 infection.
Topics: Adult; Aged; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Enoxaparin; Female; | 2020 |
VTE in ICU Patients With COVID-19.
Topics: Adult; Aged; Anticoagulants; Betacoronavirus; C-Reactive Protein; Computed Tomography Angiography; C | 2020 |
Saddle pulmonary embolism and thrombus-in-transit straddling the patent foramen ovale 28 days after COVID symptom onset.
Topics: Aged; Anticoagulants; Computed Tomography Angiography; COVID-19; Dyspnea; Echocardiography; Enoxapar | 2020 |
Use of awake proning to avoid invasive ventilation in a patient with severe COVID-19 pneumonitis.
Topics: Anticoagulants; Betacoronavirus; Chemoprevention; Computed Tomography Angiography; Coronavirus Infec | 2020 |
COVID-19 associated with extensive pulmonary arterial, intracardiac and peripheral arterial thrombosis.
Topics: Anticoagulants; Betacoronavirus; Clinical Deterioration; Computed Tomography Angiography; Coronaviru | 2020 |
Potential role for furosemide in the treatment of acute respiratory distress syndrome (ARDS) and an unusual presentation of pulmonary embolism in a complex patient.
Topics: Aged, 80 and over; Anticoagulants; Ceftriaxone; Enoxaparin; Female; Furosemide; Humans; Pulmonary Em | 2020 |
Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience.
Topics: Aged; Anticoagulants; Antithrombins; Coronavirus Infections; COVID-19; Enoxaparin; Factor Xa Inhibit | 2020 |
Venous thromboembolism and COVID-19: a case report and review of the literature.
Topics: Aged; Anticoagulants; Betacoronavirus; Computed Tomography Angiography; Coronavirus Infections; COVI | 2020 |
Primary care physicians comprehensively manage acute pulmonary embolism without higher-level-of-care transfer: A report of two cases.
Topics: Acute Disease; Adult; Ambulatory Care; Anticoagulants; Antithrombins; Chest Pain; Computed Tomograph | 2020 |
Clinical analysis of postoperative venous thromboembolism in Japanese patients after colorectal cancer surgery.
Topics: Aged; Anticoagulants; Asian People; Colorectal Neoplasms; Enoxaparin; Female; Fibrin Fibrinogen Degr | 2021 |
Pulmonary embolism in patients with severe COVID-19 treated with intermediate- to full-dose enoxaparin: A retrospective study.
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; Pulmonary Embolism; Retrospective Studies; SARS-CoV-2; | 2021 |
Massive Pulmonary Embolism in an Adolescent With Multisystem Inflammatory Syndrome Due to COVID-19.
Topics: Adolescent; Computed Tomography Angiography; COVID-19; Enoxaparin; Female; Fibrinolytic Agents; Huma | 2021 |
Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism.
Topics: Enoxaparin; Factor Xa Inhibitors; Female; Gastrointestinal Neoplasms; Hemorrhage; Humans; Liver Neop | 2021 |
A cost comparison of warfarin vs enoxaparine or new oral anticoagulants used for the treatment of patients with pulmonary embolism.
Topics: Administration, Oral; Adult; Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Female; Humans; Male | 2016 |
Pharmacological management of cerebral venous sinus thrombosis with full-dose IV heparin infusion and its clinical outcomes.
Topics: Anticoagulants; Comorbidity; Drug Administration Schedule; Enoxaparin; Female; Heparin; Humans; Infu | 2017 |
Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; D | 2017 |
Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece.
Topics: Aged; Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Fibrinolytic Agents; Greece; Humans; Middle | 2017 |
Spontaneous liver rupture associated with anticoagulant therapy A case report.
Topics: Anticoagulants; Drug Therapy, Combination; Enoxaparin; Fatal Outcome; Hematoma; Hepatectomy; Humans; | 2017 |
Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Enoxaparin; Factor X | 2017 |
Treatment of suspected pulmonary embolism in a morbidly obese patient.
Topics: Anticoagulants; Drug Monitoring; Enoxaparin; Female; Humans; Obesity, Morbid; Pulmonary Embolism; Tr | 2017 |
Thromboembolic Events Following Splenectomy: Risk Factors, Prevention, Management and Outcomes.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Humans; Male; Mesenteric Ischemia; Middle Aged; Ope | 2018 |
Bilateral Femoral Neuropathy Following Psoas Muscle Hematomas Caused by Enoxaparin Therapy.
Topics: Anticoagulants; Enoxaparin; Female; Femoral Neuropathy; Hematoma; Humans; Middle Aged; Psoas Muscles | 2017 |
Wound Discharge After Pharmacological Thromboprophylaxis in Lower Limb Arthroplasty.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2018 |
Pulmonary Embolism Presenting as Persistent Hiccups.
Topics: Anticoagulants; Baclofen; Computed Tomography Angiography; Elective Surgical Procedures; Enoxaparin; | 2018 |
Severe Pulmonary Cement Embolism.
Topics: Anticoagulants; Bone Cements; Chest Pain; Dyspnea; Enoxaparin; Heparin, Low-Molecular-Weight; Humans | 2017 |
Are factor Xa inhibitors effective thromboprophylaxis following hip fracture surgery?: A large national database study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Databases, Factual; Enoxapa | 2017 |
Topics: Clinical Trials, Phase III as Topic; Enoxaparin; Germany; Guideline Adherence; Humans; Pulmonary Emb | 2018 |
Behçet's Disease: Pulmonary Aneurysm Resolution with Oral Therapy and HLA B72 Allele Association.
Topics: Aneurysm; Anticoagulants; Behcet Syndrome; Cyclophosphamide; Deprescriptions; Enoxaparin; Female; Gl | 2018 |
Young woman with dyspnea and upper abdominal pain.
Topics: Abdominal Pain; Acute Disease; Anticoagulants; Computed Tomography Angiography; Dyspnea; Enoxaparin; | 2019 |
Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
Topics: Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee | 2018 |
Pulmonary saddle thrombus.
Topics: Computed Tomography Angiography; Enoxaparin; Fibrinolytic Agents; Humans; Male; Middle Aged; Pulmona | 2018 |
Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Conf | 2018 |
Improvement of late life depression after therapeutic enoxaparin: two case reports.
Topics: Aged; Aged, 80 and over; Depressive Disorder; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; | 2018 |
Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Benzamides; C-Reactive Protein; Double-Blind | 2019 |
Fatal pulmonary embolism and pulmonary hemorrhage in lupus anticoagulant hypoprothrombinemia syndrome: a case report and review of literature.
Topics: Aged; Anticoagulants; Antiphospholipid Syndrome; Enoxaparin; Fatal Outcome; Female; Gastrointestinal | 2018 |
Synchronous Cardiopulmonary Consequences of the Hypercoagulable State Associated With Cancer.
Topics: Adenocarcinoma; Anticoagulants; Brain Ischemia; Computed Tomography Angiography; Endocarditis, Non-I | 2019 |
Significant Reduction of Pulmonary Embolism in Orthopaedic Trauma Patients.
Topics: Adult; Aged; Anticoagulants; Clinical Protocols; Enoxaparin; Female; Humans; Incidence; Male; Middle | 2019 |
Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; | 2020 |
Educating patients about warfarin bridging.
Topics: Arthroplasty, Replacement, Knee; Enoxaparin; Humans; Nurse-Patient Relations; Patient Education as T | 2019 |
Extended Thromboprophylaxis for Medical Patients.
Topics: Aftercare; Anticoagulants; Benzamides; Duration of Therapy; Enoxaparin; Heparin, Low-Molecular-Weigh | 2020 |
[Compliance of patients undergoing thromboprophylaxis with enoxaparin: the COMFORT study].
Topics: Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxaparin; Female; | 2013 |
[Adequation of thromboprophylaxis during former admission in patients attended in emergencies with thromboembolic disease].
Topics: Enoxaparin; Female; Fibrinolytic Agents; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; | 2013 |
[Thromboprophylaxis in medical ill patients from Emergency Department].
Topics: Enoxaparin; Female; Fibrinolytic Agents; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; | 2013 |
Is extended thromboprophylaxis necessary in elective colorectal cancer surgery?
Topics: Aged; Anticoagulants; Australia; Clinical Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; El | 2013 |
Multidisciplinary approach in pregnancy-associated thrombotic thrombocytopenic purpura: a case report.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Cesarean Section; Combined Modality T | 2014 |
Seizure as a presentation of pulmonary embolism.
Topics: Aged; Anticoagulants; Enoxaparin; Humans; Male; Pulmonary Embolism; Seizures; Tomography, X-Ray | 2014 |
Therapeutic effect of low-molecular weight heparin and incidence of lower limb deep venous thrombosis and pulmonary embolism after laparoscopic bariatric surgery.
Topics: Adolescent; Adult; Anastomosis, Roux-en-Y; Bariatric Surgery; Enoxaparin; Female; Heparin, Low-Molec | 2013 |
Pulmonary embolism as a first manifestation of intracardiac extension of an endometrial stromal sarcoma.
Topics: Anticoagulants; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Endometrial Neoplasms; E | 2014 |
A retrospective analysis of the effectiveness of low molecular weight heparin for venous thromboembolism prophylaxis in trauma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Enoxaparin; Female; Huma | 2014 |
In vitro and in vivo evaluation of chitosan graft glyceryl monooleate as peroral delivery carrier of enoxaparin.
Topics: Adhesiveness; Administration, Oral; Animals; Anticoagulants; Caco-2 Cells; Chitosan; Disease Models, | 2014 |
Invasive hepatocellular carcinoma with recurrent pulmonary embolism: use of AngioVac cannula thrombectomy device for mechanical aspiration.
Topics: Adult; Angiography; Anticoagulants; Antineoplastic Agents; Carcinoma, Hepatocellular; Enoxaparin; Fa | 2014 |
Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
Topics: Adolescent; Adult; Aged; Anticoagulants; Enoxaparin; Female; Humans; Length of Stay; Male; Middle Ag | 2014 |
Perioperative thromboprophylaxis in Cushing's disease: What we did and what we are doing?
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Aged; Anticoagulants; Antithrombin III; Case-Contr | 2015 |
Peri-operative massive pulmonary embolism management: is veno-arterial ECMO a therapeutic option?
Topics: Accidents, Traffic; Anticoagulants; Enoxaparin; Extracorporeal Membrane Oxygenation; Female; Femoral | 2014 |
Challenges in the management of iliofemoral deep vein thrombosis in a resource limited setting: a case series.
Topics: Adolescent; Adult; Anticoagulants; Developing Countries; Drug Therapy, Combination; Enoxaparin; Femo | 2014 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; E | 2015 |
Prophylactic effect of fondaparinux and enoxaparin for preventing pulmonary embolism after total hip or knee arthroplasty: A retrospective observational study using the Japanese Diagnosis Procedure Combination database.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2015 |
The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
Topics: Anticoagulants; Computer Simulation; Cost-Benefit Analysis; Drug Therapy, Combination; Enoxaparin; H | 2015 |
Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher?
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Enoxaparin; Female; Hematuria; Hemorrhage; Humans; | 2015 |
Once daily versus twice daily enoxaparin for acute pulmonary embolism in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Fo | 2016 |
A rare complication of pulmonary tuberculosis: a case report.
Topics: Adult; Antitubercular Agents; Clarithromycin; Drug Antagonism; Enoxaparin; Fatal Outcome; Female; Hu | 2015 |
Chest discomfort in a patient with cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chest Pain; Doxorubici | 2015 |
Pulmonary cement embolism presenting with dyspnea.
Topics: Aged; Anticoagulants; Bone Cements; Diagnosis, Differential; Dyspnea; Enoxaparin; Humans; Male; Pulm | 2015 |
Safety and efficacy of thromboprophylaxis using enoxaparin sodium after cesarean section: A multi-center study in Japan.
Topics: Adult; Alanine Transaminase; Anticoagulants; Aspartate Aminotransferases; Asymptomatic Diseases; Bod | 2015 |
Prescription of enoxaparin is associated with decreasing pulmonary embolism mortality rate in Germany.
Topics: Drug Prescriptions; Enoxaparin; Female; Germany; Humans; Male; Pulmonary Embolism; Survival Rate | 2015 |
Inherited antithrombin deficiency and anabolic steroids: a risky combination.
Topics: Antithrombins; Chest Pain; Dyspnea; Enoxaparin; Fibrinolytic Agents; Hemoptysis; Humans; Injections, | 2016 |
Clinical Performance of the 1st American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism after Total Knee Arthroplasty in Korean Patients.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Enoxaparin; Female; Fibrinolytic Age | 2015 |
Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban or Enoxaparin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthropl | 2016 |
Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: A case series.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hematologic Neoplasms; Hemorrhage; Heparin, Low-Molecular- | 2017 |
Large saddle embolus during cancer therapy.
Topics: Aged; Anticoagulants; Carcinoma, Squamous Cell; Chemoradiotherapy; Enoxaparin; Humans; Male; Pulmona | 2016 |
Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
Topics: Aged; Arthroplasty, Replacement, Knee; Australia; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrha | 2016 |
Acute pancreatitis complicated with deep vein thrombosis and pulmonary embolism: a case report.
Topics: Adult; Anticoagulants; Enoxaparin; Humans; Male; Pancreatitis; Pulmonary Embolism; Tomography, X-Ray | 2016 |
Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
Topics: Adult; Anticoagulants; Enoxaparin; Erythrocyte Transfusion; Factor Xa Inhibitors; Female; Hematocrit | 2016 |
Rate of Transfusions After Total Knee Arthroplasty in Patients Receiving Lovenox or High-Dose Aspirin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Blood Transfusion | 2016 |
Successful Management of Intraoperative Acute Bilateral Pulmonary Embolism in a High Grade Astrocytoma Patient.
Topics: Adult; Anticoagulants; Astrocytoma; Brain Neoplasms; Enoxaparin; Female; Humans; Intraoperative Comp | 2016 |
Repeated Thrombosis After Synthetic Cannabinoid Use.
Topics: Adult; Anticoagulants; Aspirin; Cannabinoids; Enoxaparin; Female; Humans; Infarction; Platelet Aggre | 2016 |
Effect of Plasmapheresis on the Anti-Factor Xa Activity of Enoxaparin in an Obese Adolescent Patient.
Topics: Adolescent; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Pediatric Obesi | 2017 |
Safety and efficacy of postoperative pharmacologic thromboprophylaxis with enoxaparin after pancreatic surgery.
Topics: Adult; Aged; Aged, 80 and over; Digestive System Surgical Procedures; Enoxaparin; Female; Fibrinolyt | 2017 |
Stuttering priapism complicating warfarin therapy in a patient with protein C deficiency.
Topics: Adult; Anticoagulants; Enoxaparin; Humans; Male; Priapism; Protein C Deficiency; Pulmonary Embolism; | 2008 |
Pulmonary embolism associated with protein C deficiency and abuse of anabolic-androgen steroids.
Topics: Anticoagulants; Blood Coagulation Factors; Dalteparin; Doping in Sports; Enoxaparin; Hematoma, Subdu | 2010 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Human | 2008 |
Images in cardiovascular medicine. Regression of thrombus and electrocardiographic changes with thrombolytic therapy in acute massive pulmonary embolism.
Topics: Coronary Angiography; Creatine Kinase; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Humans; | 2008 |
[Massive retroperitoneal hematoma during enoxaparin combined with aspirin treatment of acute pulmonary embolism: a case report].
Topics: Aged; Aspirin; Enoxaparin; Female; Hematoma; Humans; Pulmonary Embolism; Retroperitoneal Space | 2008 |
The efficacy of prophylactic low-molecular-weight heparin to prevent pulmonary thromboembolism in immediate breast reconstruction using the TRAM flap.
Topics: Adult; Anticoagulants; Breast Neoplasms; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; | 2009 |
[Leg venous thrombosis after work accident: serious surprise in echocardiography].
Topics: Accidents, Occupational; Adult; Casts, Surgical; Critical Care; Echocardiography, Doppler, Color; En | 2008 |
Probable enoxaparin-induced hepatotoxicity.
Topics: Adult; Anticoagulants; Chemical and Drug Induced Liver Injury; Enoxaparin; Female; Humans; Injection | 2009 |
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Fondaparinu | 2009 |
Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Therapy, Combination; Enoxaparin; F | 2010 |
[Subdural spinal hematoma and intraventricular bleeding after lumbar puncture].
Topics: Aged; Anticoagulants; Back Pain; Cerebral Hemorrhage; Cerebral Ventricles; Enoxaparin; Fatal Outcome | 2009 |
[Anesthesia in a patient with homocystinuria and severe pulmonary embolism].
Topics: Acenocoumarol; Aggression; Anesthesia, General; Anesthetics; Anticoagulants; Contraindications; Enox | 2009 |
Air travel and pulmonary embolism: "economy class syndrome".
Topics: Adult; Aircraft; Anticoagulants; Enoxaparin; Humans; Male; Middle Aged; Pulmonary Embolism; Risk Fac | 2009 |
[Prophylaxis of deep vein thrombosis with enoxaparin 40 mg in outpatients compared to hospitalized medically ill patients].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Cross-Sectional Studies; Enoxaparin | 2009 |
Neuraxial hematoma and paralysis after enoxaparin administration 3 days after attempted spinal anesthesia for total knee arthroplasty.
Topics: Aged; Anesthesia, Spinal; Anticoagulants; Arthroplasty, Replacement, Knee; Dose-Response Relationshi | 2010 |
Apixaban or enoxaparin for thromboprophylaxis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Humans; Postoperative Complications; Pu | 2009 |
Clinical and economic outcomes with appropriate or partial prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Costs and Cost Analysis; Data Collection; Enoxaparin | 2010 |
Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery.
Topics: Adenocarcinoma; Adult; Aged; Anticoagulants; Biomarkers; Carcinoma, Squamous Cell; Combined Modality | 2010 |
Bilateral pulmonary emboli in a competitive gymnast.
Topics: Abdominal Pain; Adolescent; Anticoagulants; Chest Pain; Competitive Behavior; Contraceptives, Oral; | 2010 |
Enoxaparin for the prevention of venous thromboembolism.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hospitalization; Human | 2010 |
[Parturient at full term with inferior vena cava thrombosis: anesthesia during surgical delivery].
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anticoagulants; Cesarean Section; Emergencies; | 2010 |
Prolonged thromboprophylaxis with enoxaparin in early neurological rehabilitation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; | 2011 |
Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients.
Topics: Adult; Aged; Anticoagulants; Creatinine; Enoxaparin; Factor Xa; Female; Heparin, Low-Molecular-Weigh | 2010 |
[Pulmonary embolism as a cause of a reduced performance capacity of endurance trained men - report of 2 cases].
Topics: Acute Disease; Angiography; Anticoagulants; Athletic Performance; Diagnosis, Differential; Electroca | 2010 |
Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia.
Topics: Adult; Anticoagulants; Cardiopulmonary Bypass; Echocardiography, Transesophageal; Embolectomy; Enoxa | 2010 |
[Acute pulmonary embolism].
Topics: Acute Disease; Algorithms; Diagnosis, Differential; Echocardiography; Embolectomy; Enoxaparin; Fibri | 2010 |
Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Knee; Clinical Trials, Phase II as | 2010 |
Pulmonary embolectomy in heparin-induced thrombocytopenia and thrombosis? Safety of heparin use.
Topics: Anticoagulants; Cardiopulmonary Bypass; Embolectomy; Enoxaparin; Female; Fondaparinux; Heart Arrest, | 2010 |
Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Male; Mammaplasty; Middle Aged; Plastic Surgery Procedur | 2011 |
A pilot retrospective comparison of fondaparinux and enoxaparin for the prevention of venous thromboembolism (VTE) in patients with stroke.
Topics: Aged; Aged, 80 and over; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Humans; Male; Middle | 2010 |
Mechanical thromboprophylaxis for patients undergoing hip fracture surgery.
Topics: Aged; Aged, 80 and over; Cohort Studies; Enoxaparin; Female; Fibrinolytic Agents; Fracture Fixation; | 2010 |
[Pulmonary embolism mimicking acute anterior myocardial infarction: diagnostic trap].
Topics: Acenocoumarol; Acute Coronary Syndrome; Anterior Wall Myocardial Infarction; Anticoagulants; Coronar | 2011 |
Optimal duration of anticoagulation after venous thromboembolism.
Topics: Aged; Altitude Sickness; Anticoagulants; Cholesterol, HDL; Clinical Trials as Topic; Enoxaparin; Fem | 2011 |
Drotrecogin alpha: a rational approach to the treatment of submassive pulmonary embolism?
Topics: Blood Coagulation; Enoxaparin; Female; Fibrinolysis; Fibrinolytic Agents; Humans; Male; Protein C; P | 2011 |
Metastatic osteosarcoma presenting as a single pulmonary microembolus.
Topics: Adolescent; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 2011 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Pu | 2011 |
Saddle pulmonary thromboembolism with zero Wells' score.
Topics: Anticoagulants; Blood Coagulation; Clinical Competence; Critical Pathways; Diagnosis, Differential; | 2011 |
Anticoagulant utilization evaluation in a teaching hospital: a prospective study.
Topics: Adult; Aged; Anticoagulants; Cross-Sectional Studies; Drug Monitoring; Drug Utilization Review; Enox | 2010 |
Enoxaparin-associated atraumatic compartment syndrome of the calf.
Topics: Aged; Anticoagulants; Compartment Syndromes; Enoxaparin; Female; Humans; Leg; Pulmonary Embolism | 2012 |
Outpatient management of pulmonary embolism.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Hospitalization; H | 2011 |
Safety and efficacy of heparin or enoxaparin prophylaxis in blunt trauma patients with a head abbreviated injury severity score >2.
Topics: Abbreviated Injury Scale; Anticoagulants; Brain Injuries; Disease Progression; Enoxaparin; Heparin; | 2011 |
[Gastrointestinal stromal tumor in pregnancy and control. Case report].
Topics: Adult; Anticoagulants; Cesarean Section; Embolism, Amniotic Fluid; Emergencies; Enoxaparin; Female; | 2010 |
Venous thromboembolism prophylaxis for medical service-mostly cancer-patients at hospital discharge.
Topics: Aged; Anticoagulants; Case-Control Studies; Confidence Intervals; Endpoint Determination; Enoxaparin | 2011 |
Idrabiotaparinux treatment for venous thromboembolism.
Topics: Anticoagulants; Biotin; Enoxaparin; Factor X; Female; Humans; Male; Oligosaccharides; Pulmonary Embo | 2012 |
Acute pulmonary embolism in patients with obstructive sleep apnoea: does it affect the severity of sleep-disordered breathing?
Topics: Acute Disease; Aged; Airway Resistance; Anticoagulants; Central Venous Pressure; Enoxaparin; Female; | 2012 |
Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Body Mass | 2012 |
Successful use of low molecular weight heparin in intracardiac thrombus of an extremely low birth weight infant.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Echocardiography; Enoxaparin; Female | 2013 |
Thrombotic biomarkers and left ventricle characteristics as short-term predictors of thrombotic events in patients hospitalized for acute decompensated heart failure.
Topics: Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Echocardiography; Enoxaparin; Female; Fibrin Fi | 2012 |
Pulmonary cement emboli after kyphoplasty.
Topics: Adult; Anticoagulants; Bone Cements; Breast Neoplasms; Education, Medical, Continuing; Enoxaparin; F | 2012 |
Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus.
Topics: Acute Disease; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; Drug Substitution; Em | 2013 |
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2012 |
Sixteen-year-old athlete with chest pain and shortness of breath due to pulmonary emboli.
Topics: Adolescent; Anticoagulants; Athletes; Chest Pain; Contraceptives, Oral; Dyspnea; Emergency Service, | 2013 |
The effects of location and low-molecular-weight heparin administration on deep vein thrombosis outcomes in trauma patients.
Topics: Adult; Aged; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Injury | 2013 |
A comparison of heparin/warfarin and enoxaparin thromboprophylaxis in spinal cord injury: the Sheffield experience.
Topics: Acute Disease; Adolescent; Adult; Anticoagulants; Child; Cohort Studies; Comorbidity; Drug Therapy, | 2002 |
Hemothorax and retroperitoneal hematoma after anticoagulation with enoxaparin.
Topics: Anticoagulants; Enoxaparin; Female; Hematoma; Hemothorax; Humans; Middle Aged; Pulmonary Embolism; R | 2002 |
Treatment of acute pulmonary embolism during pregnancy with low molecular weight heparin: three case reports.
Topics: Acute Disease; Adult; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnanc | 2002 |
Low-molecular weight heparin: treatment failure in a patient with primary antiphospholipid antibody syndrome.
Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Arginine; Arm; Enoxaparin; Female; Folic Acid | 2002 |
[Venous thromboembolism prophylaxis with low molecular weight heparins in polytraumatized patients in intensive care unit (extended serie)].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; APACHE; Enoxaparin; Female; Hemorrhage; | 2003 |
Fondaparinux: new preparation. No better than LMWH in preventing pulmonary embolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Evaluation; En | 2003 |
Postoperative deep vein thrombosis prophylaxis: a retrospective analysis in 1000 consecutive hip fracture patients treated in a community hospital setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Enoxaparin; Female; Frac | 2003 |
Anticoagulation in a head-injured patient.
Topics: Accidental Falls; Anticoagulants; Brain Injuries; Cerebral Hemorrhage; Contraindications; Enoxaparin | 2003 |
[New synthetic antithrombotic agent. In secondary prevention conclusive, too].
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin; Hu | 2003 |
Surveillance venous duplex is not clinically useful after total joint arthroplasty when effective deep venous thrombosis prophylaxis is used.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement; Bandages; Enoxaparin; Female; Femoral Vei | 2004 |
Post dural puncture headache in an anticoagulated patient.
Topics: Adult; Anticoagulants; Bed Rest; Blood Patch, Epidural; Dura Mater; Enoxaparin; Female; Headache; He | 2004 |
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Belgium; Cost-Benef | 2004 |
Daily vs twice daily enoxaparin in the prevention of venous thromboembolic disorders during rehabilitation following acute spinal cord injury.
Topics: Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; | 2004 |
[The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost Savings; Cost- | 2005 |
Deep-vein thrombosis in high-energy skeletal trauma despite thromboprophylaxis.
Topics: Acetabulum; Enoxaparin; Fibrinolytic Agents; Fractures, Bone; Humans; Magnetic Resonance Angiography | 2005 |
Optimal dose of enoxaparin in critically ill trauma and surgical patients.
Topics: Anticoagulants; Critical Illness; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Pro | 2005 |
[Low-molecular-weight heparin for the treatment of acute pulmonary thromboembolism. Comparison with unfractionated intravenous heparin].
Topics: Aged; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Male; Middle Aged; Pulmonary Embolism | 2005 |
Thromboprophylaxis after vaginal delivery: a district general hospital experience.
Topics: Adolescent; Adult; Anticoagulants; Bandages; Chemoprevention; Delivery, Obstetric; Enoxaparin; Femal | 2006 |
Thromboprophylaxis post vaginal delivery: are we forgetting it? Audit on thromboprophylaxis prescription post vaginal births.
Topics: Anticoagulants; Bandages; Dehydration; Delivery, Obstetric; Early Ambulation; Enoxaparin; Female; Gu | 2006 |
[Thromboembolisms endanger the internist patients, too: who needs heparin].
Topics: Age Factors; Aged; Anticoagulants; Dalteparin; Enoxaparin; Family Practice; Female; Fibrinolytic Age | 2006 |
Primary extranodal nasal-type natural killer/T-cell lymphoma of the brain: a case report.
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; CD3 Complex; CD56 Antigen; DNA, Neoplasm; Enoxapar | 2006 |
Selecting an agent for prophylaxis of venous thromboembolism.
Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Enoxaparin; Fibrinolytic Agents; Formularies, Hos | 2006 |
Fatal haemorrhage associated with enoxaparin.
Topics: Aged; Anticoagulants; Blood Transfusion; Enoxaparin; Fatal Outcome; Hemorrhage; Humans; Male; Muscul | 2007 |
Venous thromboembolism in a general hospital. An update with low molecular weight heparin prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug A | 2007 |
Thromboprophylaxis after hip fracture: evaluation of 3 pharmacologic agents.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Dextrans; Enoxaparin; Female; Fibrinolytic Agents; | 2007 |
Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
Topics: Adult; Cohort Studies; Dalteparin; Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Ag | 2007 |
A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Topics: Adult; Anticoagulants; Bayes Theorem; Canada; Cost-Benefit Analysis; Decision Support Techniques; De | 2007 |
Prevention of venous thromboembolism after acute ischaemic stroke.
Topics: Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Heparin; Humans; Ischemic Attack, Transient; Pres | 2007 |
Subacute pulmonary embolism presenting with multiple aseptic lung cavities.
Topics: Acenocoumarol; Acute Disease; Anticoagulants; Diagnosis, Differential; Enoxaparin; Female; Humans; L | 2007 |
Splenic rupture following elective caesarean delivery at term, complicated by low-molecular-weight heparin use.
Topics: Abdominal Pain; Adult; Anticoagulants; Antithrombin III Deficiency; Cesarean Section; Comorbidity; E | 2007 |
Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2007 |
Pleuritis as the first symptom of pulmonary embolism: a case report.
Topics: Anticoagulants; Chest Pain; Enoxaparin; Female; Humans; Middle Aged; Pleurisy; Pulmonary Embolism; T | 2007 |
Heparin-induced thrombocytopenia in a patient with lung embolism and left-sided pneumonia: a case report.
Topics: Aged; Antibodies; Anticoagulants; Enoxaparin; Female; Humans; Platelet Factor 4; Pneumonia; Pulmonar | 2007 |
Post discharge prophylactic anticoagulation in gastric bypass patient-how safe?
Topics: Adult; Anticoagulants; Body Mass Index; Cohort Studies; Dose-Response Relationship, Drug; Drug Admin | 2008 |
[Some acquired facts apropos of the effectiveness of heparins in the prevention of postoperative phlebitis and pulmonary embolism].
Topics: Enoxaparin; Heparin; Humans; Phlebitis; Postoperative Complications; Pulmonary Embolism | 1993 |
[General perioperative prevention of thromboembolism in gynecology with low-molecular weight heparin: clinical experiences with enoxaparin over 7 years].
Topics: Adult; Aged; Anticoagulants; Blood Coagulation Tests; Combined Modality Therapy; Dose-Response Relat | 1995 |
Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.
Topics: Adolescent; Anticoagulants; Blood Coagulation Tests; Case-Control Studies; Catheters, Indwelling; Ch | 1996 |
A short course of low-molecular-weight heparin to prevent deep venous thrombosis after elective total hip replacement.
Topics: Anticoagulants; Chi-Square Distribution; Drug Evaluation; Elective Surgical Procedures; Enoxaparin; | 1997 |
The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 1998 |
[Pulmonary embolism as one cause of death after spinal injury--the role of clexane].
Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Humans; Male; Middle Aged; Poland; Pulmonary Embolism; | 1998 |
Why didn't this patient respond to enoxaparin?
Topics: Anticoagulants; Enoxaparin; Female; Humans; Hysterectomy; Pulmonary Embolism; Venous Thrombosis | 1999 |
[Efficacy and safety of low molecular weight heparin in the treatment of pulmonary thromboembolism].
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-We | 1999 |
Enoxaparin for the prevention of VT in acutely ill patients.
Topics: Acute Disease; Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Hospitalization; Humans; Pulm | 1999 |
Enoxaparin for the prevention of venous thromboembolism.
Topics: Anticoagulants; Confidence Intervals; Enoxaparin; Hemorrhage; Humans; Pulmonary Embolism; Thromboemb | 2000 |
Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients.
Topics: Adult; Aged; Anticoagulants; Consensus Development Conferences as Topic; Enoxaparin; Humans; Middle | 2000 |
Therapeutic interchange of low-molecular-weight heparins.
Topics: Anticoagulants; Dalteparin; Enoxaparin; Humans; Pulmonary Embolism; Therapeutic Equivalency; Venous | 2000 |
A potentially expanded role for enoxaparin in preventing venous thromboembolism in high risk blunt trauma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle | 2001 |
Prophylaxis of thromboembolism in spinal injuries--results of enoxaparin used in 276 patients.
Topics: Acute Disease; Adult; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Pulmonary Embol | 2001 |
Cerebral vein thrombosis and lupus anticoagulant antibodies.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Autoimmune Diseases; Enoxaparin; Female; Humans; L | 2001 |
Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Comorbidity; Drug Administration Schedule; Enoxapari | 2001 |
Severe postoperative haemorrhage and airway obstruction following high-dose enoxaparin.
Topics: Airway Obstruction; Blepharoplasty; Enoxaparin; Female; Humans; Injections, Subcutaneous; Laryngeal | 2001 |
Cost comparison of tinzaparin versus enoxaparin as deep venous thrombosis prophylaxis in spinal cord injury: preliminary data.
Topics: Cost-Benefit Analysis; Data Collection; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agent | 2001 |
Choosing a parenteral anticoagulant agent.
Topics: Angina, Unstable; Anticoagulants; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecu | 2001 |
[Upper abdominal pain as a souvenir from the US trip].
Topics: Abdominal Pain; Aged; Anticoagulants; Enoxaparin; Estrogen Replacement Therapy; Female; Fibrinolytic | 2000 |
[Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
Topics: Anticoagulants; Body Weight; Clinical Trials as Topic; Fibrinolytic Agents; Hemorrhage; Heparin; Hep | 2003 |
[Initial results of the PROTECT Study publicized. Stroke patients need effective thrombosis prevention].
Topics: Anticoagulants; Cerebral Infarction; Double-Blind Method; Hemorrhage; Heparin; Heparin, Low-Molecula | 2005 |
[Internist patients are strongly thrombosis endangered. CERTIFY study has arrived].
Topics: Age Factors; Aged; Anticoagulants; Antifibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; | 2007 |
[Antithrombotic Treatment of Pulmonary Embolism].
Topics: Acute Disease; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fibrinoly | 2020 |
'Case of the Month' from Cambridge University, UK: managing intractable bleeding from a 375 cc prostate in an anti-coagulated patient.
Topics: Aged; Anticoagulants; Dalteparin; Diagnostic Errors; Embolization, Therapeutic; Erythrocyte Transfus | 2021 |
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; H | 2018 |
A 51-year-old woman with dyspnea.
Topics: Anticoagulants; Contraindications; Dalteparin; Dyspnea; Female; Fibrinolytic Agents; Humans; Middle | 2013 |
Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Topics: Anticoagulants; Cost-Benefit Analysis; Critical Illness; Dalteparin; Female; Health Expenditures; He | 2014 |
Venous thrombosis in pancreaticobiliary tract cancer: outcome and prognostic factors.
Topics: Aged; Anticoagulants; Biliary Tract Neoplasms; Dalteparin; Female; Humans; Male; Middle Aged; Pancre | 2015 |
Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism.
Topics: Animals; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Disease Models, Animal; Disease Prog | 2016 |
Spontaneous lingual haematoma secondary to thrombolysis.
Topics: Aged; Dalteparin; Diagnosis, Differential; Fibrinolytic Agents; Hematoma; Humans; Male; Pulmonary Em | 2016 |
Analysis of contributing factors influencing thromboembolic events after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Dalteparin; Electiv | 2017 |
Kinetics of D-dimer after general surgery.
Topics: Abdomen; Abdominal Neoplasms; Adult; Aged; Anticoagulants; Cohort Studies; Dalteparin; Female; Fibri | 2009 |
The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases.
Topics: Aged; Atrial Fibrillation; Cerebral Hemorrhage; Coronary Artery Disease; Dalteparin; Fatal Outcome; | 2009 |
Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.
Topics: Aged; Angiography; Anticoagulants; Dalteparin; Drainage; Hemothorax; Humans; Male; Pulmonary Embolis | 2009 |
High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis.
Topics: Aged; Anticoagulants; Arthroplasty; Dalteparin; Drug Administration Schedule; Elective Surgical Proc | 2010 |
PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan.
Topics: Critical Care; Dalteparin; Fibrinolytic Agents; Heparin; Humans; Injections, Subcutaneous; Intensive | 2011 |
Dalteparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Heparin; Humans; Incidence; Outcome Assessment, Health | 2011 |
Outpatient treatment of community acquired venous thromboembolism--the Christchurch experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Dalteparin; Drug Therap | 2002 |
Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study.
Topics: Anticoagulants; Cohort Studies; Dalteparin; Hemorrhage; Humans; Prospective Studies; Pulmonary Embol | 2002 |
Cancer-associated thrombosis.
Topics: Anticoagulants; Dalteparin; Humans; Neoplasms; Pulmonary Embolism; Risk Factors; Secondary Preventio | 2003 |
Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Platelets; Body Weight; Brain Neoplasms; Cohor | 2004 |
[Novel antithrombotic drugs. From the 19th Congress of the International Society on Thrombosis and Haemostasis].
Topics: Adult; Age Factors; Aged; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Female; Fibrinolytic | 2004 |
Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Cohort Studies; Dalteparin; Dose-Response Relation | 2005 |
Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Anticoagulants; Dalteparin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle | 2007 |
Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.
Topics: Aged; Anticoagulants; APACHE; Critical Illness; Dalteparin; Female; Hemorrhage; Humans; Incidence; I | 2008 |
A case of fatal pulmonary embolism raising questions about the dosing regimen for dalteparin in the very obese.
Topics: Anticoagulants; Dalteparin; Drug Administration Schedule; Fatal Outcome; Humans; Male; Middle Aged; | 2008 |
Thromboembolism treated with low molecular weight heparin in a pregnancy complicated by major placenta praevia: a case report.
Topics: Adult; Cesarean Section; Dalteparin; Female; Humans; Male; Molecular Weight; Placenta Previa; Pregna | 1997 |
Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Humans; Postoperative Complications; Pul | 1998 |
Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Humans; Postoperative Complications; Pul | 1998 |
Thromboembolic events following arthroscopic knee surgery.
Topics: Adult; Aged; Anticoagulants; Arthroscopy; Dalteparin; Female; Humans; Knee Joint; Male; Middle Aged; | 1999 |
Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Arm; Catheterization, Central Venous; C | 1999 |
[The role of low molecular weight heparin (fragmin) in the prophylaxis and treatment of venous thromboembolism in major abdominal operations].
Topics: Dalteparin; Digestive System Surgical Procedures; Heparin, Low-Molecular-Weight; Humans; Pulmonary E | 2000 |
[Low-molecular weight heparins in the prophylaxis and treatment of pulmonary thromboembolism].
Topics: Dalteparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Practice Guidelines as Topic | 2001 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Tinzaparin thromboprophylaxis prescribing practice after caesarean delivery 2009-2014.
Topics: Cesarean Section; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; History, 21st Century; | 2018 |
Ovarian vein thrombosis after delivery.
Topics: Adult; Cesarean Section; Delivery, Obstetric; Diagnosis, Differential; Female; Follow-Up Studies; He | 2018 |
Tinzaparin safety and efficacy in pregnancy.
Topics: Abortion, Habitual; Adolescent; Adult; Drug Hypersensitivity; Female; Fibrinolytic Agents; Hemorrhag | 2014 |
[Thrombolytic therapy in pregnant woman with pulmonary embolism].
Topics: Adult; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Comp | 2009 |
Treatment of pulmonary embolism in an extremely obese patient.
Topics: Acenocoumarol; Anticoagulants; Drug Dosage Calculations; Drug Monitoring; Factor Xa; Factor Xa Inhib | 2009 |
Tinzaparin: excess mortality in elderly patients with renal failure. Unfractionated heparin is best in this setting.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Fibrinolytic Agents; Heparin; Heparin, Low-Molecu | 2009 |
Splenic spontaneous rupture (SSR) and hemoperitoneum associated with low molecular weight heparin: a case report.
Topics: Aged; Anticoagulants; Carcinoma, Small Cell; Female; Fibrinolytic Agents; Hemoperitoneum; Heparin, L | 2003 |
Tinzaparin in the treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Fibri | 2003 |
A six-year old with fatal pulmonary embolism.
Topics: Child; Fatal Outcome; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Iliac Vein; Lupus | 2005 |
Outpatient tinzaparin therapy in pulmonary embolism quantified with ventilation/perfusion scintigraphy.
Topics: Ambulatory Care; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Middle Ag | 2006 |
[Docetaxel-induced acute pulmonary capillary-leak syndrome mimicking cardiogenic oedema].
Topics: Acute Disease; Anticoagulants; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capillary Leak S | 2007 |
Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; | 2007 |
Early discharge of patients with pulmonary embolism: a two-phase observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Follow-Up Studies; Heparin, Low- | 2007 |
Tinzaparin as an antithrombotic: an overview.
Topics: Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Injections, Subcutaneous; Pulmonary Embo | 1998 |
[Economic assessment of the use of tinzaparin in the treatment of acute pulmonary embolism in France].
Topics: Acute Disease; Costs and Cost Analysis; Decision Trees; Fibrinolytic Agents; France; Heparin, Low-Mo | 2001 |
Prolonged prophylaxis after joint replacement: another step sideways?
Topics: Ambulatory Care; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Administratio | 2000 |
The association between race and venous thromboembolism risk after initiation of chemotherapy: An analysis of the SAVE-ONCO trial control arm.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Agents; Control Groups; Controlled Clinical Trials as To | 2017 |